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Malignant melanoma results in 132,000 cases worldwide each year with an incidence 
rate that is increasing faster than for any other skin cancer. In the UK, cutaneous 
melanoma is the sixth most commonly diagnosed cancer and the second most 
common in young people aged 15-34 (excluding non-melanoma skin cancer). 
Furthermore, while less common than NMSC, malignant melanoma accounts for 4% 
of skin cancer cases and 74% of skin cancer-related deaths. Although early surgical 
removal of primary tumours is an effective treatment, patients that develop 
metastatic melanoma have a very poor prognosis (5 year survival rate is only 5%). 
 
Elevated expression of a number of DNA repair genes has been reported in primary 
melanomas that subsequently metastasised when compared to non-recurrent primary 
tumours. In addition, patients who do not respond to chemotherapy have elevated 
expression of DNA repair genes.  One chemotherapeutic that is effective against a 
range of other cancers, but not melanoma is cisplatin. Elevated levels of the DNA 
repair protein ERCC1, which is needed to remove cisplatin-induced DNA damage, 
has been found to be an indicator of poor prognosis in ovarian and lung cancer. 
 
To test our hypothesis that elevated ERCC1 levels account for an increased 
resistance to cisplatin in melanoma, a xenograft experiment was performed. Our 
results show that ERCC1 proficient melanoma xenografts initially responded to 
cisplatin treatment however resistance soon followed. Tumours deficient in ERCC1 
however could be cured after only two treatments of cisplatin, indicating a novel 
method to overcome chemoresistance in metastatic melanoma.  
 
The aim of the project was to identify novel compounds to improve therapy of 
melanoma. To achieve this, in collaboration with Dr Patton we performed a cell 
culture screen to identify compounds which display specificity against melanoma 




cisplatin resistance. We identified a series of nitrofuran compounds which are potent 
against melanoma and neuroblastoma cell lines and enhanced the toxicity of cisplatin 
through an ERCC1 independent pathway. In addition, we showed that melanin 
pigmentation is protective against nitrofuran toxicity. 
 
We have proposed the structure specific endonuclease, ERCC1-XPF, as a drug target 
to overcome chemoresistance. We collaborated with Professor Walkinshaw to 
perform an in silico screen for protein-protein interaction inhibitors to disrupt the 
obligate dimerization between ERCC1 and XPF. In addition we directly inhibited the 
endonuclease activity by developing XPF endonuclease domain inhibitors and 
utilised a range of biochemical, molecular biology and cell culture assays to validate 
ERCC1-XPF inhibitors. 
 
Furthermore, we developed an in vitro endonuclease assay for ERCC1-XPF, FEN1 
and DNase1 and utilised these to demonstrate compound specificity of our validated 
ERCC1-XPF inhibitors. In collaboration with MRC Technology we utilised the 
ERCC1-XPF endonuclease assay to perform a high throughput screen. We 
characterised hit compounds to demonstrate physical binding and in vitro specificity 
for ERCC1-XPF. 
 
In conclusion, we have discovered new compounds which may prove beneficial for 
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 Chapter 1: Introduction 2 
1.1 Malignant melanoma 
1.1.1 Melanoma incidence rates 
In the UK, 91,100 new cases of non-melanoma skin cancers were diagnosed in 
2009 compared to malignant melanoma where 11,877 new cases were diagnosed (1). 
Although malignant melanoma is less common, mortality is greater and resulted in 
2,203 deaths whereas non-melanoma skin cancer accounted for only 546 deaths (1). 
Excluding non-melanoma skin cancer, malignant melanoma is the sixth most 
common cancer in the UK population and is the second most common cancer in the 
15-34 year old age group (1).   
Worryingly, incident rates of malignant melanoma have increased by 70% 
between a period of 1997-9 and 2006-8, faster than any other cancer (1). 
Interestingly the incidence rate for malignant melanoma is higher in women though 
mortality rates in women are lower than in men, likely due to a greater proportion of 
thinner malignancies (1). In the UK, 5-year survival rates for malignant melanoma 
are 90% for women and 81% for men though once the tumour reaches >3.5mm in 
thickness, this reduces to 55% and 47% respectively (1). For metastatic disease, this 
is further reduced to around 5%. 
 
1.1.2 Melanoma risk factors 
The main risk factor for malignant melanoma is exposure to UV radiation 
however risk can also be correlated with other factors. For example, patients with a 
single atypical naevus have a 60% increased risk of melanoma or 10-fold increased 
risk for those with 5 or more atypical naevi (2). Previous medical history of atopic 
dermatitis is associated with increased risk (3) and Parkinson’s disease patients have 
a 7-fold increased risk (4). Although the reason for this is unknown, it may be linked 
to variations in pigmentation genes which are associated with both conditions (5, 6). 
In addition, being fair skinned, freckled, or having red hair is also associated with a 
3-8 fold increased risk of developing melanoma (7). It is thought that about 10% of 
melanomas are as a result of inherited mutations, as such previous history of 
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melanoma, or family history of melanoma, are therefore associated with increased 
melanoma risk (8). 
Sunburn has also been correlated with increased risk of developing melanoma 
with childhood sunburn being even more damaging than adulthood sunburn (9, 10). 
People who have had a single event of bad sunburn are twice as likely to develop 
malignant melanoma (11). In addition, studies show that regular sunbed use before 
the age of 30 results in a 75% increased risk of developing melanoma (12, 13). 
Studies show that use of sun creams does help to reduce damage caused by UV 
radiation and lowers risk of developing melanoma (14, 15). 
 
1.1.3 Genetic changes in melanoma 
A common mutation found in 40-70% of metastatic melanomas is a V600E 
mutation in B-Raf that results in a 10 times greater activity of the MAPK pathway 
than with wild type B-Raf (16–18). A second common mutation which activates the 
MAPK pathway occurs in N-Ras which is activated in 10-15% of metastatic 
melanomas (19). Activation of B-Raf or N-Ras initially promotes cell proliferation 
and naevus development. However, prolonged activation of the MAPK pathway 
results in cell cycle arrest and cellular senescence by activation of cyclin-dependent 
kinase inhibitors such as p21Cip1, p16Ink4a and p27Kip1 (19). It is therefore 
necessary for other factors to become mutated (such as p53 deregulation, p16Ink4a 
loss or by Akt3 activation) to overcome cell cycle arrest in naevi and facilitate 
progression to melanoma (19). 
To overcome cellular senescence, activation of the PI3K pathway occurs in 
70% of sporadic melanomas and is often found in conjunction with V600E B-Raf 
mutations (19, 20). Typically PI3K pathway activation occurs due to loss of PTEN or 
by activation of Akt3 and facilitates the deregulation of apoptosis and promotes 
chemoresistance (19). It has been shown that activated Akt3 phosphorylates V600E 
B-Raf resulting in reduced MAPK pathway activity thus restoring cell proliferation 
as observed in early naevus development (19). 
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The role of p16Ink4a in melanoma is also well established and is frequently 
mutated in 10-50% of melanoma cases (21, 22). Furthermore through alternative 
splicing of the CDKN2A gene, the two products p16Ink4a and p14ARF are 
transcribed from exons 1α, 2 and 3 or exons 1β and 2 respectively (21, 23). It is 
thought that p16Ink4a disrupts the transition from G1 to S phase of the cell cycle by 
forming a complex with CDK4/6 (21, 23). This inhibits CDK4/6 binding to Cyclin D 
proteins and results in decreased phosphorylation of Rb and prevents transcription of 
genes required for S phase transition (21, 23). When p16Ink4a is deleted in 
melanoma, phosphorylation occurs on Rb protein and allows transcription of S phase 
genes, thus resulting in increased cell proliferation (21, 23). 
Unlike many other cancers, in melanoma p53 mutations occur in only 20-25% 
of cases (24). The p53 pathway is instead altered by loss of p14ARF (24). This acts 
by reducing inhibition of MDM2 and thus increased suppression of p53 by MDM2 
promoting melanomagenesis and an escape from senescence (24). 
 
1.1.4 DNA repair in melanoma 
Genomic instability and mutation is an enabling characteristic for the 
development of cancer, as described by Hanahan and Weinberg (25). In cancer, 
mutation is often achieved by mutagenic agents, loss of DNA damage detection, or 
by loss of DNA repair ability (25). In patients with the DNA repair deficiency 
syndrome, xeroderma pigmentosum (XP), patients have a  >1000-fold increased risk 
of developing UV-induced skin cancers (26). This shows that a decrease in DNA 
repair ability promotes tumour formation. In contrast, once a cancer has established it 
is then favourable to have higher levels of DNA repair as this protects against 
chemotherapy. 
It is proposed that a reduced DNA repair capacity acts as a predisposing factor 
for melanoma. As such, several studies have identified gene polymorphisms which 
correlate with an increased risk of melanoma. These include Broberg et al. who 
identified variants of RMI1 with an odds ratio (OR) of 1.5 (27). This protein is 
known to associate with the BLM helicase involved in homologous recombination 
(27). Tomescu et al. identified three polymorphysims in the XPD gene which result 
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in OR of 2.0, 2.6 and 2.8 (28). Zhang et al. found a single nucleotide polymorphism 
(SNP) in the PARP1 gene with an OR of 1.89 (29). Furthermore, they found that 
association was highest in sun exposed sites, particularly on the head and neck (29).  
Kauffmann et al. looked at the difference between DNA repair gene expression 
in primary melanoma tumours that metastasized within a 4 year time period versus 
those that did not metastasize (30). They showed that proteins involved in several 
DNA repair pathways are increased in metastatic tumours, including the Nucleotide 
Excision Repair (NER), Base Excision Repair (BER), Mismatch Repair (MMR), 
Trans-Lesion Synthesis (TLS) and Double Strand Break Repair (DSBR) pathways 
(30).  
In a study by Jewell et al., they found that there was an association between 
over-expression of certain DNA repair genes, and poor relapse-free survival (31). 
These included RAD51, RAD52, TOP2A and RAD54B. Furthermore, they showed 
that following chemotherapy (the majority of cases were treated with dacarbazine) 
DNA repair gene expression was also increased (31). This included genes involved 
in the removal of DNA bases through direct reversal (MGMT), NER (ERCC1, 
XPA), BER (XRCC1), MMR (MLH1, MSH2) and non-homologous end joining 
(NHEJ) (XRCC5, XRCC6) pathways (31). Importantly however, this study did not 
reach statistical significance due to a low sample size. Increased expression of 
TOPO2A and XRCC5 has since been confirmed by Song et al. (32). 
 
1.2 Current therapeutics and clinical trials 
1.2.1 Dacarbazine 
Currently the DNA alkylating agent dacarbazine is the main front line therapy 
for metastatic melanoma and was first approved for treating metastatic melanoma in 
1975. However, response rates to dacarbazine are low and observed responses are 
nearly always partial (33). In clinical studies, dacarbazine has a response rate of 7-
20% resulting in a median survival of 6-9 months (33, 34). Furthermore, in a study 
by Chapman et al., the Dartmouth regimen (dacarbazine, cisplatin, carmustine and 
tamoxifen) was shown to have an increased response rate of 18.5% versus 10.2% for 
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dacarbazine alone however median survival time was unchanged at 7 months for 
both regimes (35). In  a study by Bedikian et al. combination of dacarbazine with the 
Bcl-2 antisense oligonucleotide, oblimersen,  showed an improved overall response 
(36). They found that the overall response rate was 13.5% while 2.8% of patients 
showed complete response (36). In contrast, patients treated with dacarbazine alone 
showed an overall response rate of 7.5% and only 0.8% of patients had complete 
response (36). Furthermore progression free survival was deemed to be longer (2.8 
months versus 1.6 months) and median overall survival was increased (9.0 months 
versus 7.8 months) with combinational therapy (36).  
Dacarbazine is therefore far from the ‘ideal’ therapy and more effective 
therapies are urgently needed. Herein we review the response rates of other agents 





-benzylguanine is a potent inhibitor of the O
6
-alkylguanine DNA 
alkyltransferase (AGT) DNA repair protein (gene name MGMT) and is expressed at 
high levels in melanoma (37). O
6
-benzylguanine was developed in the early 1990’s 
and during this time preclinical data showed benefit for melanoma therapy in cell 
culture models (38). The purpose of O
6
-benzylguanine was to enhance toxicity of 
existing alkylating agents used for melanoma therapy (38). During DNA damage, 
AGT functions to repair DNA alkylating lesions by binding, and accepting the alkyl 
group from the O
6
 position on guanine residues onto a cysteine residue of the AGT 
active site (39). 
In preclinical trials of O
6
-benzylguanine with the DNA alkylating agent 
temozolimide, mouse melanoma xenografts showed delayed tumour growth upon 
O
6
-benzylguanine treatment (39). Similar levels of delayed tumour growth were also 
observed with an additional DNA alkylating agent, carmustine (39).  
A Phase 2 clinical trial of O
6
-benzylguanine with carmustine has been 
reported measuring clinical response following previous chemotherapeutic treatment 
(37). In the chemotherapy naive cohort, 6% patients showed complete response while 
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22% showed stable disease (37). In the prior-chemotherapy cohort, only 17% of 
patients displayed stable disease (37). In addition, median overall survival of 
chemotherapy naive patients was recorded to be 211 days whereas this was only 120 
days for those with prior chemotherapy (37). Toxicity issues were also observed in 
both cohorts with 55-63% of patients showing grade 2 or 3 toxicity including 
neutropenia, thrombocytopenia and anaemia symptoms (37).  
Although AGT was depleted in all patients by O
6
-benzylguanine, the response 
rate was poor and was not significantly greater than that expected for higher dose 
carmustine alone (37). The authors for this study suggest that because O
6
-
benzylguanine augments toxicity of carmustine in all cells, a lower dose of 
carmustine is therefore required and is equivelant to a higher dose of carmustine 
alone (37). They also propose that with AGT depleted, an alternative pathway may 
be utilized for DNA repair (37). Further exploration of O
6
-benzylguanine and 
carmustine was not supported by the authors (37). That being said, the evaluation of 
O
6
-benzylguanine and temozolomide on melanoma remains to be assessed. 
 
1.2.3 Cisplatin 
Cisplatin (cis-diamminedichloroplatinum(II)) is generally regarded as 
ineffective against malignant melanoma. In clinical trials however, cisplatin was 
shown to have objective response in 10.4% of patients with 6% patients showing 
partial remission (40). Furthermore, in combination with other chemotherapeutics, 
response rates are often better. In combinational therapy, treatment of melanoma 
with cisplatin and dacarbazine showed response rates of 24-55% (41). Another 
combination which has shown promise is combination of cisplatin with amifostine 
(WR-2721) which protects normal tissues from the toxic effects of alkylating agents 
and cisplatin (42, 43). This combination was reported to show an objective response 
of 45% (42, 43). In a more recent study, the response rate was reported to be 23.3% 
compared to 16.3% for those receiving cisplatin only (44). The duration of response 
was 7.3 months (44). Taken together, the response rates of cisplatin against 
melanoma are poor; however they are comparable to dacarbazine which remains the 
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standard therapy for melanoma. Development of combinational therapy with 
cisplatin for the treatment of melanoma remains a possibility.  
 
1.2.4 Vemurafenib (PLX4032) 
The serine-threonine protein kinase B-RAF is found to be mutated in 40-60% 
of patients with malignant melanoma resulting in constitutive activation of the 
mitogen activated protein kinase (MAPK) pathway (18). In contrast, B-RAF is only 
mutated in 7-8% of most other cancer types (18). Vemurafenib (PLX4032) is an 
inhibitor of mutated B-RAF with selective potency against B-RAF harbouring the 
V600E mutation (34). Vemurafenib made headlines after successfully passing Phase 
1 and 2 trials in 2010 and then passed Phase 3 clinical trials in 2011 against 
malignant melanoma (18, 34).  Vemurafenib was subsequently approved for clinical 
use by the Federal Drug Agency (FDA) in 2011 (34).  
In the Phase 3 trials for vemurafenib against metastatic melanoma, 2107 
patients with unresectable stage 3C or 4 disease were screened for B-RAF status 
(34). Of these, 675 tested positive for B-RAF V600E and were subsequently 
randomized for treatment with either vemurafenib or dacarbazine (34). At 6 months, 
the overall survival for patients receiving vemurafenib was 84% whereas overall 
survival for those receiving dacarbazine was 64% (34). Furthermore, progression 
free survival was 5.3 months for those receiving vemurafenib and only 1.6 months 
for those receiving dacarbazine (34). In this study, most patients receiving 
vemurafenib had a decrease in tumour size with a 48% confirmed objective response 
rate and median time to response of 1.45 months (34). Of the vemurafenib group, 10 
patients were later discovered to harbour a V600K mutation, and 40% of these had 
shown a partial response (34). In comparison, most patients treated with dacarbazine 
showed no detectable decrease in tumour volume and only 5% had a confirmed 
response (34). In addition, the median time to response was 2.7 months (34). 
Although vemurafenib shows significantly better response rates than 
dacarbazine, there are increased side effects associated with this treatment. In Phase 
3 clinical trials, adverse side effects lead to dose modification or interruption of 
treatment in 38% of patients, predominantly due to cutaneous events, arthralgia, 
fatigue or photosensitive skin reactions (34). In 18% of patients, cutaneous 
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squamous-cell carcinoma, keratoacanthoma, or both developed (34). In patients 
receiving dacarbazine alone, dose modification or interruption of treatment only 
occurred in 16% of patients, predominantly due to fatigue, nausea, vomiting and 
neutropenia (34). 
In a long term follow-up of the Phase 2 clinical trial at a median follow-up 
time of 12.9 months, the confirmed overall response rate was 53%, of which 6% of 
patients showed complete response (45). Furthermore, they showed that the median 
duration of response was 6.7 months and the median progression free survival was 
6.8 months (45). In contrast to the Phase 3 study, they document 26% of patients 
treated by vemurafenib to develop cutaneous squamous-cell carcinoma or 
keratoacanthoma (45). Median overall survival was assessed to be 15.9 months (45). 
 
1.2.5 Mechanisms of vemurafenib resistance 
During vemurafenib treatment, it is known that resistance eventually 
develops despite inhibition of mutant B-RAF (46, 47). This is known to correlate 
with an increase of RAS-GTP, C-RAF and p-AKT (46). Furthermore, sequencing 
has revealed that an additional acquired mutation occurs in K-RAS (K117N) (46). 
Research shows that overexpression of K-RAS harboring the K117N mutation in 
melanoma cell lines resulted in a 5-7 fold increase in vemurafenib resistance (46). 
Mutations of K-RAS are known to activate pathway signaling and thus it is likely 
this results in acute activation of C-RAF resulting in stabilization of C-RAF 
homodimers and thus downstream MEK activation (46). In vemurafenib resistant 
melanoma cell lines, siRNA directed against C-RAF resulted in a 5-7 fold increase of 
vemurafenib sensitivity whereas no effect was observed in vemurafenib sensitive cell 
lines (46). Overexpression of C-RAF in vemurafenib sensitive cell lines resulted in 
an 18 fold increase in vemurafenib resistance (46). 
An additional mechanism of vemurafenib resistance is thought to occur due 
to dimerization of aberrantly spliced B-RAF harboring the V600E mutation (47). In 
six out of 19 patients with acquired resistance to vemurafenib, splice isoforms of B-
RAF V600E allowed dimerization in a RAS-independent manor (47). This resulted 
in a 61kDa isoform of B-RAF V600E lacking exons 4-8 encoding a protein lacking 
the N-terminal region which negatively regulates the C-terminal kinase domain and 
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Ipilimumab is a human IgG1 monoclonal antibody therapy that specifically 
blocks the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) which acts as a 
negative regulator of T-cell activation and proliferation. Inhibition of CTLA-4 
facilitates lymphocyte infiltration into the tumour leading to tumour cell death (48, 
49).  In 2011, ipilimumab was the first new drug since dacarbazine to be licensed for 
use against melanoma by the Federal Drug Agency (FDA) and European Medicines 
Agency (EMA) (48, 50). In April 2012, use of ipilimumab in Scotland was prevented 
by the Scottish Medicines Consortium (SMC) citing that the cost of treatment in 
relation to the health benefits and economic case was not sufficient to gain 
acceptance by the SMC. 
In a Phase 3 clinical trial studying the effects of ipilimumab and a glycoprotein 
100 peptide vaccine in a randomized double-blind study, it was shown that 
ipilimumab is active against melanoma (51). This vaccine was used as an active 
control and is derived from the melanosomal protein gp100 (51). In monotherapy, 
gp100 illicts an immune response but has limited antitumour activity (52). However 
it has been shown to improve efficacy of high-dose interleukin-2 therapy in 
metastatic melanoma (53). They observed median overall survival of patients 
receiving ipilimumab and the gp100 vaccine to be 10.0 months, ipilimumab alone to 
be 10.1 months and the gp100 vaccine only cohort to be 6.4 months (51). This 
resulted in overall survival of patients receiving ipilimumab to be 45.6% at 12 
months reducing to 23.5% after 24 months (51). For those receiving only the gp100 
vaccine, this corresponded to only 25.3% at 12 months and 13.7% at 24 months (51). 
These observations are consistent with the Phase 2 trial of ipilimumab monotherapy 
on melanoma (54). In addition, for those receiving ipilimumab only versus gp100 
only, a 36% reduction in risk of progression was observed (51). Furthermore, in the 
Phase 3 study, ipilimumab was assessed to have a 10.9% overall response rate with 
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stable disease in a further 17.5% of patients (51). Of the responders, 60.0% continued 
to show objective response for at least 2 years of treatment (51). 
Side effects of ipilimumab treatment have been reported in 60% of patients 
with 10-15% of patients showing grade 3 or 4 symptoms (51). In the main side 
effects are immune-related with events often affecting the skin or gastro-intestinal 
tract (51). Side effects include diarrhoea, vitiligo, colitis, anorexia, fatigue, 




Sorafenib is a multikinase inhibitor with known activity against RAF, VEGF, 
c-Kit and Ret kinases (55). In melanoma therapy, sorafenib has been shown to have a 
limited objective response rates of only 16% in patients and only show stable disease 
(56). More recently however, various clinical trials with sorafenib have focused on 
combinational therapeutic strategies with the aim of achieving greater response rates. 
These include combinations with dacarbazine (57, 58), carboplatin and paclitaxel 
(55, 59). 
In Phase 1 and 2 clinical trials, combinational therapy of sorafenib and 
dacarbazine has been shown to have an objective response rate of 12% with the 
median time to response of 48 days, and a median response of 46.7 weeks (58). An 
additional 37% of patients showed stable disease with a median duration of 13.3 
weeks (58). In an earlier clinical trial, the overall response rate was assessed to be 
24% (57). Furthermore, this trial was of double-blind format and assessed 
progression free survival of combinational therapy to be 21.1 weeks versus 11.7 
weeks in the dacarbazine only cohort (57). That being said, no difference in the 
overall survival was observed between these two groups (57). 
Combinational therapy of sorafenib with carboplatin and paclitaxel has not 
been of clinical benefit (59). Although in Phase 1 clinical trials 62% of patients had 
stable disease or an objective response (55), this was not mirrored in a phase 3 
clinical trial (59). In this Phase 3 clinical trial looking at sorafenib, carboplatin and 
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paclitaxel as a second line treatment for melanoma, the progression free survival of 
sorafenib with carboplatin and paclitaxel was assessed to be 17.4 weeks and had a 
response rate of 12% (59). In the carboplatin and paclitaxel only cohort, the 
progression free survival was 17.9 weeks and had a response rate of 11% indicating 
no additional benefit conferred by sorafenib (59). 
 
 
1.3 DNA repair and the role of ERCC1-XPF 
The ERCC1-XPF heterodimer is a 5′-3′ structure-specific endonuclease that is 
involved in a number of DNA repair pathways in mammalian cells. It is essential for 
nucleotide excision repair (NER) and has important roles in interstrand crosslink 
(ICL) repair and double-strand break repair (DSBR). As such it has a key role in the 
response of cancers to a range of DNA-damaging chemotherapeutics. In the ERCC1-
XPF heterodimer, ERCC1 is catalytically inactive and instead regulates DNA and 
protein-protein interactions, while XPF provides the endonuclease activity and also 
contains an inactive helicase-like motif and is involved in DNA binding and 
additional protein-protein interactions.  
 
1.3.1 Overview of DNA repair mechanisms 
One of the main risk factors associated with melanoma is thought to arise from 
UVB radiation due to nucleic acids absorbing light within the 260-280nm 
wavelength (1, 60). DNA damage resulting from UVB radiation is categorised into 
two main subtypes, cyclobutane-pyrimidine dimers (CPDs) and 6-4 photoproducts 
(6-4PPs) (61). CPDs are the most abundant accounting for 75% of the lesions 
whereas 6-4 photoproducts account for 25% of lesions (61). Although CPDs are the 
more common, 6-4 photoproducts are more serious as they cause greater helical 
distortions. As shown in Figure 1.1, DNA damage resulting from UVB radiation is 
predominantly repaired by the nucleotide excision repair (NER) pathway. 
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Figure 1.1: Summary of DNA damaging agents and the repair mechanisms used to 
repair DNA damage. Figure from (62). 
 
1.3.2 ERCC1-XPF is essential for nucleotide excision repair 
UV irradiation-induced cyclobutane pyrimidine dimers (CPDs) and 
pyrimidine-(6,4)-pyrimidone photoproducts (6-4PPs), chemically-induced helix-
distorting and bulky DNA lesions are all repaired by NER (63). In vivo NER requires 
around 30 proteins, but the incision step can be reconstructed in vitro with just six 
core factors, XPC/RAD23B, XPA, RPA, TFIIH, XPG and ERCC1-XPF (64). To 
complete NER in vitro, PCNA, DNA polymerases δ, ε, and κ, DNA ligases I and III, 
RFC, RPA and XRCC1 are also involved. In global genomic NER (GG-NER) (65), 
DNA damage is recognised by the XPC/RAD23B complex which detects helical 
distortions rather than the lesion itself. This is shown in Figure 1.2. It is thought that 
XPC/ RAD23B binding induces further bending of the DNA which may act as the 
trigger for recruiting additional factors to the lesion. For recognition of DNA damage 
such as CPDs, which only mildly distort DNA, the XPE/UV-DDB complex is also 
 
 Chapter 1: Introduction 14 
required. In transcription-coupled NER (TC-NER) (66), repair is triggered when 
RNA polymerase II stalls at a lesion, resulting in recruitment of several proteins 
including CSA and CSB. Following either of these damage recognition steps, a 
common repair mechanism proceeds with recruitment of the TFIIH complex, 
containing XPB and XPD, which possess ATP-dependent helicase activities to 
unwind DNA around the damage site to form an open complex. XPA and RPA 
proteins are then recruited to stabilise the NER intermediate. XPA recognises a 
helical kink at the damage site (67) and acts as a scaffold for binding to TFIIH, RPA 
and ERCC1-XPF, while RPA binds to ss-DNA. ERCC1-XPF and XPG 
endonucleases are then recruited to incise the damaged DNA strand 5′ and 3′, 
respectively, to the lesion. Recruitment of ERCC1-XPF is thought to be mediated by 
both ERCC1/XPA and XPF/RPA interactions (68, 69). 
 
 
Figure 1.2: Figure showing the nucleotide excision repair pathway. (A) A bulky DNA 
lesion shown by the purple triangle is recognised by XPC-RAD23B. (B) This then facilitates 
recruitment of the TFIIH complex. (C) The lesion is verified by XPD allowing recruitment 
of XPA, RPA and XPG. (D) The ERCC1-XPF complex is then recruited and incises the 
 
 Chapter 1: Introduction 15 
DNA 5′ to the DNA damage lesion. (E) XPG then incises the DNA 5′ to the DNA damage 
lesion and (F) repair is completed by Polδ/κ, PCNA and DNA ligase IIIα or ligase I. Figure 
from (70).  
 
1.3.3 ERCC1-XPF is involved in double-strand break repair 
(DSBR) 
Double-strand DNA breaks (DSBs), induced by ionising radiation, free radicals 
and chemotherapeutics, such as cisplatin, mitomycin-C and the topoisomerase 
inhibitor, etoposide, can be repaired by homologous recombination (HR), or non-
homologous end joining (NHEJ). While the main HR pathway is error-free, NHEJ 
involves the ligation of free DNA ends in a Ku70/Ku86-dependent process resulting 
in error-prone repair, due to addition or loss of bases, or to ligation of the wrong 
ends. The importance of ERCC1-XPF in DSBR was initially shown in budding 
yeast, where mutations in RAD10, or RAD1, the yeast orthologues of ERCC1 and 
XPF, suppressed HR (71). Mammalian cells with mutant ERCC1-XPF are sensitive 
to DSBs (72) and both the HR and NHEJ pathways for DSBR are attenuated (73–
75). The key activity of ERCC1-XPF in both types of DSBR is its ability to remove 
non-homologous 3′ single-stranded flaps at broken ends before they are rejoined 
(72). This is achieved in the error-prone RAD52-dependent single-strand annealing 
(SSA) subpathway of HR (76, 77) and in the mechanistically distinct RAD52 and 
Ku70/Ku86-independent microhomology-mediated end-joining (MMEJ) subpathway 
of NHEJ (72, 78, 79). 
 
1.3.4 ERCC1-XPF is involved in interstrand crosslink repair 
ICL repair operates to remove crosslinks induced by chemotherapeutics such as 
cisplatin, psoralens and mitomycin-C (80). Such lesions are particularly toxic since 
they prevent helix unwinding and so act as a potent block to transcription and 
replication. A review of the sensitivity of mammalian NER mutants to ICL agents 
found that, while all NER mutants were more sensitive than wild-type cells, mutants 
in ERCC1 or XPF were in general hypersensitive (80). In eukaryotes the mechanism 
of ICL removal depends on the phase of the cell cycle during which the lesion is 
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encountered (81). If incision adjacent to an ICL occurs in G0 or G1 then repair may 
be completed during this stage. Alternatively, if the ICL persists into S phase it will 
be converted into a DSB when it causes replication to stall. Incisions are thought to 
be made to either side of the crosslink on one DNA strand to unhook the lesion and 
allow stalled replication complexes to proceed. The DNA is repaired by HR using 
the newly synthesised strand as template and may use a NER-dependent mechanism 
to remove the remaining lesion (82). Although the precise mechanism is not known, 
most models for ICL repair employ an ERCC1-XPF- dependent step (80, 81). 
Importantly, ERCC1-XPF is able to incise to either side of an ICL (83) and, although 
not the only nuclease involved, ERCC1-XPF has been shown to be required for both 
S-phase-dependent and -independent ICL repair (84, 85). 
 
1.3.5 Non-repair related roles for ERCC1 and XPF 
ERCC1-XPF is involved in telomere maintenance and the interactions made 
with the telomere protein, TRF2, are described in a later section. A role for ERCC1, 
but not XPF, in mitotic progression has been suggested by the observation that 
knock-down of ERCC1, but not XPF, in human hepatocellular carcinoma cells 
caused cell cycle delay and multinucleation (86).  This result is not readily 
reconcilable with the premature polypoidy observed in the livers of both ERCC1 
knockout (87) and XPF knockout mice (88) and could result from unrepaired 
endogenously generated interstrand crosslinks uncoupling the normal relationship 
between replication and cell division, rather than a non-repair related role for 
ERCC1. A similar role in mitosis, but this time for XPF, has been proposed from 
studies where knocking down XPF in cultured cells led to abnormal nuclear 
morphology and mitosis (89). XPF was found to interact and colocalise with the 
kinesin protein, Eg5 (89). Again the effect of XPF knock-down on mitosis could be 
indirect, resulting from unrepaired endogenous DNA damage rather than a direct role 
in mitosis. An alternative explanation perhaps made more likely by the observation 
that Eg5 boosted ERCC1-XPF activity in the standard in vitro assay. Recently a role 
for ERCC1-XPF has been proposed during transcription initiation (90, 91). Le May 
et al. propose a model whereby ERCC1-XPF and the NER machinery are required to 
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demethylate DNA in some promoter regions creating DNA strand breaks that 
facilitates the transcription factor CTCF (CCCTC-binding factor) binding and DNA 
loop formation (91).  
 
1.3.6 Nucleotide excision repair deficiency disorders  
Inherited defects in human NER genes result in rare syndromes such as 
xeroderma pigmentosum (XP), Cockayne syndrome (CS), or trichothiodystrophy. 
While XP is considered a repair syndrome, CS and trichothiodystrophy are regarded 
as transcription syndromes (63). Diagnostic features of XP are dry scaly skin, 
abnormal pigmentation patterning in sun-exposed areas and severe photosensitivity, 
resulting in >1000-fold increased risk of developing UV-induced skin cancers (26). 
In 20-30% of XP patients there is also progressive neurological degeneration, 
emphasising the importance of NER in repair of endogenous DNA damage (63). CS 
patients are also photosensitive, but do not exhibit pigmentation abnormalities, or an 
increased cancer risk (63, 26). CS patients also show developmental defects and 
neurological symptoms (63). In XP, GG-NER is always defective and TC-NER may 
also be affected, while in CS, TC-NER is lost, but GG-NER is retained (63, 26).  
Characterisation of the ERCC1 (92) and XPF genes (93, 94) made possible the 
identification of mutations in patients. Mutations in the ERCC1 or XPF genes can 
result in the even rarer XF-E syndrome (95). Patients show characteristics of XP and 
CS, but also exhibit additional neurologic, hepatobiliary, musculoskeletal and 
haematopoietic symptoms (95). In addition to a complete loss of TC- and GG-NER, 
cells derived from XF-E patients also show hypersensitivity to ICL agents due to the 
additional role of ERCC1-XPF in ICL repair (95). This distinguishes the XF-E 
syndrome from either XP, CS, or combined XP/CS (95). 
 
1.3.7 Patients with ERCC1-XPF mutations  
Only two patients with ERCC1 mutations have been observed: one (XP202DC) 
harbouring a Lys226X nonsense mutation with a IVS6-26G-A splice mutation, a 
second (165TOR) with a Gln158Stop mutation inherited from the mother and a 
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Phe231Leu mutation from the father (96, 97). XPF mutations have been 
characterised in 14 patients, 9 harbour an Arg799Trp mutation (96). This is proposed 
to be situated in an interaction domain between the XPF nuclease and ERCC1 central 
domains (98). An Arg153Pro mutation in the helicase-like domain may disrupt 
protein-protein interactions resulting in XF-E syndrome (95). Other mutations 
observed are Pro379Ser and Arg589Trp, both in the helicase-like domain (96). While 
it is yet to be shown for any of the XPF mutations that they actually disrupt specific 
protein-protein interactions, there is evidence that the Arg153Pro XF-E mutation 
results in the protein failing to reach the nucleus, probably due to  misfolding (99). 
The locations of ERCC1 and XPF mutations resulting in amino-acid substitutions are 
shown in Figure 1.3. 
 
1.4 The ERCC1-XPF structure-specific endonuclease 
The ERCC1-XPF complex is a structure-specific endonuclease which cleaves 
DNA at ds- to ss- junctions, nicking the ds- DNA on the 5′ strand 2 nucleotides from 
the junction (100). This structure-specificity was first demonstrated for RAD10-
RAD1, the yeast orthologues of ERCC1 and XPF (101). ERCC1-XPF is active in in 
vitro  endonuclease assays utilising a variety of substrates, including stem-loops and 
structures with 3′ overhangs (100). The minimum loop size required for cleavage is 6 
nt, but the preference is for larger, 22-40 nt loops (100, 102). 
 
1.4.1 Domain architecture of the ERCC1-XPF complex 
The ERCC1 protein is thought to have arisen from a gene duplication of XPF 
in the eukaryotic lineage (103). In Archaebacteria only XPF is present, forming 
homodimers with each protein containing nuclease and HhH2 domains. Archaeal 
XPF monomers interact primarily through HhH2 domains, with an additional 
interaction through the β5 strand of the nuclease domains (98). In addition to 
nuclease and C-terminal HhH2 domains, mammalian XPF also contains an N-
terminal helicase-like domain, but lacks residues essential for helicase activity (104). 
An overview of the ERCC1 and XPF domains is shown in Figure 1.3. The ERCC1 
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protein differs from XPF in that it contains a catalytically inactive central domain 
and lacks the helicase-like domain. ERCC1 mediates DNA binding and many of the 
protein-protein interactions of the ERCC1-XPF complex. The HhH2 domains of 
ERCC1 and XPF show a high degree of conservation (103, 105). In human XPF, the 
second HhH motif lacks the characteristic GhG hairpin, instead being replaced by a 




Figure 1.3: Domain architecture of ERCC1 and XPF proteins. The active site within the 
XPF nuclease domain is shown as a green box. Confirmed protein-protein interacting regions 
are mapped and identified with black text; undefined or unconfirmed protein-protein 
interactions are identified by grey text. Amino acid substitution mutations identified in XP or 
XF-E patients are also indicated. NLS, putative nuclear localisation signal. The same colour 
scheme shown here to identify the protein domains is used in all the Figures. 
 
1.4.2 Dimerisation of ERCC1 and XPF occurs through their HhH2 
domains 
The key protein-protein interaction of ERCC1 and XPF is the dimerization of 
their hydrophobic C-terminal regions to form a stable heterodimer through the 
double helix-hairpin-helix motifs in their HhH2 domains (105, 106). It is thought that 
during protein folding XPF acts as a scaffold for ERCC1 and that ERCC1 may be 
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unable to fold correctly in vitro in the absence of XPF (105). Without dimerization it 
was conventionally thought that neither protein was stable and each was rapidly 
degraded due to aggregation following exposure of their hydrophobic interaction 
regions (105, 107). However, recent siRNA experiments have indicated that, while 
XPF protein levels were decreased when ERCC1 was knocked down, the converse 
was not true (108). There is no catalytic activity in the absence of dimerization. 
Indeed, although the catalytic domain is within XPF and ERCC1 is catalytically  
inactive, ERCC1 remains indispensable for activity of the complex (105).  
 
1.4.3 What residues are essential for dimerization?  
The ERCC1 and XPF HhH2 domains have a 1534Å
2
, predominantly 
hydrophobic, interacting surface (105). Each domain forms five core α-helical 
structures (XPF: H1, 849-853; H2, 860-868; H3, 873-877; H4, 881-887; H5, 891-
903. ERCC1: H1, 233-240; H2, 247-257; H3, 260-265; H4, 268-272; H5, 280-288), 
with ERCC1 forming an additional α-helical structure in its N-terminus (ERCC1, 
226-229) (107). In both ERCC1 and XPF the H1 and H2 helices constitute the first 
HhH motif, with H4 and H5 constituting the second motif (105). From cross-
saturation techniques, XPF residues from Gln849 to Ala906 appear to interact with 
ERCC1 residues Arg234 to Leu294 (107). 
Two residues essential for interaction are XPF Phe905 and ERCC1 Phe293, 
which anchor the two proteins together (see Figure 1.4). ERCC1 Phe293 positions 
into a 280Å
2
 hydrophobic pocket on XPF (105). This interaction is protected by 
ERCC1 Leu294 which locks Phe293 in position (105). In mutational studies, deletion 
of ERCC1 Phe293 resulted in abolition of dimerization and enzyme activity (93, 
109). A reciprocal arrangement exists for the XPF Phe905 residue, which positions 
into a 220Å
2
 hydrophobic pocket on ERCC1, although no mutational studies have 
been performed on this XPF residue (105). In the human patient 165TOR, ERCC1 
encoded by the allele with the Gln158Stop mutation cannot form active protein due 
to its inability to heterodimerize. The second allele from this patient, with the 
Phe231Leu mutation, does produce functional protein. Reduced binding affinity for 
XPF Phe905, due to the Phe231Leu mutation in the ERCC1 interaction pocket, could 
 
 Chapter 1: Introduction 21 
explain the reduced levels of ERCC1-XPF complex and moderate sensitivity to UV 
and crosslinking agents observed in cells from this patient (97).  
 
 
Figure 1.4: Interaction of ERCC1 and XPF through their HhH2 domains. (A) 
Heterodimer of the HhH2 domains of ERCC1 (red) and XPF (blue). (B) Expanded cartoon 
representation of the region boxed on XPF, identifying key interacting residues in the XPF 
pocket for ERCC1 Phe293. (C) Expanded cartoon representation of the region boxed on 
ERCC1, identifying key interacting residues in the ERCC1 pocket for XPF Phe905. Figure 
created using PyMOL v0.99 with the ERCC1-XPF HhH2 domain crystal structure (PDB 
code 2A1J)(106). 
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1.4.4 How does DNA binding by the HhH2 domains influence 
endonuclease activity?  
It has been proposed that the ERCC1-XPF HhH2 domains form two 
independent binding sites to complex with ss-DNA (105, 106). This interaction is 
thought to be necessary for the proper orientation of ERCC1-XPF at the ds- to ss-
DNA junction (100). Tripsianes et al. monitored chemical shift perturbations upon 
DNA binding and found that both hairpin regions of ERCC1 contacted DNA, 
proposing that residues Val245 and Asn246 of the first HhH motif and Gly276, 
Leu277, Gly278 and Lys281 of the second hairpin interact with DNA (105). Under 
their experimental conditions, Tripsianes et al. could not detect DNA interaction by 
XPF (105). Similarly, Tsodikov et al. proposed DNA contacts to be made by ERCC1 
residues Lys243 and Lys247 of the first and Gly276 and Gly278 of the second HhH 
domains (106). In contrast however, they proposed XPF makes DNA interactions via 
Gly857, Lys861 and Gly889 (106). They showed that the recombinant ERCC1-XPF 
HhH2 domain complex binds with 6-fold preference to two ss-DNA strands over ds-
DNA and measured the binding affinity (KD) to be 0.2 µM (106). Interestingly, Su et 
al. showed that recombinant ERCC1-XPF protein harbouring ERCC1 Lys247Ala 
and Lys281Ala mutations had a 2-fold reduced DNA binding affinity and was 
inactive in vitro, whereas XPF harbouring Lys861Ala and Arg864Ala mutations had 
a 1.6-fold reduction in DNA binding affinity and retained in vitro activity (110). 
Furthermore, in vivo only the ERCC1 double mutant resulted in a mild NER defect, 
suggesting that defects in DNA binding of the ERCC1-XPF complex can be partly 
overcome by the other NER proteins (110). Das et al. utilised an XPF HhH2 
homodimer and demonstrated that this can bind ds-DNA and form a stable complex 
with ss-DNA (111). They showed that upon binding of two, 10 nt ss-DNA fragments 
to the homodimer, chemical shift perturbations were observed for XPF residues 
between Lys861 and Val870 and  proposed that Lys861, Arg864, Ser865, His868, 
His869 and Asn890 were directly involved in making DNA contacts (111). In 
addition, they showed that the bases are orientated away from the HhH2 domain with 
the exception of one base that orientates into a 140Å
2
 pocket in the XPF HhH2 
domain (111). This pocket is formed due to an altered conformation for Lys861 and 
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Asn890 upon DNA binding and proposed hydrogen bond formation with the side 
chain of Asn890 (111).  
 
1.4.5 A model for the structure of ERCC1-XPF bound to DNA 
Das et al. proposed a model for ERCC1-XPF whereby the ds- and ss- DNA 
binding of the ERCC1-XPF HhH2 domains position the complex at the ds- to ss- 
DNA junction, incorporating the nucleotide binding pocket that they mapped onto 
the XPF HhH2 domain in the XPF HhH2 homodimer crystal structure (111). In their 
model, the ERCC1 central domain does not make contact with DNA as shown by 
Tsodikov et al. (106, 112). In addition the non-cleaved DNA strand winds around the 
back of the ERCC1-XPF HhH2 domain before contacting the nucleotide binding 
domain and the model does not show how the central and HhH2 domains of ERCC1 
are connected. 
Bowles et al. showed in an in vitro endonuclease assay that ERCC1-XPF may 
have a sequence-specific preference for nucleotides immediately surrounding the 
cleavage site (102). As a result, they have also proposed a model whereby XPF 
contains a nucleotide binding pocket, but instead, although there is no evidence in 
support, they suggest that this may reside in the nuclease domain, rather than in the 
XPF HhH2 domain as shown above by Das et al. (111). Their very schematic model 
shows the helicase domain inside the loop of the stem-loop substrate DNA. The 
minimum loop size for ERCC1-XPF enzymatic activity is 6 nucleotides (100, 102). 
Based upon our homology model, the narrowest part of the XPF helicase-like domain 
would require a minimum loop size of approximately 12 nucleotides to be 
accommodated, so this model seems unlikely. In addition, in their model the ERCC1 
central and XPF HhH2 domains do not make the DNA contacts shown by Tsodikov 
et al. (106, 112).  
Using the published crystal structures, and homology models for ERCC1 and 
XPF domains, we propose an alternative model for how the ERCC1-XPF complex 
associates with DNA (113). This model takes into account all of the known protein-
protein, and protein-DNA interactions made by ERCC1 and XPF as published in the 
literature (113) (and reviewed in this introduction) (Figure 1.5). Unlike the other 
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models, our model also has the C-terminal end of each ERCC1 and XPF domain in 
close proximity to the N-terminal end of the next domain in the sequence. Similar to 
the other models, we show the ERCC1 HhH2 domain making contact with ds-DNA,  
however after the DNA strands have separated, we additionally show the ERCC1 
central domain also making contact with ss-DNA. With regards to XPF, instead of a 
nucleotide binding domain on the XPF central domain as suggested by Bowles et al. 
(102), we show the nucleotide binding domain to be present in the HhH2 region of 
XPF as demonstrated by Das et al. (111). We further propose that this is localised 
adjacent to the XPF nuclease domain and so may act to present the DNA backbone 
towards the XPF nuclease domain for catalysis. Our predicted structure of the XPF 
helicase domain has a clamp-like structure and, although there is no evidence to 
indicate how it is positioned with respect to the rest of the protein, we have shown it 
clamped around the nuclease domain with its RPA binding site in a suitable position 
to contact RPA bound to the non-damaged DNA strand. 
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Figure 1.5: Proposed model for ERCC1-XPF interaction with the DNA substrate. (A) 
Showing the ERCC1 HhH2  and central domains (red) and XPF HhH2 and nuclease domains 
(blue). DNA binding regions are shown in yellow; the XPF nuclease active site is shown in 
green; the nucleotide binding pocket on the XPF HhH2 domain is shown in orange; the XPA 
binding site on the ERCC1 central domain is coloured magenta. The ERCC1 nuclear 
localisation signal (ERCC11-98) and XPF domain linking regions (XPF666 and XPF825-847) are 
not shown as crystal structures are not available and there is insufficient sequence 
conservation for homology modelling. (B) Same view as in A, but with the addition of the 
proposed position of the XPF helicase-like domain and omitting the DNA substrate. The 
RPA binding site on the XPF helicase-like domain is shown in cyan. (C) As in B, but with a 
90
°
 anti-clockwise rotation of the ERCC1-XPF complex. (D) As in B, but with a 90
° 
clockwise rotation of the ERCC1-XPF complex. Figure created in PyMOL v0.99 using the 
ERCC1-XPF HhH2 domain crystal structure (PDB code 2A1J)(106), the ERCC1 central 
domain crystal structure (PDB code 2A1I)(106) and PHYRE-generated homology models of 
the XPF endonuclease and helicase-like domains. The model was created by firstly 
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identifying the known interacting regions on each domain, and then positioning each domain 
such that their known biological role could be performed while facilitating known 
interactions. The length of protein domain linker regions were also taken into account. 
 
1.4.6 Do ERCC1 and XPF interact through regions other than their 
HhH2 domains?  
It is unclear whether the XPF nuclease domain interacts with the central 
domain of ERCC1, similar to the nuclease domain interactions observed with 
Archaebacterial XPF (106). In several studies stable interactions between these 
domains did not form, although transient interactions cannot be excluded (109, 106). 
In support of this notion, the XPF patient carrying the Arg799Trp mutation exhibited 
5-fold decreased NER activity due to ERCC1-XPF instability. Based on sequence 
alignments to Archaeal Hef (similar to human XPF), Nishino et al. mapped the 
Arg799Trp mutation to the middle of the β5 strand of the XPF nuclease domain, 
proposing an interaction with the ERCC1 central domain (98). Further evidence is 
required to prove the existence of this interaction in human ERCC1-XPF.  
 
1.4.7 Are human XPF homodimers of functional significance? 
XPF HhH2 interaction domains form homodimers in vitro mimicking the 
homodimerisation of Archaeal XPF (114). In mixtures of ERCC1 and XPF HhH2 
domains at ambient temperatures the heterodimer is the predominant form, but at 
temperatures over 50˚C ERCC1 HhH2 domains aggregate leaving XPF HhH2 
domains to homodimerise. It has been proposed that XPF homodimers may act as an 
inactive storage complex in cells to protect against the risks of non-specific DNA 
cleavage (107). However, if human XPF does form homodimers in vivo it must be at 
very low levels since, in ERCC1-deficient cells, or after ERCC1 siRNA knockdown, 
only low levels of XPF are found (103, 108). 
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1.4.8 The XPF nuclease domain 
The nuclease site of the ERCC1-XPF complex has been mapped to XPF 
residues 681-751, it contains a V/IERKX3D motif conserved between XPF protein 




 as a metal co-factor (115). The presence of 
the metal is not necessary for DNA binding and does not alter the DNA binding 
affinity.  
 
1.4.9 Key residues for catalytic activity  
Active site mutations identified Asp687, Asp715, Lys727 and Asp731 as 
essential for catalytic activity, whereas mutation of residues Arg689 and Arg726 
resulted in residual activity (115). Asp687, Glu690, Asp715 and Glu725 have all 
been directly implicated in metal binding (115). Enzlin and Schärer proposed that 
residues Asp687 and Asp715 coordinate metal ion binding and residue Asp731 may 
function to activate a water molecule to act as a nucleophile for phosphodiester bond 
hydrolysis (115). Mutation of residues Glu690 and Glu725 led to reduced nuclease 
activity in the presence of Mg
2+
 but not Mn
2+
, suggesting an altered active site 
incompatible with the greater stringency requirements for Mg
2+
 compared to Mn
2+
 
binding (115). This suggests that the biologically relevant metal cofactor is Mg
2+
 , 
but in in vitro ERCC1-XPF endonuclease assays Mn
2+
 is the preferred metal (102, 
106). Although an Arg689Ala mutation resulted in residual nuclease activity in vitro, 
activity was retained in vivo but with a shifted incision pattern, suggesting that this 
residue may be involved in correct positioning of the substrate in the active site for 
incision (110). Positioning of key amino acids in the nuclease site of XPF is shown 
in Figure 1.6. 
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Figure 1.6: The nuclease domain of XPF. Cartoon representation of XPF identifying amino acids 
and their side chains. Residues Asp687, Glu690, Asp715 and Glu725 are implicated in metal binding 
(67). No metal ion has been shown. Figure created using PyMOL v0.99 with a homology model of 
XPF generated using the Protein Homology/analogY Recognition Engine v2.0 (PHYRE)(108). 
 
1.4.10 The XPF helicase-like domain 
The XPF helicase-like domain is related to superfamily-2 helicases, it 
comprises five sub-domains, but lacks critical residues essential for helicase activity 
(103, 104, 116). In the first of the Walker A motifs, usually required for ATP and 
DNA binding, the GKT consensus is not present (104, 117). The second Walker B 
motif lacks acidic residues present in the DEAD/DExH box motif, meaning that 
Mg
2+
 is unable to bind and catalytic activity is lost (104, 117). Instead,  it is thought 
that the helicase-like domain binds at the junction between ds- and ss-DNA and 
contributes to substrate specificity (103, 116). The presence of leucine-rich motifs 
indicates a potential role for protein-protein interactions (118, 119). An Arg153Pro 
substitution within this domain resulted in XF-E syndrome, with hypersensitivity to 
UV irradiation and ICL agents (95). Although hypersensitivity may have resulted 
from disruption of protein-protein interactions required for both NER and ICL repair, 
it is most likely this was due to XPF misfolding resulting from substitution of the 
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basic Arginine residue for the hydrophobic Proline. This is in agreement with the 
reduction in nuclear ERCC1-XPF levels observed (95).  
 
1.4.11 The ERCC1 central domain 
The ERCC1 central domain is weakly homologous to the XPF nuclease 
domain, but has lost the active site residues required for metal binding and catalytic 
activity (106). Instead, the ERCC1 central domain has acquired the ability to bind 
DNA and form additional protein-protein interactions, particularly with XPA to 
recruit the ERCC1-XPF complex for NER. Deletion of the first 91 amino acids of 
ERCC1 does not affect endonuclease activity, while deletion of an additional 11 
residues results in a loss of activity, although it is not known whether this is due to 
protein instability, or loss of a key interaction activity (93).  
 
1.4.12 Central domain binding to DNA  
The ERCC1 central domain surface has a V-shaped groove lined by basic 
(Arg106, Arg108, Arg144, Arg156) and aromatic (Phe140, Tyr145 and Tyr152) 
residues, thought to constitute both the DNA binding and XPA interaction domains 
(106, 112). Through chemical shift perturbations the DNA interacting region has 
been identified as residues Asn99, Ile102, Leu132, Lys213, Ala214 and Gln134 
(120). This region binds preferentially to ss-DNA in an orientation-dependent 
manner, with an 8-fold greater preference for 5' than 3' overhangs (106). In low salt 
conditions, the ERCC1 central domain binds ds-DNA with comparable affinity to ss-
DNA (106). However, at physiologically relevant salt concentrations, it has a binding 
affinity (KD) of 2.5-10µM for ss-DNA, while binding of ds-DNA is almost 
undetectable (106, 120). 
 
1.4.13 Central domain interaction with XPA  
The interaction between ERCC1 and XPA  maps to ERCC1 residues 92-119 
and XPA residues 59-114 (68, 121). In the XPA-binding domain on ERCC1, two 
motifs are present; a TGGGFI motif essential for binding, and an EEEEEEE motif 
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shown to be contributory, but not essential for interaction (121). Interestingly, the 
TGGGFI motif was not identified in any other mammalian proteins (112). Binding 
studies, with a truncated XPA59-93 peptide, confirmed the involvement of Gly72, 
Gly73 and Gly74 in the binding to ERCC1 (112). A second truncated XPA67-80 
peptide bound stably to ERCC196-214 in a stoichiometric 1:1 ratio, with a binding 
affinity (KD) of 0.78µM (112). 
An  XPA peptide bound to the hydrophobic V-shaped groove on ERCC1 with 
the Gly72, Gly73 and Gly74 residues of XPA forming a U-turn in the 1039Å
2 
ERCC1 binding site (112). A number of interactions between individual XPA and 
ERCC1 residues have been described at this binding site, although there are some 
differences in interpretation of the same crystal structure (112, 122, 123). There is 
main chain hydrogen bonding between XPA Gly72, Gly73 and Gly74 and adjacent 
ERCC1 residues and stacking of aromatic side chains, making the binding site an 
attractive candidate for small molecule ligands (see below). Furthermore, an XPA 
Phe75Ala mutation abrogates binding to ERCC1 (112). Tsodikov et al. and 
Tripsianes et al. have measured the binding affinity (KD) of XPA to ERCC1 to be 
540nM and 1µM, respectively (112, 120). 
 
1.4.14 Is simultaneous binding of ERCC1 to DNA and XPA 
possible?  
Interaction of XPA and ERCC1 is required for NER activity in vivo, 
confirming its role in recruiting ERCC1-XPF to DNA damage, but in vitro nuclease 
activity of ERCC1-XPF does not require XPA (112). It is controversial whether 
ERCC1 is able to bind DNA and XPA simultaneously. Tsodikov et al. used 
fluorescence anisotropy and measured competitive binding of XPA and DNA to the 
ERCC1 central domain (112). In contrast, Tripsianes et al. monitored chemical shift 
perturbations upon XPA binding, showing that the strongest response from ERCC1 
was in residues Leu139, Phe140 and Phe141 in the deep hydrophobic groove (120). 
In addition, other residues important for ERCC1/XPA interaction were Gln107, 
Asn110, Ser142, Arg144, Asn147 and Arg156 (120). Tripsianes et al. concluded that 
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XPA and DNA have distinct binding sites on ERCC1 and suggested that 
simultaneous binding is possible (120).  
 
1.4.15 How does the ERCC1-XPF complex associate with XPA? 
XPA binds at ds- to ss-DNA junctions and localises at the junction 5′ to the lesion to 
recruit ERCC1-XPF (124). However, in light of a model proposed by Das et al., 
positioning ERCC1-XPF at the DNA junction 5′ to the damage lesion (111), Shell 
and Chazin argued that, for steric reasons, XPA must instead localise to the 3′ DNA 
junction (125). For this latter model to be correct and for the ERCC1/XPA 
interaction to occur, both DNA junctions would need to be in close proximity. 
Instead, we propose that XPA binds at the 5′ DNA junction and recruits the ERCC1-
XPF complex, forcing the DNA junction to advance and so make space for ERCC1-
XPF to bind DNA. In support of this, partial unwinding of the DNA junction occurs 
in vitro facilitating XPF cleavage 2 nt upstream of the junction. This process could 
be driven by a domain rearrangement within ERCC1-XPF upon DNA binding, 
similar to that known to occur in Archaeal XPF (126).  
 
1.4.16 Mutation of the XPA binding site of ERCC1 affects NER but 
does not affect repair of interstrand crosslinks 
Endonuclease activity and DNA binding of the ERCC1-XPF heterodimer were not 
affected by ERCC1 mutations lacking the Asn110, Tyr145 and Tyr152 residues 
required for interaction with XPA (122). Proteins containing the XPA binding site 
mutations expressed in ERCC1-deficient cells failed to associate with XPA and were 
only able to partially restore UV resistance (122). However, expression of these 
mutant proteins in ERCC1-deficient cells fully restored resistance to mitomycin-C, 
cisplatin and ionising radiation (122), suggesting that the ERCC1/XPA interaction is 
required for NER, but not for ICL or DSB repair. Given that cisplatin causes mainly 
monoadducts and intrastrand crosslinks, which are both repaired by NER, in addition 
to the much less frequent, but more genotoxic, interstrand crosslinks that are repaired 
by a combination of endonucleolytic cleavage and HR, partial, rather than complete 
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restoration of cisplatin resistance by an ERCC1 protein that cannot interact with 
XPA would have been anticipated.  
 
1.4.17 Interaction of XPF with RPA  
During NER the ERCC1-XPF complex binds to the ss-DNA binding protein 
RPA, which protects the undamaged strand, in addition to XPA, but the RPA 
interaction is less well understood (69, 127–129). Using affinity columns, Bessho et 
al. demonstrated that XPA binds ERCC1, whereas interaction with RPA was 
mediated by XPF (69). Furthermore, in a pull-down assay ERCC1-XPF bound 
weakly to DNA and binding was unaffected by XPA addition (127). However, upon 
adding RPA, the ERCC1-XPF complex was recruited to DNA more efficiently (127). 
Mutant XPF constructs and a yeast two-hybrid approach showed that XPF binds to 
the p70 subunit of RPA via its N-terminus (128). In addition, XPF containing a 
Pro85Ser substitution was unable to interact with RPA, but still interacted with 
ERCC1 and retained nuclease activity in vitro, although the interpretation was 
complicated by the additional observation that the mutant XPF was mislocalised to 
the cytoplasm (128). XPF Arg86Ala and Thr89Ala substitutions may also inhibit 
interaction with RPA (128). Furthermore, addition of RPA increased specificity and 
activity of ERCC1-XPF cleavage of DNA in in vitro  endonuclease assays, whereas 
addition of XPA had no effect (127). When wild-type and Pro85Ser mutant XPF 
were expressed in XPF-defective CHO UV41 cells, only the control protein fully 
restored NER ability and UV resistance, suggesting that the XPF/RPA interaction is 
required for NER (127).  
 
1.5 Important non-NER related interactions of ERCC1-XPF  
1.5.1 XPF/SLX4 interaction in ICL repair 
Recent research has identified SLX4 (also known as FANCP) as a molecular 
scaffold for endonucleases SLX1, ERCC1-XPF and MUS81/EME1 to facilitate the 
processing of branched DNA substrates (130–135). The SLX4 scaffold may also 
bind additional factors, such as mismatch repair proteins MSH2/MSH3, telomere 
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binding proteins TRF2/RAP1 and polo-like kinase 1 (131). Depletion of SLX4 
induced hypersensitivity to DNA crosslinking agents, but not to UV-induced DNA 
damage (130, 136). In a comparison of SLX4- and ERCC1-deficient mouse 
embryonic fibroblast (MEF) cell lines with two Fanconi anaemia cell lines (FANCA, 
FANCC), where there is hypersensitivity to ICLs, the SLX4 and ERCC1 mutants 
showed the greatest sensitivity and only the ERCC1-deficient cell line also showed 
hypersensitivity to UV (136). 
Size exclusion chromatography indicated two cellular pools of ERCC1-XPF, 
one associated with the SLX4 complex and presumed responsible for the HR/ICL 
repair activities of ERCC1-XPF, and the other interacting with XPA and RPA and 
presumed responsible for NER (130). Direct interaction of the ERCC1-XPF complex 
with SLX4 has been demonstrated by yeast two-hybrid assays. The interaction is 
mediated within the N-terminal 669 residues of SLX4, probably through a conserved 
MLR domain, but the interaction domain on XPF is unmapped (130, 131). 
Expression of SLX4 lacking the SLX1 interacting motif (a C-terminal deletion 
mutant) in SLX4-deficient MEF cells was sufficient to complement hypersensitivity 
to mitomycin-C, while expression of SLX4 deficient in the interaction with XPF (N-
terminal deletion) was unable to complement mitomycin-C hypersensitivity, 
indicating the importance of  the SLX4/XPF interaction in ICL repair (136). 
Interestingly, an endonuclease assay, utilising a DNA stem loop to determine 
cleavage specificity of ERCC1-XPF and SLX4/SLX1, showed that SLX1 nicked ds-
DNA on the opposite strand to ERCC1-XPF (132).  
 
1.5.2 FANCG and the ERCC1 central domain 
FANCG-deficient cells are sensitive to ICL agents due to an inability to make a 
dual incision at the site of a crosslink (81). In a yeast two-hybrid assay the ERCC1 
central domain was reported to interact with FANCG, which forms part of the 
Fanconi anaemia core complex (137). The ERCC1/FANCG interaction is believed 
necessary to recruit ERCC1-XPF to the crosslink. Direct interaction of ERCC1 with 
FANCG could explain how XPF has previously been shown to colocalise with 
FANCA in cells, presumably through a ternary complex with FANCG (138). Site- 
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directed mutagenesis indicated that the FANCG/ERCC1 interaction occurred through 
tetratricopeptide repeats (TPR) in FANCG (137). Complementation of FANCG-
deficient cells with mutant FANCG proteins indicated that TPR 1, 2, 5 and 6 were all 
important in correcting sensitivity to the crosslinking agent mitomycin-C (139).  
 
1.5.3 MSH2 interaction with ERCC1 
Using a yeast two-hybrid approach it has been proposed that the mismatch 
repair protein MSH2 interacts with RAD10, the yeast homologue of human ERCC1, 
along with several other NER proteins (140). In humans, MSH2 forms a heterodimer 
with MSH6 (heterodimer known as MutSα), or MSH3 (known as MutSβ) (141). To 
facilitate repair, MutSβ recognises an ICL, then in association with ERCC1-XPF, is 
required for the initial processing and unhooking of the lesion (141). It is thought that 
the ERCC1/MSH2 interaction, involving  ERCC1 residues 184-260, is required for 
ICL repair and cisplatin resistance in an XPA-independent mechanism (142).  
 
1.5.4 RAD52 interaction with XPF 
ERCC1-XPF and RAD52 are important for single-strand annealing (SSA), a 
DNA double-strand break repair mechanism that involves annealing homologous 
single-stranded ends to bridge double-strand breaks (143). Direct physical interaction 
has been demonstrated between ERCC1-XPF and RAD52 in vitro (144). It is thought 
that the interaction promotes cleavage of 3′ overhangs allowing processing of non-
homologous ends for repair (143). XPF interacts with the N-terminal DNA binding 
region of RAD52 in a DNA-independent manner (144). RAD52 forms a heptamer 
around DNA and when a 6:1 ratio of RAD52:XPF is reached the endonuclease 
activity of ERCC1-XPF increases 3-fold. Super-stoichiometric amounts of RAD52 
inhibit XPF activity, presumably by binding to DNA and inhibiting ERCC1-XPF 
recruitment (144).  
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1.5.5 TRF2 interaction with ERCC1-XPF in telomere maintenance 
ERCC1-XPF is involved in telomere maintenance and it is thought that this 
occurs by its interaction with the TRF2 complex independent of DNA binding (145). 
To protect telomeres from being recognised as double-strand breaks, 3′ overhangs at 
the ends of chromosomes, known as G-strands, loop back and insert into duplex 
DNA to form t-loops (145). TRF2 promotes t-loops and associates with ERCC1-XPF 
at telomeres (145). In TRF2-deficient cells, a partial  loss of telomeres and associated 
3′ overhangs was observed that was dependent on ERCC1-XPF expression (145, 
146). Overhangs are retained in ERCC1-deficient cells following inhibition of TRF2, 
suggesting that ERCC1-XPF is the main nuclease responsible for 3′ overhang 
cleavage and is inhibited by TRF2 (145).  
Only a minor fraction (~1%) of ERCC1-XPF complexes with TRF2, while 
other proteins essential for NER did not associate, suggesting an NER-independent 
mechanism for ERCC1-XPF in telomere maintenance (145). As no direct interaction 
of ERCC1-XPF to TRF2 has been demonstrated, the interaction may occur through a 
tertiary complex. TRF2 can interact with SLX4 independently of XPF and it is 
therefore possible that interaction with XPF is through the SLX4 scaffold (131, 132).  
It has also been proposed that XPF may have a nuclease-independent role in 
negatively regulating TRF2-mediated control of telomeres (147). Mutant XPF 
proteins with nuclease site mutations deficient in endonuclease activity still localised 
with TRF2 and were able to complement TRF2-mediated telomere shortening in 
XPF-deficient cells, with activity similar to that of wild-type XPF (146, 147). 
However, nuclease activity of XPF is required for TRF2 binding to telomeric DNA, 
suggesting the mechanism of negative regulation of TRF2 by nuclease inactive XPF 
is due to ternary complex formation with TRF2, likely via SLX4 and inhibiting DNA 
binding (148). 
 
1.6 Aim of thesis 
The aim of this project was to identify novel compounds that could be beneficial 
for the treatment of malignant melanoma. Herein, we document our efforts to 
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perform both a phenotypic drug screen for novel compounds, and a targeted 
approach to identify inhibitors of the ERCC1-XPF complex. We utilise high 
throughput and in silico screening methods to identify compounds and utilise a range 
of biochemical, biophysical and cell culture techniques to validate compounds. 
In Chapter 3, we characterise the effect of standard chemotherapeutic agents on 
melanocytes and melanoma. Furthermore we perform a phenotypic drug screen to 
identify novel compounds active against melanoma. Finally, in this chapter we 
identify a class of nitrofuran compounds and demonstrate activity against melanoma. 
In Chapter 4, we identify ERCC1-XPF as a drug target to overcome 
chemoresistance to platinum based chemotherapy. We establish an in vitro 
endonuclease assay suitable for high throughput compound screening. Furthermore, 
we setup two specificity assays that can be utilised for screening compounds.  
In Chapter 6, we identify target sites on the ERCC1-XPF protein and collaborate 
with Professor Malcolm Walkinshaw from the University of Edinburgh to perform 
an in silico drug screen. We identify, and characterise ERCC1-XPF inhibitor 
compounds through a range of biochemical, biophysical and cell culture techniques. 
In Chapter 7, we perform further in silico screening and collaborate with Dr 
Barbara Saxty at MRC Technology to perform a high throughput screen and identify 
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2 Chapter 2: Materials and Methods 
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2.1 Materials 
2.1.1 General reagents 
Reagents obtained from MRC Human Genetics Unit general stores: 
1M Tris pH8.0 
5M NaCl 
20x TBE 
0.5M EDTA pH8.0 
Phosphate Buffered Saline: 140mM NaCl, 3mM KCl, 2mM KH2PO4, 10nM 
Na2HPO4 pH7.4. 
 
Reagents obtained from Sigma-Aldrich: 
1M MgCl2 (Sigma-Aldrich M1028-10x1ML) 
1M MnCl2 (Sigma-Aldrich M1787-100ML) 
1M KCl (Sigma-Aldrich 60142-100ML-F) 
1M CaCl2 (Sigma-Aldrich 21115-100ML) 
DTT: 10mM DL-Dithiothreitol (Sigma-Aldrich D0632). Stored at -20°C 
Dimethyl sulfoxide (DMSO) 
2-Mercaptoethanol (BME)  
N′-Tetramethylethylenediamine (TEMED) (Sigma-Aldrich T9281-25ML) 
Ammonium persulphate (APS) (Sigma-Aldrich 3678) 
Tween-20 (Sigma-Aldrich P9416)  
 
Consumables obtained from Greiner: 
Black 96-well plates (Greiner 655086)  
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Consumables obtained from Star labs: 
Solution basins (Star labs 25-0051N) 
 
Reagents from general lab supplies: 
Urea 
0.22µm syringe filters 
Formamide 
40% Acrylamide Bis-Acrylamide Solution (w/v Acrylamide 19:1 Bis-Acrylamide) 
Glacial acetic acid 





2.1.2 Mammalian cell culture 
Consumables obtained from Beckman Coulter: 
Coulter Isoton® II diluent (Beckman Coulter NC9343512) 
 
Reagents obtained from Invitrogen: 
Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen GIBCO® 41965) 
RPMI Medium 1640 (Invitrogen GIBCO® 11875) 
100x Non-Essential Amino Acids (Invitrogen GIBCO® 11140) 
100x Sodium Pyruvate (Invitrogen GIBCO® 11360) 
 
Reagents obtained from MRC Human Genetics Unit general stores: 
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Foetal Calf Serum (FCS) 
100x L-glutamine: 200mM L-glutamine 
200x Penicillin-Streptomycin: 7g/l Penicillin (10x10
8
U/l), 13g/l Streptomycin. 
Trypsin/Versene: 50% (v/v) Trypsin, 50% (v/v) Versene  
Trypsin solution: 2g/l Trypsin, 0.001% (v/v) Phenol Red, 0.06g/l Penicillin, 0.13g/l 
Streptomycin, PBS pH 7.8. 
Versene solution: 0.4g/l Sodium EDTA, 0.001% (v/v) Phenol Red, PBS 
 
Reagents obtained from Sigma-Aldrich: 
12-O-tetradecanoylphorbol-13-acetate (TPA) 
Freezing medium: Produced from supplemented cell culture medium with additional 
FCS (20% final) and 10% (v/v) DMSO. Freezing medium stored at -20°C prior to 
use. 
 
Cell lines used: 
Cell line Species Origin Source 
A375 Human Melanoma The European Collection of Cell 
Cultures (ECACC) 
HBL Human Melanoma Gentaur (Brussels, Belgium) 
SH5Y5Y Human Neuroblastoma Prof. D.J. Porteous Molecular 
Medicine Centre, University of 
Edinburgh 
PEO4 Human Ovarian Cancer Dr G.C. Sellar, Cancer Research 
Centre, University of Edinburgh 
MRC5v1 Human Fibroblast Prof. A.R. Lehmann. MRC Cell 
Mutation Unit, University of Sussex 
3-1-1-T1a  
(Ercc1 proficient) 
Mouse Melanocyte (149) 
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3-1-1-T1a cre neo #5  
(Ercc1 deficient) 
Mouse Melanocyte (149) 
Melan A Mouse Melanocyte Prof. D.C. Bennett. Biomedical 
Sciences Research Centre, 
University of London 
13-4-1  Mouse Melanocyte Melton group 
13-4-2  Mouse Melanocyte Melton group 
13-4-S1B-S1B2W Mouse Melanocyte Melton group 
PF20
T
 Mouse Fibroblast (150) 
 
2.1.3 Protein gel 
Tris-glycine running buffer: 192mM Glycine (Fisher G/0800/60), 25mM Tris (VWR 
103156X), 0.1% (w/v) SDS, pH8.3. 
Transfer buffer: 192mM Glycine (Fisher G/0800/60), 25mM Tris (VWR 103156X), 
pH8.3. 
4x Stacking Buffer: 492mM Tris-HCl, pH6.8. 
4x Resolving Buffer: 1.56M Tris pH8.8.  
5x protein loading buffer: 225mM Tris-HCl pH6.8, 5% SDS, 50% Glycerol, 0.05% 
(w/v) Bromophenol Blue (Sigma-Aldrich B5525). 
Fermentas PageRuler™ Plus Prestained Protein Ladder (Fermentas SM1811) 
Expedeon InstantBlue™ Coomassie Blue Satin (Expedeon ISB01L) 
 
2.1.4 Western blotting 
Merck Millipore Immobilon-P PVDF transfer membrane (Merck IPVH00010) 
TBS-T: 5mM Tris-HCl, 75mM NaCl, 0.05% (v/v) Tween-20, pH7.4. 
Blocking buffer: 10% (w/v) milk powder, TBS-T.  
Amersham ECL Plus Western Blotting Detection System (Amersham RPN2132)  
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Amersham Hyperfilm™ ECL (Amersham 28906837) 
 
Antibodies used: 
Target Protein Primary antibody  Secondary antibody  
ERCC1 FL297  
Rabbit polyclonal antibody 
1:1000 





XPF XPF Ab-5 (Clone 51) 
Mouse monoclonal antibody 
1:1000 






Mouse monoclonal antibody 
1:20000 






2.1.5 Sulphorhodamine B assay 
TCA Solution: Trichloroacetic acid (Sigma-Aldrich T4885-500G) prepared as 100% 
(w/v) stock solution and diluted to a 25% (w/v) TCA working solution. 
SRB solution: 0.4% (w/v) Sulphorhodamine B (Sigma-Aldrich S9012-5G), 1% (v/v) 
acetic acid solution. 
1% (v/v) Acetic acid solution: 1% (v/v) of glacial acetic acid (BDH reagents 10001)  
10mM Tris pH10.5: 10mM Tris (VWR 103156X), pH10.5. 
 
2.1.6 Propidium iodide FACS Assay 
Stock Solution: For 2 litres: 2000mg Trisodium Citrate, 121mg Tris Base, 1044mg 
Spermine Tetrahydrochloride, 2mL Nonidet NP40, pH7.6. 
Solution A: 10mg Trypsin in 500mL Stock Solution, Stored at -20ºC. 
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Solution B: 250mg Trypsin Inhibitor and 50mg RNAse A in 500mL Stock Solution, 
Stored at -20ºC. 
Solution C: 208mg Propidium Iodide and 500mg Spermine Tetrahydrochloride in 
500mL Stock Solution, Stored at -20ºC. 
 
2.1.7 Annexin V Apoptosis Assay 
eBioscience® Annexin V Apoptosis Detection Kit FITC (eBioscience® 88-8005) 
 
2.1.8 Standard ERCC1-XPF assay 
ERCC1-XPF: Purified recombinant ΔERCC1-XPF produced by Dr Martin Wear. 
See later for details of expression and purification protocols. Purified recombinant 
ΔERCC1-XPF stored on ice at 4°C. Protein remained stable for 1-2 weeks before 
significant breakdown observed. Protein remained active for ~6 months. 
Protein buffer: PBS pH7.4, 5% (v/v) Glycerol. 
ERCC1-XPF Buffer: Assay buffer prepared prior to use. See later for details. 
 
ERCC1 assay substrate 
ERCC1-XPF substrate 
(Purchased from ATDBio) 
6FAM-GCC AGC GCT CGG TTT TTT TTT 
TTT TTT TTT TTT TCC GAG CGC TGG C-
BHQ-1 
 
2.1.9 FEN1 assay 
FEN1: Recombinant human FEN1 protein purchased from Abcam (ab95382) and 
stored at -20°C in aliquots. Once thawed, FEN1 stored on ice for up-to 2 weeks. 
10x FEN1 buffer: 0.5M Tris pH8.0, 0.1M MgCl2, 10mM DTT, 0.1% (v/v) Tween-
20. Buffer aliquoted and stored at -20°C prior to use. 
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FEN1 assay substrates 
FEN1 assay specific substrates*  
(Purchased from Sigma-Aldrich) 
CAC GTT GAC TAC CGC TCA ATC CTG 
ACG AAC ACA TC-BHQ-1 
6FAM-GA TGT CAA GCA GTC CTA ACT 
TTG AGG CAG AGT CCG C 
GC GGA CTC TGC CTC AAG ACG GTA 
GTC AAC GTG 
ERCC1-XPF substrate 
(Purchased from ATDBio) 
6FAM-GCC AGC GCT CGG TTT TTT TTT 
TTT TTT TTT TTT TCC GAG CGC TGG C-
BHQ-1 
*FEN1 assay specific substrates annealed in 50mM Tris pH 8.0, 100mM KCl, 5mM 
MgCl2 by first incubating the mixture at 95
o
C for 5 min, followed by gradual cooling 
to room temperature. The annealed double-stranded DNA substrates were stored at -
20
o
C as 25µM stocks. 
 
2.1.10 DNase1 assay 
DNase1: Lyophilized Deoxyribonuclease 1 from bovine pancreas purchased from 
Sigma-Aldrich (Sigma-Aldrich DN25). Powder resuspended at 10mg/ml and stored 
in aliquots at -20°C prior to use. 
10x DNAse1 buffer: 0.5M Tris pH8.0, 0.1M CaCl2, 0.1M KCl. Buffer aliquoted and 
stored at -20°C prior to use. 
 
DNase1 assay substrate 
DNase1 assay specific substrate 
(purchased from ATDBio) 
6FAM-CCC-GGG-CCC-GGG-CCC-BHQ-1 
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2.1.11 DNA Sequencing Gel 
DNA formamide/EDTA sample buffer: 10mM EDTA pH8.0, 98% (v/v) formamide. 
BPB containing formamide/EDTA sample buffer: 10mM EDTA pH8.0, 98% (v/v) 
formamide, 0.05% (w/v) Bromophenol Blue (Sigma-Aldrich B5525).  
DNA marker: prepared using 0.4µM (final concentration) of the following DNA 
oligos. DNA marker stored at -20°C. For use on sequencing gels, DNA marker was 
diluted 10x in the appropriate enzyme reaction buffer then sample buffer was added.  
 
Name Source  Sequence 
6FAM Sigma-Aldrich 6FAM 
6FAM+6 Sigma-Aldrich 6FAM-GCC AGC  
6FAM+7 Sigma-Aldrich 6FAM-GCC AGC G  
6FAM+8 Sigma-Aldrich 6FAM-GCC AGC GC 
6FAM+9 Sigma-Aldrich 6FAM-GCC AGC GCT  
6FAM+10 Sigma-Aldrich 6FAM-GCC AGC GCT C 
6FAM+15 (DNase1 substrate) 6FAM-CCC-GGG-CCC-GGG-CCC-BHQ-1 
6FAM+24 (Gifted by Marion 
Walker) 
6FAM-CCCTGGGCTCTGTAAAGAATAGTG 
6FAM+36 (FEN1 substrate) 6FAM-GA TGT CAA GCA GTC CTA ACT 
TTG AGG CAG AGT CCG C 
6FAM+46 (ERCC1-XPF 
substrate) 
6FAM-GCC AGC GCT CGG TTT TTT TTT 
TTT TTT TTT TTT TCC GAG CGC TGG C-
BHQ-1 
 
2.1.12 Protein Crystallisation 
Crystallisation Screens obtained from Molecular Dimensions Inc. 
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JCSG-plus™ Screen (Molecular Dimensions MD1-37) 
Morpheus™ (Molecular Dimensions MD1–46/MD1–47) 
PGA-LM HT-96 Crystallization Screen™ (Molecular Dimensions MD1-51) 
Clear Strategy Screen™ I (HT-96) (Molecular Dimensions MD1-31) 
Clear Strategy Screen™ II (HT-96) (Molecular Dimensions MD1-32) 
Structure Screen 1 & 2 (HT-96) (Molecular Dimensions MD1-30) 
ProPlex (HT-96) (Molecular Dimensions MD1-42) 
Stura Footprint Screen™ + MacroSol™ (HT-96) (Molecular Dimensions MD1-43) 
 
Consumables obtained from Molecular Dimensions Inc. 
Greiner 24 well Combo Plate (SBS format) (Molecular Dimensions MD3-16) 
The MRC Crystallization Plate (Molecular Dimensions MD11-00) 
ClearVue Sheets (Molecular Dimensions MD6-01S) 
 
2.1.13 Biacore Surface Plasmon Resonance Assay 
Consumables obtained from Biacore 
Ni
2+
-nitrilotriacetic acid (NTA) sensor chips 
1-ethyl-3-(3-diaminopropyl) carbodiimide hydrochloride (EDC)  
N-hydroxysuccinimide (NHS)  
Running buffer: PBS pH7.4, 5% (v/v) Glycerol,  
 
2.1.14 Thermal Denaturation Assay 
BioRad iQ Real-Time PCR Plates (BioRad 223-9441) 
BioRad Microseal® ‘B’ Adhesive Seals (BioRad MSB-1001) 
5000x SYPRO® Orange Protein Gel Stain (Invitrogen S6650) 
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Protein buffer: PBS pH7.4, 5% (v/v) Glycerol,  
 
2.1.15 Size-exclusion chromatography 
Superdex-200 size-exclusion column 
Running buffer: 50mM Tris pH8.0, 50mM NaCl, 0.5mM MgCl2, 1mM BME, 
 
2.1.16 Compounds 
Cisplatin (Faulding Pharmaceuticals DBL®, 100mg/100ml) 
Oxaliplatin (Sigma-Aldrich O9512) 
Dacarbazine (Sigma-Aldrich D2390) 
Bio1E7 (Maybridge BTB05727, ACD Code:MFCD00276733) 
UCN-01 (Sigma-Aldrich U6508) 
Emodin (Sigma-Aldrich E7881) 





™ Library (Sigma-Aldrich LO1280) 
BIOMOL® Kinase Inhibitor Library (Enzo® Life Sciences BML-2832-0100) 
BIOMOL® Phosphatase Inhibitor Library (Enzo® Life Sciences BML-2834-0100) 
All compounds selected for follow-up from Sigma LOPAC
1280
™ Library were 
purchased direct from Sigma-Aldrich using the supplied product code.  
 
ERCC1-XPF Inhibitor Compounds 
ERCC1-XPF Inhibitor compounds typically purchased in 10mg aliquots and 
prepared to 100mM in DMSO. Compounds were aliquoted and stored at -20°C. 
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Compound Supplier Product Code 
UOE #1 Specs AK-918/43077820 






UOE #26 Specs AN-023/15595059 
UOE #44 Specs AP-845/41686949 
 
2.1.17 Software 
Adobe Photoshop CS4 for image analysis and image manipulation. 
ChemAxon Marvin Beans (64bt) Suite for compound structure viewing and drawing. 
DeLano Scientific PyMOL v0.99 for protein structure viewing and manipulation. 
FlowJo 7.6.4 for cell cycle and Annexin V assay analysis. 
ImageJ for Western Blot quantification. 
Microsoft Office 2010  
SigmaPlot 12.0 for graphical analysis of IC50 and thermal denaturation assays. 
SPSS Inc. 12.0 for statistical analysis. 
 
2.2 Methods 
2.2.1 Mammalian cell culture  
Cell lines were maintained using standard aseptic technique in a Class II 
biological safety cabinet. Cell culture flasks were incubated at 37°C in 5% CO2. 
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2.2.2 Maintenance of cell lines 
Cells were maintained in DMEM or RPMI supplemented with 10% FCS, Non-
Essential Amino Acids, Sodium Pyruvate, L-glutamine and Penicillin-Streptomycin. 
Ercc1 proficient and Ercc1 deficient mouse melanocytes were additionally 
supplemented with TPA. 
Cells were passaged every 2-4 days by removing cell culture medium, washing 
the cells in PBS, then incubating with the serine-protease trypsin for 5 minutes until 
cells were detached. Cells were then re-suspended in fresh medium and centrifuged 
at 1,300rpm for 5 minutes. The cell pellet was re-suspended in fresh medium for 
future culture or plating. Cells were routinely passaged at 1/4 to 1/16
th
 confluences 
dependent upon the cell line and culture period. 
 
2.2.3 Cryogenic storage of cell lines 
For cryogenic preservation of cells, cells were trypsinised and pelleted as 
described above then re-suspended in freezing medium. Cells were transferred to       
-70°C then subsequently transferred to liquid nitrogen stocks. Conversely to thaw 
cells, vials were rapidly warmed at 37°C then diluted in medium to dilute DMSO. 
Cells were centrifuged at 1,300rpm for 5 minutes to pellet cells and remove 
remaining DMSO, then re-suspended in cell culture medium before plating into a cell 
culture flask. Medium was changed 24 hours later or cultures were split if confluent.  
 
2.2.4 Counting cells 
Cell suspension was diluted 1:100 in Coulter Isoton® II diluent then counted 
using a Coulter Counter Z series. 
 
2.2.5 Compound preparation 
Compounds purchased for in vitro validation were solubilized in DMSO using 
standard aseptic technique. Compounds were then stored at -20
o
C in aliquots to 
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minimize freeze thaw cycles. Compounds were typically prepared at 100mM or at 
their highest DMSO compound solubility.   
 
2.2.6 Compound screening on cell lines 
To screen compounds on cell lines in either single or combined regimes, 
compounds were diluted in medium to 2x their maximum working concentration 
then added directly to the plate. For a concentration series, typically a 2-fold dilution 
series (100µl) would be performed in the assay plate with culture medium prior to 
the addition of cells (100µl). The DMSO concentration was maintained at less than 
0.75% DMSO to negate DMSO induced toxicity. A single cell suspension was 
prepared by trypsinisation and counted as above. Cells were added directly to the 
plate at a predetermined concentration. Plates were transferred to the incubator at 
37°C and 5% CO2 for a predetermined period then the assays were stopped as per the 
SRB protocol below. For A375 cells, 500 cells per well were incubated for 5 days. 
For 3-1-1-T1a cells, 1000 cells per well were incubated for 6 days. 
 
2.2.7 Analysis of IC50 data 
Analysis of IC50 data was performed using SigmaPlot 12.0. Data were fitted to 
a one-site competition algorithm using the following formula; 
 
In all cases, the maximum was constrained to 100% activity and the minimum was 
constrained to 0% activity. If data were not compatible with this algorithm, a 
sigmoidal dose-response curve algorithm with variable hillslope was utilized. This 
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2.2.8 Sulphorhodamine B assay 
96 well cell culture plates were fixed with 50µl 25% (w/v) TCA added directly 
to culture medium for 1 hour at 5°C, and then washed 10x with water using a 
Titertek® Handiwash 110 plate washer. Plates were dried at 60°C for 45 minutes or 
dried overnight at RT. Cells were stained with 50µl SRB for 30 minutes and then 
washed 4x with 1% acetic acid solution to remove unbound dye. Following drying, 
bound SRB dye was extracted in 150µl 10mM Tris pH10.5 and the plate was shaken 
for 1 hour at 600rpm using a Heidolph Titramax 1000. Plates were read using a plate 
reader at 540nm. 
 
2.2.9 Protein quantification 
Protein concentration was measured using the Pierce® BCA Protein Assay Kit. 
25µl of protein samples were added to a 96 well plate (if within the 0.025-2mg/ml 
assay detection limit) alongside known concentrations of Bovine Serum Albumin 
(BSA) standards. 100µl of prepared BCA was added per well and the plate was 
incubated for 30 minutes at 37°C and read at 562nm using a spectrophotometer. 
Protein concentrations were determined based upon the BSA standards curve.  
 
2.2.10 SDS-Page Gel 
Protein gels were prepared and run using the BioRad Mini-PROTEAN3™ 
electrophoresis system using a Tris-glycine buffering system. Either 10% 
Acrylamide or 16% Acrylamide gels were prepared dependent upon whether protein 
breakdown was expected. The top of the resolving gel was leveled using isopropanol, 
which was removed prior to the stacking gel being poured. Both gels were prepared 

















4x Buffer 2.5 2.5 1.25 ml 
dH2O 4.8 3.5 3.2 ml 
40% Acrylamide 2.5 4 0.5 ml 
10% SDS 100 100 50 µl 
10% APS 100 100 50 µl 
TEMED 10 10 5 µl 
 
Samples were mixed with 5x protein loading buffer and heated to 80°C for 5 
minutes before loading. Gels were run at 70V then increased to 120V when the 
proteins aligned at the interface between the stacking and resolving gels. 
 
2.2.11 Coomassie Staining 
Proteins were visualized by coomassie blue staining using Expedeon 
InstantBlue™ coomassie stain. Firstly the gel was removed from its glass plates then 
briefly washed in H2O. The gel was then placed into InstantBlue™ for 1 hour. 
Unbound dye was removed from the gel by washing in H2O. Gels were imaged using 
a flatbed scanner at 600dpi for electronic record. 
 
2.2.12 Western Blotting 
Proteins were transferred from SDS-Page gel onto an Immobilon-P PVDF 
transfer membrane using methods described by Towbin et al. (151). Transfer was 
performed using the BioRad Mini-Trans-Blot system at either 40mA overnight at 
4°C or at 400mA for 1 hour at 4°C using an icepack and magnetic stirrer. Following 
transfer, the membrane was removed from the cassette and washed for 5 minutes in 
TBS-T. Membranes were then placed in blocking buffer for 1 hour followed by a 
further three TBS-T washes. Membranes were then incubated with the primary 
antibody for the appropriate duration and conditions then washed a further 3 times in 
TBS-T. Membranes were then incubated with the secondary antibody for 1 hour at 
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the appropriate secondary antibody dilution then washed a further 3 times in TBS-T. 
Membranes were then incubated with ECL-plus chemoluminescent reagent for 1 
minute then visualized using autoradiography film or using the GE ImageQuant LAS 
4000 system. 
 
2.2.13 Propidium iodide FACS Assay 
The Propidium iodide Assay was performed in order to analyze DNA content 
in the cells. The method used was a modified version of that documented by 
Vindeløv et al. (152).  
To perform the assay, cells were plated in 35mm petri dishes then varying 
concentrations of cisplatin were added 24 hours later. After a predetermined 
treatment time, cells were harvested with trypsin and centrifuged. Cells were then 
washed with PBS and the pellet was re-suspended in 100µl citrate buffer. Cells were 
stored at -20°C until all samples were collected. Samples were processed by addition 
of 450µl of solution A for 2 minutes, 375µl of solution B for 10 minutes then finally 
250µl of solution C for 10 minutes. Samples were stored on ice prior to analysis. 
Cells were analyzed in collaboration with Elizabeth Freyer (MRC Human 
Genetics Unit Technical Services) using a BD Biosciences FACSAria™ II FACS 
machine. Data were analyzed using FlowJo v7.6.4.  
 
2.2.14 Annexin V Apoptosis Assay 
The Annexin V assay functions by use of a fluorescently labeled Annexin V 
dye which binds to phosphatidylserine proteins. Under normal conditions, 
phosphatidylserine is predominantly located in the inner leaflet of the plasma 
membrane and so is unavailable for dye binding. Upon initiation of apoptosis, 
phosphatidylserine translocates to the outer leaflet of the plasma membrane marking 
the cell as a target for phagocytes. Here, Annexin V FITC binds labeling the cell as 
undergoing the early phases of apoptosis. In combination with propidium iodide 
staining which is excluded from cells during the early stages of apoptosis, early stage 
apoptosis can be differentiated from from late stage apoptosis and necrotic cells.  
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To perform the assay, cells were plated in 35mm petri dishes with phenol red-
free medium then varying concentrations of cisplatin were added 24 hours later. 
After 48 hours treatment, cells were harvested by either cell scraper or detachment 
with trypsin and processed using the eBioscience® Annexin V Apoptosis Detection 
Kit. Briefly, cells were washed in PBS then 1x binding buffer before being re-
suspended at 1-5x10
5
 cells in 100µl 1x binding buffer. 5µl Annexin V FITC was 
added for 15 minutes then cells were washed with 1x binding buffer. Cells were then 
resuspended in 200µl binding buffer and stored on ice in the dark. Prior to analysis, 
cells were resuspended and 5µl propidium iodide staining solution was added. 
Cells were analyzed in collaboration with Elizabeth Freyer (MRC Human 
Genetics Unit Technical Services) using a BD Biosciences FACSAria™ II FACS 
machine. Data were analyzed using FlowJo v7.6.4.  
 
2.2.15 Recombinant ERCC1-XPF expression and purification 
Protein expression was performed by Ann-Marie Ritchie and protein 
purification was performed by Dr Martin Wear. Briefly, codon optimized ERCC1 
and XPF constructs were cloned into pET-28a expression vectors for expression in E. 
coli. Constructs were designed to contain cleavable N-terminal His-tags. Optimized 
expression conditions were determined by standard 3x3x3x2 matrix of expression 
conditions including heat/cold shock protocols resulting in 54 conditions tested per 
construct.  
Optimized expression conditions for the Δ95ERCC1 construct containing the 
ERCC1 central and HhH2 domains were in the BL21 (DE3) Star strain in LB 
medium with 1% glucose, heat/cold shock, 1mM IPTG, 15˚C O/N. Protein 
expression yield was 3-5mg/l and ~50% of ERCC1 protein was in the soluble 
fraction. Purification from scale up cultures of 2-4l was performed by 3-step process 
by IMAC (1ml IMAC FF), Gel filtration (Superdex 200) and Cation IEX (1ml SP 
HP). The immobilized metal ion affinity chromatography (IMAC) column was used 
to coordinate and purify his-tagged protein. The Gel filtration column was then used 
to further purify the sample to remove traces of remaining proteins by size exclusion 
chromatography. The final Cation IEX column was then used to further purify the 
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protein by ion exchange chromatography separating ΔERCC1 from any other 
remaining proteins based upon their ionic charge. Purified protein was deemed to be 
>95% purity with a final yield of ~1mg/l from the original culture. Protein was stable 
and existed as a soluble mono-disperse protein with the expected Mr of 22.78kD plus 
a 3.56kD N terminal his-tag. Optimized conditions for the Δ666XPF construct 
containing the XPF nuclease and HhH2 domains were expression in BL21 (DE3) Star 
strain in LB medium with 1% glucose, heat/cold shock, 1mM IPTG, 15˚C O/N. 
Protein expression yield was 5-7mg/l however only ~5% of XPF was in the soluble 
fraction. Refolding protocols resulted in >95% soluble protein with a final yield of 1-
2mg/l however the gel filtration indicated an apparent Mr of 150-180kDa rather than 
the expected Mr of 27.82kD with a 3.56kD N terminal his-tag. This was thought to 
resemble an octamer or XPF dimer in a TX-100 detergent micelle. XPF was unstable 
in the absence of detergent.  
Coexpression of ERCC1 and XPF was performed using Δ95ERCC1 cloned into 
the pET28a Kan
R
 and the Δ666XPF expression cassette recloned into an Amp
R
 
plasmid backbone. Purified protein was deemed to be >95% purity with a final yield 
of ~10mg/l from the original culture. Protein was stable and existed as a soluble 
mono-disperse protein with the expected Mr of 50.6kD plus the two N terminal his-
tags totalling 7.12kD.  
 
2.2.16 Standard ERCC1-XPF assay 
The ERCC1-XPF assay was performed in black 96-well plates at a final 
volume of 100µl. Each reaction contained 50mM Tris pH8.0, 50mM NaCl, 5mM 
MnCl2, 1mM BME, 100nM recombinant ΔERCC1-XPF protein and 200nM 
substrate. Assays were set up and run at RT. 
To screen compounds against ΔERCC1-XPF, assays were set up by first 
preparing compounds in the assay plate using a 2-fold dilution series with a 40µl 
final volume. DMSO concentrations were maintained at a maximum of 1%. 
ΔERCC1-XPF buffer was prepared fresh and 50µl was added to each well then 
mixed briefly on a plate shaker (20”, 600rpm). The assay was incubated for 30’ at 
RT to allow compound to bind to the ΔERCC1-XPF protein then 10µl of substrate 
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was added. Plate was read using PerkinElmer Victor 3 multilabel plate reader and 
analysed at 3 hours post substrate addition. Data were analysed using Microsoft 
Excel 2010 and IC50 values were generated using SigmaPlot 12.0 software. 
 
2.2.17 Pre-incubated ERCC1-XPF assay 
The pre-incubated ERCC1-XPF assay was performed in black 96-well plates at 
final volume of 100µl. Prior to reaction, ΔERCC1-XPF was incubated at RT in 1x 
reaction buffer for 72 hours. Each reaction contained 50mM Tris pH8.0, 50mM 
NaCl, 0.5mM MgCl2, 1mM BME, 50nM recombinant ΔERCC1-XPF protein and 
200nM substrate. Assays were set up and run at RT. 
To screen compounds against pre-incubated ΔERCC1-XPF, assays were set up 
as for the standard ERCC1-XPF assay (Section 2.2.14) except the plates were 
analysed at 1 hour post substrate addition. 
 
2.2.18 FEN1 assay 
The FEN1 assay was performed in black 96-well plates at a final volume of 
100µl. Each reaction contained 10µl of 10x FEN1 buffer, 20nM recombinant FEN1 
protein and 50nM substrate. Assays were set up and run at RT. 
To screen compounds against FEN1, assays were set up by first preparing 
compounds in the assay plate using a 2-fold dilution series with a 40µl final volume. 
DMSO concentrations were maintained at a maximum of 1%. 1x FEN1 buffer was 
prepared from 10x stock and recombinant FEN1 added. Tubes were mixed by gentle 
inversion. 50µl FEN1 buffer was added to each well and mixed briefly on a plate 
shaker (20”, 600rpm). Assay was incubated for 30’ at RT then 10µl of ERCC1-XPF 
assay substrate was added. Plate was read using PerkinElmer Victor 3 multilabel 
plate reader and analysed at 1 hour post substrate addition. Data were analysed using 
Microsoft Excel 2010 and IC50 values were generated using SigmaPlot 12.0 
software. 
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2.2.19 DNase1 assay 
The DNase1 assay was performed in black 96-well plates at a final volume of 
100µl. Each reaction contained 10µl of 10x DNase1 buffer, 0.5ng DNase1 protein 
and 200nM substrate. Assays were set up and run at RT.  
To screen compounds against DNase1, assays were set up by first preparing 
compounds in the assay plate using a 2-fold dilution series with a 40µl final volume. 
DMSO concentrations were maintained at a maximum of 1%. 1x DNase1 buffer was 
prepared from 10x stock and DNase1 was added following a 1:40 dilution from 
stock. Tubes were mixed by gentle inversion. 50µl DNase1 containing buffer was 
added to each well and mixed briefly on a plate shaker (20”, 600rpm). Assay was 
incubated for 30’ at RT then 10µl substrate was added. Plate was read using a 
PerkinElmer Victor 3 multilabel plate reader and analysed at 30 minutes post 
substrate addition. Data were analysed using Microsoft Excel 2010 and IC50 values 
were generated using SigmaPlot 12.0 software. 
 
2.2.20 DNA “Sequencing” Gel 
DNA sequencing gel was prepared from 5g urea, 5ml 40% acrylamide 
solution, 0.5ml 20x TBE and 0.7ml H2O. Gel was warmed to 80°C to dissolve urea 
then 0.22µm syringe filtered. 75µl APS and 7.5µl TEMED were added then a 1.0mm 
thick gel was cast with a 15 well comb using the Bio-Rad Mini-PROTEAN3 
electrophoresis system. No stacking gel was added. Electrolyte chambers were filled 
with 1x gel running buffer. 
Gel was pre-warmed at 15mA for 10 minutes prior to rinsing urea from wells 
and loading samples. Samples were prepared by mixing 10µl sample with 6µl sample 
buffer then heating to 80°C for 5 minutes before loading. Gels were loaded with 6µl 
sample buffer containing BPB in lane 1 and 6 µl DNA marker/sample buffer in lane 
2. Samples in subsequent lanes were prepared in sample buffer without BPB as this 
comigrated with 4nt DNA obscuring potential DNA bands. DNA fragments were 
separated by running at 15mA until BPB was ¾ of the way down the gel. DNA 
 
 Chapter 2: Materials and Methods 58 
sequencing gels were visualised using the GE Healthcare ImageQuant LAS4000 v1.0 
or FujiFilm FLA-5100 Fluorescent Image Analyser. 
 
2.2.21 Protein Crystallisation 
ΔERCC1-XPF protein crystallisation screens were set up using a 24 well 
vapour diffusion hanging drop format or 96 well vapour diffusion sitting drop 
format. 24 well screens were setup using 500µl reservoir solution and a 1µl protein: 
1µl reservoir solution hanging drop. The 96 well screens were setup using a Douglas 
Instruments Oryx8 crystallisation robot with 50µl reservoir solution and a 0.5µl 
protein: 0.5µl reservoir solution sitting drop. Screens were setup at 4°C and 18°C. 
Protein was concentrated to 10mg/ml prior to use and used within 5 days of 
production. 
 
2.2.22 BIAcore Surface Plasmon Resonance Assays 
The BIAcore Surface Plasmon Resonance (SPR) assay is a highly sensitive 
assay used to monitor molecular interactions in real time. It functions by exploiting a 
phenomenon called Surface Plasmon Resonance and occurs in thin conducting films 
at an interface between different refractive indexes. Under total internal reflection 
conditions, reflecting light causes an electric field intensity termed an evanescent 
wave field, which leaks across into the medium of lower refractive index. As such, at 
a certain angle of reflection a drop in intensity of light is observed, this is termed the 
SPR angle. Changes to the surface of the sensor chip caused by binding of small 
molecules to target protein on the chip, results in changes to the refractive index and 
can be measured as a change in the SPR angle. The change in angle is then converted 
to response units (RU).  This is shown in Figure 2.1. 
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Figure 2.1: Diagram showing the principals of the Biacore SPR assay. (A) Showing 
ΔERCC1-XPF bound to the sensor chip. Upon total internal reflection, the Surface Plasmon 
Resonance phenomenon causes a minimum in the reflected light known as the SPR angle. 
(B) The SPR angle can be measured. An inhibitor bound to ΔERCC1-XPF would change the 
refractive properties and alter the SPR angle.  
 
 The SPR assays were performed in collaboration with Dr Martin Wear using 
a BIAcore T100 machine. Assays were performed by first immobilising and 
covalently stabilising His-tagged ΔXPF or ΔERCC1-XPF proteins to a Ni
2+
-
nitrilotriacetic acid (NTA) sensor chip using a protocol developed by Wear et al. 
(153). Briefly an NTA sensor chip was Ni
2+
 primed with 25µl of 500μM NiSO4 at 5 
μl/min then the dextran surface carboxylate groups were activated with 20μl of 0.2M 
1-ethyl-3-(3-diaminopropyl) carbodiimide hydrochloride (EDC); 50mM N-
hydroxysuccinimide (NHS) at 5μl/min. His-tagged ΔXPF or ΔERCC1-XPF proteins 
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were then captured and covalently stabilized on the surface by injection at 25µl/min. 
Non-covalently bound proteins were removed from the surface using assay running 
buffer supplemented with 250mM EDTA at 20μl/min. 
 Compounds were initially examined in the BIAcore SPR assay using a single 
concentration screen and maintained at 1% DMSO. Following analysis and ‘hit’ 
identification, a concentration screen was performed using an 8 point, 2-fold dilution 
series of compound. Results were analysed using the software supplied with the 
instrument (v2.02, GE Healthcare). 
 
2.2.23 Thermal Denaturation Assay 
Thermal Denaturation Assays of ΔERCC1-XPF were performed on a modified 
BioRad IQ5 ICycler RT-PCR machine. This RT-PCR machine has been setup for 
Thermal Denaturation and use with the environmentally sensitive SYPRO Orange 
dye. Thermal Denaturation functions by proteins unfolding with increased 
temperature resulting in an increase in exposed hydrophobic regions of proteins. This 
results in a large increase in fluorescence from the SYPRO Orange dye when 
measured at an excitation of 485nm and emission spectrum of 575nm. 
TDA was performed in a 96 well plate format with a well volume of 50µl. 
Firstly additional protein buffer and then 5µM ΔERCC1-XPF were added to the 
plate. Protein buffer contained PBS with 5% glycerol and 1mM MgCl2. Compounds 
were then diluted and added at a 500µM final concentration. SYPRO Orange was 
added to the plate at 5x standard concentration (diluted from 5,000x stock). The 
wells were then mixed by gently pipetting and the plate was centrifuged at 4,000rpm 
for 5 minutes. Reaction plates were placed in the BioRad IQ5 ICycler RT-PCR 
machine and cycled from 20°C to 80°C with 30 second 1°C increments. Interaction 
of compounds with ΔERCC1-XPF was observed by a change in the transition 
melting temperature (ΔTm). Data were analysed using Microsoft Excel 2010 and Tm 
values were generated using SigmaPlot 12.0 software. 
 
 
 Chapter 2: Materials and Methods 61 
2.2.24 Size-exclusion chromatography 
Size exclusion chromatography was performed on ΔERCC1-XPF protein using 
a Superdex 200 size exclusion column. This column has a dynamic range of 10kDa 
to 600kDa and an exclusion limit of 1.3MDa.   
The size exclusion column had previously been calibrated by Dr Martin Wear 
with control proteins and a standard curve was adopted for these experiments. 
Standard curve was based upon: Protein (Velution)[Mr]: IgG (1.25ml)[150kDa]; BSA 
(1.5ml)[67kDa]; beta-Lactoglobulin (1.6ml)[18.4kDa]; Cytochrome-C 
(1.85ml)[12.3kDa]; Vitamin B12 (2.05ml)[1.4kDa]; Cytidine (2.2ml)[0.3kDa]; The 
total column volume (Vt) was 2.38ml and the column void volume (Vo) was 0.78ml. 
Protein samples were prepared by incubation at room temperature for 24 hours 
with, or without 200µM compound UOE #18. ΔERCC1-XPF was additionally 
loaded without preincubation. Size exclusion chromatography was performed by 
directly injecting sample onto the column with a 50µl/min flowrate in running buffer. 
Eluent from the column was subsequently collected in 50µl fractions into a 96 well 
plate. All experiments were performed at 4°C in refrigerated cabinets. Elution 
profiles were monitored and elution volumes were calculated. 
   
2.2.25 Protein structure visualisation  
Protein homology modelling was performed using the Protein 
Homology/Analogy Recognition Engine v2.0 (PHYRE
2
) (154).  
Crystal structures from the Protein Data Bank and predicted PHYRE
2
 protein 
models were visualised using PyMOL v0.99.  
 
2.2.26 In silico Drug Screening and Molecular docking 
In silico drug screening and molecular dockings were performed by Dr 
Steven Shave and Dr Douglas Houston from Professor Malcolm Walkinshaw’s 
Group. The first series of in silico screening, corresponding to Chapter 5 herein was 
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performed by Dr Steven Shave. The second series of in silico screening, 
corresponding to Chapter 6, was performed by Dr Douglas Houston. 
For the initial in silico ERCC1-XPF interaction screen, Dr Steven Shave used 
the ERCC1-XPF crystal structure (PDB code; 2A1J) to generate a series of site 
points mapping the target site on the XPF protein. He then used the Ligand 
Discovery at Edinburgh University (LIDAEUS) program (155) to screen the 
Edinburgh University Ligand Selection System (EDULISS) database (156). 
LIDAEUS is a rigid docking program used for high-throughput virtual screening and 
uses the EDULISS database of >5 million commercially available compounds as its 
compound library (155, 156). He then used the Ultra Fast Shape Recognition with 
Atom Types (UFSRAT) tool, which uses 48 descriptors defining molecular shape 
and electrostatic properties, to discover additional molecules capable of making 
similar interactions. This generated a list of ~460 compounds from the Chembridge, 
Maybridge and Specs dataset with similar structures to the defined sets of points. The 
compounds were then further screened using the program Autodock. The compounds 
were filtered to remove duplicate structures and by mlogP (if under 3.5 then there is 
an 80% chance of being soluble) to remove insoluble compounds. The final lists 




 LE = Ligand efficiency (kcal/mol/N) 
 R = Gas Constant (J/K/mol) 
 T = Temperature (K) 
 KD = Dissasociation constant (M) 
 N = Number of non-hydrogen atoms 
 
A similar in silico screen was performed for the XPF endonuclease domain. As no 
human XPF endonuclease domain crystal structure exists, a homology model was 
first created using the Protein Homology/Analogy Recognition Engine (PHYRE) and 
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optimised by energy minimisation with the GROMACS tool (154). In silico 
screening was performed on an Archaeal XPF homologue crystal structure (PDB 
code; 2BGW) and the homology model. 
 A second more elaborate in silico screen was subsequently performed by Dr 
Douglas Houston. Here a Combined Docking and Similarity Search (CODASS) 
programme was used. This process also utilised EDULISS and LIDAEUS and the 
top scoring 50,000 were screened again in a flexible docking programme (155, 156). 
The top scoring 100 were then run through a battery of similarity search algorithms 
creating a tailored database of 20,000 compounds. These were then rescreened 
through the flexible docking programme and the top scoring 5,000 rescreened in an 
iterative process. Finally, the top 5,000 were run through a second independent 
programme and were filtered in pose match and scoring algorithms to generate a list 
of 300 compounds.
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3 Chapter 3: Cell based drug screen for compounds active 
against melanoma 
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3.1 Aim of chapter 
The aim of this chapter was to understand the effect of standard therapeutics 
and identify novel therapeutics for the treatment of malignant melanoma. We aim to 
identify two classes of compounds using cell based screening methods, those which 
are selectively active against malignant melanoma, and secondly, compounds which 




3.2.1 Mechanism of cisplatin resistance 
Cisplatin is a platinum based chemotherapeutic agent known to have efficacy 
against a wide range of solid malignancies including testicular cancer, ovarian cancer 
and lung cancer (157, 158). Importantly, although initial response is often 
documented, resistance commonly occurs in a fraction of tumours which initially 
respond (157).  In malignant melanoma, cisplatin is predominantly ineffective from 
the outset.  
Cisplatin adducts result in helical distortions to the DNA and in doing so 
activate multiple DNA damage repair mechanisms, notably nucleotide excision 
repair and mismatch repair (157). Concurrent with this, cisplatin damage is known to 
result in arrest at the S and G2 phases of the cell cycle allowing an opportunity for 
the genome to restore integrity and facilitate cell cycle progression (157). Should 
repair not be possible, the onset of apoptosis follows (157). 
In response to cisplatin a wide range of signaling mechanisms are triggered 
notably activation of apoptosis through p53 and activation of stress response through 
the MAPK pathway (157). It is thought that activation of p53 occurs through a 
signaling cascade involving the ATM, ATR and CHEK1 proteins which then 
phosphorylate and stabilize p53 through serine 20 (157). This leads to nuclear and 
cytoplasmic effects that result in permeabilisation of the mitochondrial membrane or 
increased signaling of death receptors (157). It is also thought that activation of the 
 
 Chapter 3: Cell based drug screen for compounds active against melanoma 66 
MAPK pathway occurs through CHEK1 activation at various pathway branch points 
(157). 
One major mechanism of cisplatin resistance is through decreased 
accumulation of intracellular cisplatin levels and this can occur through a plethora of 
transporter proteins involved in both cisplatin influx and efflux (157). Two proteins 
involved in cisplatin accumulation which when aberrantly regulated in cancer result 
in decreased intracellular cisplatin levels are the copper transporter 1 (CTR1) protein 
and the multidrug resistant protein 2 (MRP2) (159, 160). Firstly, cisplatin uptake into 
the cells is known to occur through the CTR1 protein (159). As such, it has been 
shown that pretreatment of cells with copper, the main substrate for CTR1, results in 
a cisplatin protective effect (161, 162). In contrast, cells treated with copper chelators 
result in cisplatin accumulation and potentiation of cisplatin toxicity (161, 162). 
Secondly, it has been shown that ABC ATPase like multidrug resistance proteins, 
particularly MRP2, are responsible for the majority of cisplatin efflux (160, 163). As 
such, high expression of MRP2 mRNA has been shown to correlate with resistance 
to cisplatin while inhibition with siRNA reduced chemoresistance (163). 
Furthermore, patients harbouring polymorphisms of MRP2 in non-small cell lung 
carcinoma have been shown to have significantly increased response to platinum-
based chemotherapy (160). 
Cancer cells can also become resistant to cisplatin via increased efficiency of 
DNA repair or by increased coping strategies when DNA damage is present (157). 
One mechanism of increased DNA repair is through the NER pathway and as such, 
increased ERCC1-XPF endonuclease mRNA or protein levels have been implicated 
in response to cisplatin based regimes (157). It is also thought that the translesion 
synthesis is upregulated allowing transcription to proceed even in the presence of 
DNA damage lesions (157).  
Cisplatin resistance is a major problem for treatment of solid malignancies with 
platinum-based chemotherapy and novel chemotherapeutics are necessary to 
overcome resistance. In this chapter, we aim to identify novel compounds to 
potentiate the toxic effects of cisplatin in melanoma cells. Here we utilize a non-
targeted approach to identify novel inhibitors as a plethora of mechanisms exist that 
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may overcome cisplatin resistance including increased intracellular cisplatin 
accumulation, initiation of apoptosis, or by inhibiting DNA repair. 
 
3.2.2 Nitrofurans 
Nitrofuran compounds, including Nifurtimox, are the main frontline treatment 
for the parasitic infection Chagas disease (164). Chagas disease is the commonest 
parasitic infection of Southern America, resulting from infection by Trypanosoma 
cruzi (164). It is thought that nitrofuran compounds act as prodrugs undergoing 
enzyme based activation by nitroreductases (164). The nitroreductase family of 
proteins is sub-divided into two classes, Type 1 enzymes are oxygen insensitive and 
contain an FMN cofactor functioning by reducing the nitro-group using a two 
electron reduction reaction promoting DNA damage as shown in Figure 3.1 (164, 
165).  Type 2 nitroreductases are oxygen sensitive and contain FAD or FMN 
cofactors (164, 165). These enzymes act by reducing the nitro-group by a one 
electron reduction to generate an unstable nitro-radical which in the presence of 
oxygen undergoes futile cycling to generate superoxide (O2
-
) and regeneration of the 
parent nitro-compound, this is shown in Figure 3.1 (164, 165). In trypanosomes and 
bacteria, the Type 1 mechanism is utilized for nitrofuran activation whereas in 
humans, both Type 1 and Type 2 activation can be utilized (164). 
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Figure 3.1: Showing the mechanism of nitrofuran activation by nitroreductases. Type 1 
nitroreductases function by reducing the nitro-group by a two electron reduction reaction to 
form nitroso (2), hydroxylamino (3) and amino group intermediates (4). The Type 2 
nitroreductases function by reducing the nitro-group by a one electron reduction to generate 
an unstable nitro-radical (5) which in the presence of oxygen generates superoxide and the 
parent nirofuran (1) through futile cycling. In the absence of oxygen, the unstable nitro-
radical (5) can be reduced to the nitroso intermediate (2). Figure from reference (165). 
 
In human cells, nitrofuran compounds result in a significant increase in 
superoxide formation and result in increased DNA damage (164, 166). Additionally, 
in  alkaline comet assays following treatment with nitrofuran compounds, a dose 
dependent increase in the tail moment occurs indicating the formation of DNA single 
and/or double strand breaks (166). Furthermore, DNA damage is more potent on 
mitochondrial DNA rather than nuclear DNA (166).  
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In E.coli where nitrofuran activation occurs through Type 1 nitroreductases it is 
controversial whether nucleotide excision repair is the predominant mechanism for 
DNA damage repair (164, 167). In contrast to early research, Ona et al. show that 
E.coli harbouring NER defects were hypersensitive to treatment with nitrofuran 
compounds (167). Furthermore, they show that E.coli harbouring mutations in the 
translesion synthesis pathway, particularly Pol IV, were also hypersensitive to 
nitrofuran induced DNA damage (167). This suggests E.coli tolerates nitrofuran 
induced DNA damage by means of translesion synthesis and DNA repair by NER 
(167). It remains to be determined whether this is also the case in humans.  
 
3.2.3 Nifurtimox in neuroblastoma 
In 2006, a 5 year old patient with recurrent neuroblastoma who was 
unresponsive to salvage chemotherapy contracted Chagas disease (168). In addition 
to continued attempts with salvage chemotherapy, the patient was also administered 
Nifurtimox to treat Chagas disease (168). Upon this combination, the patient showed 
clinical response and the neuroblastoma went into remission (168). The clinical 
response of the neuroblastoma was attributed to the Nifurtimox treatment (168).  
Since then, Nifurtimox has undergone and passed Phase 1 clinical trials for 
relapsed or refractory neuroblastoma (169). A further Phase 2 clinical trial for 
refractory or relapsed neuroblastoma or medulloblastoma is currently under way with 
an estimated primary completion date in 2014. In addition, a study by Koto et al. has 
furthered the notion of Nifurtimox in cancer therapy showing that in combinational 
therapy with tetrathiomolybdate (which is an inhibitor of the cellular antioxidant 
protein, SOD1) it can act synergistically to increase cellular ROS and apoptosis in 
medulloblastoma (170).  
 Currently Nifurtimox is of considerable focus in neuroblastoma and 
medullablastoma due to impressive response rates such as reported in 2006 (168). 
We postulate that, as the precursor cells to neuroblastoma and melanocytes both arise  
from the neural crest lineage in early development, it may be possible nifurtimox will 
also be active on refractory or relapsed melanoma. In this chapter, we explore this 
theory further.  
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3.2.4 Role of melanin in response to UV and ROS  
The role of melanin in cells is thought be for the protection of cells from UV 
radiation (171). Two main forms of melanin exist, eumelanin and pheomelanin. 
Eumelanin is the most common and is a brown-black polymer. This differs 
structurally from pheomelanin which is less common and is red-brown in colour. 
Protection from UV by melanin has been proposed to occur through two distinct 
mechanisms, firstly by directly absorbing UV acting as a UV filter, and secondly by 
scavenging ROS formed upon UV radiation (171). As the mechanism of Nifurtimox 
induced DNA damage is due to formation of ROS during nitrofuran activation, it is 
proposed that melanin may also absorb nitrofuran induced ROS. Furthermore 
melanin, particularly pheomelanin, has been reported to act as a potent UVB 
photosensitizer by production of ROS upon UV light (171, 172). In this chapter, we 
explore whether nitrofuran compounds are also affected by melanin.  
 
3.3 Results 
3.3.1 Cell culture assay validation 
To investigate the effect cisplatin and other DNA damaging agents have upon 
melanoma cell lines a colourimetic Sulphorhodamine B (SRB) assay was validated 
for use (173). The cell lines chosen for the majority of experiments were the human 
malignant melanoma cell line A375, and Ercc1 proficient and Ercc1 deficient mouse 
cell lines. The Ercc1 proficient mouse melanocyte cell line (herein referred to as 3-1-
1-T1a) was previously generated by transformation of isolated primary melanocytes 
from an Ercc1
Flox/Flox
 mouse as described by Selfridge et al.(174). Following 
xenograft, cells were re-isolated with the histological and pathological appearance of 
mouse melanoma as described by Song et al.(149). An isogenic Ercc1 deficient 
derivative cell line was produced following Cre-mediated recombination (Ercc1 3-1-
1-T1a cre/neo #5) (149).  
The SRB assay was chosen due to the repeatability and robustness of this 
technique for compound screening. To maximise the therapeutic effect of compound 
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inhibition on our cell lines, it was considered that a 5-6 day culture period would be 
optimal. As such, to determine the optimal plating density, cells were plated at 
varying concentrations and monitored over a 4-6 day period. At each of the time 
points, cells were fixed by TCA as detailed in the SRB staining protocol. Fixed 
plates were stored until all plates were collected then they were stained and analysed 
together. As shown in Figure 3.2A, the optimal plating density for the 3-1-1-T1a cell 
line was deemed to be 1000 cells per well over an incubation period of 6 days. In 
Figure 3.2B, the optimal plating density for the A375 cell line was deemed to be 500 
cells per well with an incubation period of 5 days. 
To validate the assay for compound screening, the effect of DMSO on our 
cell lines was determined. As shown in Figure 3.2C, DMSO was plated at increasing 
concentrations on A375 cells and cell growth was monitored after 5 days. Here no 
effect was observed up to 0.75% DMSO. In all experiments, DMSO concentration 
was limited to 1% with a DMSO control and reduced to below 0.75% whenever 
possible.  
As results of assays would be expressed and interpreted relative to control 
growth values, it was important to determine whether SRB bound to cells 
proportionately to an increasing cell density. This would be expected as SRB binds 
the basic regions of cell surface proteins (173, 175). In Figure 3.2D, cells were plated 
at a known density then fixed shortly following cell adhesion. We confirm that 
binding of SRB to cells was linear with respect to cell density. 
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Figure 3.2: Validation experiments of the SRB assay.  (A) Showing the effect of 
increasing 3-1-1-T1a and (B) A375 plates cell number upon cell growth at 4, 5 and 6 days 
post plating. Growth was expressed as OD540 following SRB staining +/- SEM.  (C) 
Showing the effect of DMSO upon growth of A375 cells after 5 days (seeded at 500 cells per 
well into DMSO containing medium). Growth values expressed as percentage of non-treated 
control +/- SEM following SRB staining. (D) Showing A375 cells plated at a known density 
then fixed and stained with SRB following adhesion. Total SRB bound following staining of 
cells was measured at OD540.  
 
3.3.2 Effect of standard chemotherapeutic agents 
 We sought to observe the effect of common chemotherapeutics upon our cell 
lines and determine whether ERCC1 was required to repair the resulting DNA 
damage. For this, we chose to use the isogenic Ercc1 proficient and Ercc1 deficient 
mouse melanoma cells. As shown in Figure 3.3A, we also performed a toxicity curve 
of cisplatin upon the human A375 cell line showing an IC50 concentration of 0.5µM. 
As predicted, repair of DNA following cisplatin damage was dependent upon Ercc1. 
In Figure 3.3B, the Ercc1 deficient cell line was around 20-fold more sensitive to 
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cisplatin damage with the Ercc1 deficient cisplatin IC50 of 3.4±0.7nM, compared to 
56.5±3.4nM for the Ercc1 proficient cells. With oxaliplatin which has a similar 
mechanism of DNA damage but is less toxic, Figure 3.3C shows that the Ercc1 
deficient cell line was also 28-fold more sensitive to oxaliplatin treatment, with the 
Ercc1 deficient cisplatin IC50 of 26nM compared to 740nM for the Ercc1 proficient 
cells. This indicates that ERCC1 is required for the repair of DNA damage caused by 
both cisplatin and oxaliplatin. An analogous experiment was performed with the 
alkylating agent dacarbazine. In Figure 3.3D, the IC50 of the Ercc1 proficient cell 
line was 2.6µM compared to 2.4µM of the Ercc1 deficient cell line indicating no 
increased sensitivity was observed and confirming that DNA damage resulting from 
dacarbazine treatment does not require ERCC1 for repair. This is as predicted as 
dacarbazine is known to cause DNA damage requiring BER for repair, a pathway in 
which ERCC1 has no known role, thus no enhanced toxicity would be expected in 
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Figure 3.3: Showing the effect of chemotherapeutics upon cell lines. (A) Toxicity curve 
of cisplatin on the A375 cell line following 5 day drug treatment. (B) Toxicity curve of 
Cisplatin, (C) Oxaliplatin and (D) Dacarbazine on the Ercc1 proficient (3-1-1-T1a) and 
isogenic Ercc1 deficient (3-1-1T1a Cre Neo #5) cell lines. Growth values expressed as 
percentages of the non-treated control +/- SEM. 
 
3.3.3 FACS analysis in response to cisplatin treatment 
 We sought to determine if the typical G2/S-phase arrest in response to 
cisplatin occurred in melanoma. This ‘standard’ response is thought to occur due to 
increased interstrand crosslinks caused by cisplatin which holds DNA strands 
together thus preventing DNA replication and subsequent anaphase segregation of 
sister chromosomes. To assess cell cycle changes in response to cisplatin, a FACS 
assay using propidium iodide staining was employed. In Figure 3.4, three 
concentrations of cisplatin were chosen, 0.3µM cisplatin as this has little effect on 
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A375 cell growth rate, 1µM cisplatin as growth in response to this concentration is 
almost static and 3µM cisplatin which is toxic. As expected at 3µM cisplatin, 
significant growth arrest was observed with cells being arrested in S-phase and 
leading to a significant sub-G1 population, likely as a result of apoptotic cell death. 
At both 0.3µM and 1µM cisplatin following 24-hours of treatment, substantial 
increases in S and G2-phase populations were observed. At 48-hours and 72-hours of 
cisplatin treatment, the proportion of cells observed in S and G2-phase were reduced. 
This result was surprising. It is thought that this could represent a cisplatin induced 
change to the DNA repair or stress response pathways enabling the cells to better 
cope with cisplatin induced damage. It is hypothesised that this ‘recovery’ may be as 
a result of an increased expression of ERCC1-XPF in response to cisplatin, which is 
known to occur at the same time (176).  
We then sought to determine whether presence of ERCC1 would affect cell 
cycle progression following cisplatin treatment. As demonstrated in Figure 3.3B, the 
Ercc1 deficient melanocyte cell line is 20-fold more sensitive to cisplatin than the 
isogenic, Ercc1 proficient melanocyte cell line. As such, 100nM and 300nM cisplatin 
concentrations were chosen for the Ercc1 proficient cell line and lower 
concentrations of 10nM and 30nM were chosen for the Ercc1 deficient cell line. In 
Figure 3.5A, we show using the propidium iodide cell cycle analysis that in both 
Ercc1 proficient and Ercc1 deficient cells a G2 arrest and increased sub-G1 
populations are observed following cisplatin treatment. This observation was most 
pronounced for the 300nM and 30nM cisplatin concentrations. We then sought to 
determine whether this cisplatin induced sub-G1 population was as a result of 
apoptotic cell death in both cell lines. In Figure 3.5B, we show using Annexin V 
FACS analysis that after 48 hours cisplatin treatment of 300nM for the Ercc1 
proficient cells, and 30nM for the Ercc1 deficient cells, that cisplatin results in an 
Annexin V positive, propidium iodide positive Q2 population of 19% and 24% 
respectively indicating late apoptotic cells. This is concurrent with a much smaller 
increase in their Annexin V positive, propidium iodide negative (Q3) population 
indicating early apoptosis. Furthermore, in both cell lines, the Q1 and Q2 populations 
of the Annexin V staining is correlatable to the magnitude of the sub-G1 population 
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in the propidium iodide cell cycle assay. The increased sub-G1 population observed 
in the propidium iodide analysis can therefore be attributed to apoptotic cell death. 
 
 
Figure 3.4: Propidium iodide FACS analysis following cisplatin treatment on A375 
cells. Total DNA content was measured following 24, 48 and 72 hours treatment with 
increasing cisplatin concentrations. This experiment was performed in duplicate and results 
are representative of both repeats. 
 




Figure 3.5: FACS analysis of cisplatin treatment upon Ercc1 proficient (3-1-1-T1a) and 
Ercc1 deficient melanocytes (3-1-1-T1a cre/neo #5). (A) Showing propidium iodide 
staining for total DNA content following 48h cisplatin treatment. In this assay, all cells were 
collected and analysed. Gating was set to include the sub-G1 population. (B) Quantification 
of apoptosis by Annexin V staining following 48h cisplatin treatment. Shown are the 
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respective quadrants and the percentage of cells in each quadrant is shown. The Q1 quadrant 
represents necrotic cells, the Q2 quadrant represents late apoptotic cells, the Q3 quadrant 
represents early apoptotic cells and the Q4 quadrant represents live cells. Both experiments 
were performed in duplicate and results are representative. 
 
3.3.4 Phenotypic drug screen for novel compounds 
Utilization of zebrafish for phenotypic compound screening has many 
advantages. Firstly, this technique allows for the direct visualization of discrete 
tissues and organs in real time in a whole embryo by light microscope (177). 
Furthermore, screening is rapid with organ progenitors being visible from 36 hours 
post fertilization (hpf) and hatching occurring at 46-72 hpf (177). Independent 
feeding occurs at 5 days post fertilization (177). For assessing the effect of 
compounds on specific cell types in vivo, transgenic techniques where cells express 
GFP under the control of specific promoters can be utilized to label cells (177). In 
the case of the melanocytes, these can be directly visualized in wild-type embryos 
due to expression of melanin. A schematic figure showing a zebrafish pigmentation 
screen and tail regeneration screen is shown in Figure 3.6. 
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Figure 3.6: Phenotypic drug screen on zebrafish. Showing a schematic of a zebrafish 
screen. Zebrafish embryos are plated into 96-well plates. Compounds are added and the 
phenotypes are monitored. Screens commonly performed are pigmentation screens where a 
disappearance of pigmentation is sought or a regeneration screen following tail clipping. 
Figure from (177). 
  
A drug screen was established to discover two novel classes of compounds for 
the treatment of malignant melanoma. The first class of compounds we sought to 
discover were those which were specifically active on melanoma. To assess if 
compounds were specifically active on melanoma, and to assess general in vivo 
toxicity, data from our cell culture screen was compared to that from an in vivo 
zebrafish screen performed by a post-doctorate researcher of Dr Elizabeth Patton, Dr 
Nicholas Temperley. Comparing both in vivo and in vitro data would allow us to 
determine if the observed effect on the zebrafish melanocytes was due to direct 
interaction with the melanocytes rather than a melanocyte developmental defect. A 
schematic of the screening approach is shown in Figure 3.7A. 
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The second class of compounds were those which sensitise melanoma cells to 
cisplatin. The rational for this class was that Ercc1 deficient melanocytes were 20-
fold more sensitivity to cisplatin when compared to Ercc1 proficient melanocytes. 
Furthermore, deletion of ERCC1 in a melanoma xenograft experiment leads to 
sensitivity to cisplatin. Using our established cell culture model with the Ercc1 
proficient and deficient cell lines shown in Figure 3.3B, we decided to screen 
potential compounds on our Ercc1 proficient cell line in the presence and absence of 
10nM cisplatin. At this chosen concentration, should a compound replicate the 
enhanced sensitivity caused by a genetic deletion we would range from almost 
control growth to almost complete toxicity. In addition we opted to screen compound 
libraries at 10µM and 1µM. These concentrations were chosen to maximum our 
chances of finding compounds with activity taking into account differing potencies 
of the screened compounds.  
 For the screen, we initially opted to use the Sigma LOPAC
1280
™ Library. 
This library consists of 1280 compounds which are pharmaceutically active and have 
a known mechanism. Furthermore, this screen has the advantage that compounds can 
be readily purchased for compound validation. We subsequently also used the 
BIOMOL® Kinase Inhibitor and BIOMOL® Phosphatase Inhibitor libraries. These 
libraries contain 80 and 33 compounds respectively and have well defined activity as 
kinase or phosphatase inhibitors in key cell signalling pathways including the 
MAPK, PI3K, PTEN and NF-κB pathways. 
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Figure 3.7: Schematic of drug screening approach and summary of results (A) 
Schematic of drug screening approach. The zebrafish screening arm was performed by a 
post-doctorate researcher of Dr Elizabeth Patton, Dr Nicholas Temperley (B) Summary of 
compound validation. * indicates compounds which demonstrated contracted, or less 
melanocytes in zebrafish and reduced growth of melanoma in cell culture. ** indicates 
compounds showing more than 50% enhancement of cisplatin toxicity in melanoma in cell 
culture. 
 
To select compounds which were selectively active on melanocytes and thus 
may have activity against melanoma, we deemed compounds to be of interest if they 
met the following criteria; firstly they must have shown contracted or less 
melanocytes in the zebrafish screen; and secondly they must have shown toxicity in 
our cell culture screen as defined by <40% growth at either 1µM or 10µM. Using 
these selection criteria, we identified 19 compounds to be of interest. Subsequent 
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literature searches reduced this number to 5 compounds and these were then 
purchased for follow up validation. Compounds were deemed to be of interest in the 
literature search if activity against cancer, or on a pathway known to be active in 
melanoma had been published. Compounds of interest are shown in Table 3.1. The 
second selection criterion for compounds was those which enhanced the toxicity of 
cisplatin in our cells. Using this criterion, 5 compounds showed greater than a 50% 
increase in toxicity when combined with cisplatin. Following a literature search for 
activity against cancer, or activity on a pathway known to be active in melanoma, 
this was further reduced to 3 compounds and these were purchased for follow up 
validation. These compounds are shown in Table 3.2. The screening strategy is 
summarised in Figure 3.7B. 
 
3.3.5 Compound validation 
To validate compounds which showed specificity against melanocytes, we 
decided to perform two additional assays. The first was to determine the IC50 
concentration on the 3-1-1-T1a cell line following a 6 day incubation with the 
compound. The results of this experiment are shown in Table 3.1. The second assay 
performed was to screen each compound in a panel of cell lines and determine if 
there was cell line specificity against melanocyte or melanoma cell lines as 
determined by a lower IC50 on melanoma/melanocytes than the other cell lines 
tested. The cell lines chosen were the human melanoma A375 cell line, the human 
SH5Y5Y neuroblastoma cell line, the human PEO4 ovarian cancer cell line and the 
human MRC5v1 fibroblast cell line. In addition, the Ercc1 proficient mouse 
melanocyte cell line (3-1-1-T1a), the mouse Melan A melanocyte cell line and finally 
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Compound Name IC50 (µM) Cell line specificity? 
Roscovitine 5.0 No 
Chloro-APB hydrobromide 5.6 Yes 
Doxycycline hydrochloride 5.8 No 
Mephetyl tetrazole 30.2 No 
Tyrphostin AG 528  2.8 No 
Table 3.1: Summary of compounds showing melanocyte specificity in the compound 
screen. Summary of results from compounds selected for follow-up based upon selection 
criteria of contracted or less melanocytes in zebrafish and reduced growth of melanocytes in 
cell culture. IC50 calculated for 3-1-1-T1a cell line following 6 day drug treatment and 
growth assessed by SRB assay. Cell line specificity determined by plating against a panel of 
cell lines. 
 
Of the compounds purchased for follow-up based upon showing melanocyte 
specificity, only one compound showed an indication of cell line specificity in our 
follow up assay. As shown in Table 3.1, Chloro-APB hydrobromide was the only 
compound to display any specificity against melanoma. As shown in Figure 3.8A, 
Chloro-APB hydrobromide is more potent on the human melanoma and 
neuroblastoma cell lines when compared to the human ovarian and fibroblast cell 
line. However, in mouse cell lines as shown in Figure 3.8B, this specificity was 
reversed and it was more potent on the mouse fibroblast than melanocyte cell lines. 
Based upon conflicting results between species, it was decided not to proceed further 
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Figure 3.8: Cell line specificity of Chloro-APB hydrobromide. Toxicity curves of 
Chloro-APB hydrobromide on various cell lines. (A) Showing the effect of Chloro-APB 
hydrobromide on the growth of the human melanoma (A375), neuroblastoma (SH5Y5Y), 
ovarian cancer (PEO4) and fibroblast cell lines (MRC5v1). (B) Showing the effect of 
Chloro-APB hydrobromide on the growth of the mouse melanocyte (3-1-1-T1a and Melan 
A) and fibroblast cell lines (PF20). Growth values expressed as a percentage of the non-
treated control ± SEM. 
 
 In order to validate compounds which enhanced the toxicity of cisplatin as 
shown in Table 3.2, we first generated IC50 values against the 3-1-1-T1a cell line. 
We then chose three concentrations of approximately IC10, IC30 and up to the IC50 
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concentrations and plated these with cells in the presence and absence of 10nM and 
30nM cisplatin. At these cisplatin concentrations, we expected to observe an 
enhanced toxicity of the drugs. In these assays, no such enhanced toxicity was 
observed indicating these compounds were all false positives from the initial screen. 
No further work was carried out with these compounds. 
 
Compound Name IC50 (µM) 
Enhanced toxicity of 
cisplatin? 
Chlorprothixene hydrochloride 8.0 No 
PD 169316 5.2 No  
Terfenadine  2.5 No 
Table 3.2: Summary table of compounds which showed enhanced toxicity with cisplatin 
in the compound screen. Summary of results selected for follow-up based upon a selection 
criterion of more than 50% enhancement of cisplatin toxicity in melanocytes. IC50 
calculated for 3-1-1-T1a cell line following 6 day drug treatment and growth assessed by 
SRB assay. Enhancement of cisplatin toxicity assessed by co-treatment of compound with 
10nM or 30nM cisplatin on 3-1-1-T1a cells. Enhanced toxicity quantified by reduction from 
control growth in cisplatin alone as measured by the SRB assay. 
 
3.3.6 Bio1E7 is more potent than other nitrofurans 
 In parallel with screening the Sigma LOPAC
1280
 Library, work was carried 
out on a previously identified nitrofuran identified by Dr Hironori Ishizaki and Dr 
Elizabeth Patton, termed Bio1E7.  This had been identified in an earlier zebrafish 
screen and resulted in contracted melanocytes. Interestingly this compound also 
showed structural similarity to the antibiotic Nifurtimox used to treat Chagas disease 
and which is in clinical trials for neuroblastoma. 
 To characterise this nitrofuran compound, we first sought to determine its 
potency when compared to nifurtimox and other commercially available nitrofuran 
compounds. From Figure 3.9, it was clear that Bio1E7 is vastly more potent than the 
other nitrofurans tested. It was proposed that the common nitrofuran group is 
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Figure 3.9: Toxicity of nitrofuran compounds on A375 cells. (A) Showing effect of 
increasing nitrofuran compound concentration upon growth of A375 cells following 5 day 
treatment. Growth values expressed as a percentage of the non-treated control ± SEM. (B) 
Structure of Bio1E7, nifurtimox and other commercially available nitrofuran compounds. 
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3.3.7 The nitrofuran group is essential for activity 
To determine a structure activity relationship for Bio1E7, a collaboration with 
Linna Zhou from Dr Nicholas Westwood’s group at the University of St Andrews 
was established with Dr Elizabeth Patton. Here, Linna Zhou created a series of 
Bio1E7 derivative compounds. Upon testing in cell culture upon A375 and SH5Y5Y 
cells, all compounds showed similar toxicity levels and enhanced the toxicity of 
cisplatin except for compound NFN1.1. As shown in Figure 3.10B, compound 
NFN1.1 had no activity on A375 cells (or SH5Y5Y cells, data not shown) even at 
6µM, a concentration at which Bio1E7 is toxic. When considering the structural 
differences, NFN1.1 lacks the nitro group from the furan ring indicating that the 
intact nitrofuran functional group is essential for activity of these molecules. 
 
 
Figure 3.10: The nitrofuran group is essential for activity. (A) Showing the structure and 
activity of Bio1E7 on A375 melanoma cells. (B) Showing the structure and activity of 
NFN1.1 on A375 melanoma cells. Cell growth measured following 5 day drug treatment and 
analysed by the SRB assay. Values expressed relative to control growth +/- SEM.  
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3.3.8 Enhanced toxicity of Bio1E7 and cisplatin 
 It is thought that the mechanism of nitrofuran activity may involve production 
of superoxide resulting in DNA damage; as such we aimed to determine whether 
Bio1E7, would enhance the toxicity of cisplatin. To answer this, we chose to use the 
human melanoma cell line, A375, and the human neuroblastoma cell line, SH5Y5Y. 
Both cell lines showed similar toxicity to single agent treatment with either cisplatin 
or Bio1E7 (data not shown). As shown in Figure 3.11, growth values have been 
normalised to their respective cisplatin controls and thus account for the effect of 
cisplatin alone. Enhanced toxicity was observed with both cell lines. This 
corresponds to 31% and 32% enhancement (= growth reduction) at 0.1µM Bio1E7 
for the A375 and SH5Y5Y cell lines respectively. 
 After confirming that Bio1E7 could enhance the toxicity of cisplatin, we next 
sought to determine whether DNA damage induced by Bio1E7 required an ERCC1-
XPF dependent pathway for repair. To answer this, we utilised our Ercc1 proficient 
and Ercc1 deficient mouse melanocyte cell lines. As shown in Figure 3.12, a lower 
dose of cisplatin was used on the Ercc1 deficient cell line than the Ercc1 proficient 
cell line as Ercc1 deficient cells are hypersensitive to cisplatin. In addition, Figure 
3.12 shows that Bio1E7 is similarly toxic to both the Ercc1 proficient and deficient 
cell line. Had Ercc1 been required for repair of Bio1E7 damage, it would be expected 
that Ercc1 deficient cell line would be hypersensitive to Bio1E7. Furthermore, 
enhanced cisplatin toxicity was observed for both Ercc1 proficient and Ercc1 
deficient cells. Taken together, this shows that Bio1E7 toxicity and enhancement of 
cisplatin toxicity is independent of ERCC1-XPF and NER. 
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Figure 3.11: Enhanced toxicity of Bio1E7 and cisplatin on a melanoma and 
neuroblastoma cell line. (A) Enhanced toxicity of Bio1E7 and cisplatin on the A375 
melanoma cell line. (B) Enhanced toxicity of Bio1E7 and cisplatin on the SH5Y5Y 
neuroblastoma cell line. Growth of cells after 5 days treatment was measured by SRB 
staining and is expressed relative to their respective cisplatin controls. Results calculated 
from average of three independent experiments (+/- SEM). Statistical significance calculated 
by Mann-Whitney U Test (**, P<0.01).  
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Figure 3.12: Enhanced toxicity of Bio1E7 and cisplatin on an Ercc1 proficient and 
Ercc1 deficient cell line. (A) Enhanced toxicity of Bio1E7 and cisplatin on an Ercc1 
proficient (3-1-1-T1a) melanocyte cell line. (B) Enhanced toxicity of Bio1E7 and cisplatin 
on an Ercc1 deficient (3-1-1-T1a cre/neo #5) melanocyte cell line. Growth of cells after 6 
days treatment was measured by SRB staining and expressed relative to their respective 
cisplatin treated controls ± SEM.  
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3.3.9 Cell line specificity of Bio1E7 toxicity 
 Although Bio1E7 appears to show a melanocyte effect in zebrafish, it is 
difficult to determine whether this is specific for melanocytes as only the pigmented 
cells can be observed. To investigate whether Bio1E7 displays cell line specificity in 
cell culture, we assayed Bio1E7 against a panel of cell lines. Although Bio1E7 was 
generally more potent against mouse cell lines compared to human cell lines, we 
noticed that the presence of pigmentation may be protective against Bio1E7 toxicity. 
As such, a larger panel of cell lines was screened to include a greater number of 
pigmented lines. As shown in Table 3.3, the presence of pigmentation correlated with 
protection against Bio1E7 toxicity however level of pigmentation was not predictive 
of the level of sensitivity. Attempts were made to reduce pigmentation levels in our 
cell lines by inhibiting tyrosinase and melanin synthesis with phenylthiourea (PTU) 
to determine if sensitivity could be restored, however the level of pigmentation was 
not sufficiently altered to enable any conclusion about the reduction of pigment 
levels on Bio1E7 sensitivity (data not shown). 
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Cell line IC50 (µM) 95% CI Cell Type Origin Pigment 
MRC5v1 0.39 0.19 to 0.79 Fibroblast Human No 
A375 0.71 0.50 to 1.02 Melanoma Human No 
SH5Y5Y 1.30 0.69 to 2.45 Neuroblastoma Human No 
PEO4 2.79 1.17 to 6.65 Ovarian Cancer Human No 
HBL 6.58 2.73 to 15.90 Melanoma Human Black 
3-1-1-T1a 0.08 0.05 to 0.13 Melanocyte Mouse No 
PF20 0.34 0.16 to 0.72 Fibroblast Mouse No 
SIB2W 1.21 0.60 to 2.43 Melanocyte Mouse V.Black 
Melan A 1.91 1.23 to 2.95 Melanocyte Mouse Grey 
13-4-1 2.40 1.59 to 3.64 Melanocyte Mouse Black 
13-4-2 4.55 1.79 to 11.62 Melanocyte Mouse Grey 
Table 3.3: Cell line specificity of Bio1E7 toxicity. Data shows Bio1E7 IC50 
concentrations, 95% confidence intervals (CI), species origin and pigmentation status for 
each cell line. Table ordered by species then increasing IC50 value. Bio1E7 IC50 values 
calculated by SRB assay.  
 
3.4 Discussion 
In this chapter we aimed to characterise the sensitivity of melanoma cells to 
standard chemotherapeutic agents and the role of ERCC1 in repair of the DNA 
damage they cause. We show that dacarbazine which is the standard 
chemotherapeutic agent for melanoma is potent with an IC50 of 2.6µM however no 
significant difference exists when toxicity is compared between an Ercc1 proficient 
and deficient cell line. This observation was as predicted for this compound as 
dacarbazine is known to be an alkylating agent causing DNA adducts that would 
require base excision repair rather than NER (178). On the other hand, the 
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chemotherapeutic agents cisplatin and oxaliplatin are both known to cause 
monofunctional adducts, interstrand and intrastrand DNA crosslinks (157). Repair of 
monofunctional adducts and intrastrand crosslinks are known to involve NER 
whereas repair of interstrand cross links is by a different pathway. Both the NER and 
ICL DNA repair pathways involve ERCC1 thus the hypersensitivity of Ercc1 
deficient cells is expected.  
To confirm the effect of cisplatin on our cells we utilised propidium iodide cell 
cycle analysis and an Annexin V apoptosis assay. On A375 human melanoma cells, 
we observed S phase and G2 phase arrests following cisplatin treatment as has been 
previously published for other cell lines (179, 180). It is thought that this is due to 
accumulation of DNA damage preventing further DNA replication and allowing for a 
cisplatin induced change to the DNA repair pathways, thus enabling the cells to 
better cope with cisplatin induced damage (157, 181). In addition, an increased sub-
G1 population was observed which we attribute to be as a result of apoptosis. 
Interestingly, the cell cycle profiles at 24 hours following cisplatin treatment showed 
an S phase and G2 phase arrest, but surprisingly by 48 hour and 72 hours of 
treatment this arrest was reduced. We hypothesise that this recovery is as a result of a 
coping strategy employed by the melanoma cell line. In this regard, cisplatin has 
previously been reported to induce an ERCC1 increase over the same period (176).  
Our results confirm that ERCC1-XPF is required for the repair of DNA 
damage caused by cisplatin (182). Consequently, we considered whether ERCC1 
was a suitable target for drug discovery. It is of note that testicular cancers have very 
low levels of ERCC1 and are effectively treated by cisplatin (183). High expression 
of ERCC1 has been linked with poor responses to chemotherapy in numerous cancer 
types, including non-small cell lung cancer, squamous cell carcinoma and ovarian 
cancer (184–191).  
Increased levels of ERCC1 mRNA have been reported in melanoma and 
ovarian cancer cell lines in response to cisplatin-induced DNA damage (176, 192). In 
ovarian cancer cells, increased levels of the transcriptional activators, c-fos and c-
jun, were involved in the cisplatin response (192). Treatment of melanoma cell lines 
with cisplatin resulted in increased phosphorylation of the extracellular signal-
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regulated kinase (ERK) (193).The MAPK pathway also has an important role in the 
regulation of ERCC1 expression by epidermal growth factor in human hepatoma 
cells (194). Importantly, MAPK pathway-dependent increased levels of both ERCC1 
and XPF proteins have been demonstrated after cisplatin treatment of melanoma cells 
(176).  
We next sought to identify novel inhibitors through a small molecule drug 
screen. Two classes of compounds were initially sought, those which were 
selectively active in melanoma and those which enhanced toxicity of cisplatin. From 
our screen, 19 compounds were initially found to be selectively active on 
melanocytes when comparing the cell based and zebrafish screens. Of these, 5 were 
purchased for follow up and only Chloro-APB hydrobromide showed cell line 
specificity upon retesting. Although a high number of compounds did not confirm, 
this represents a false positive rate of 1.4% (18/1280) which is reasonable, 
particularly when considering this was based upon results from two very different 
screens being combined. 
Although Chloro-APB hydrobromide showed some specificity on the human 
cell lines, no specificity was observed in the mouse cell lines. Chloro-APB 
hydrobromide is known to be a D1 dopamine receptor agonist. In published studies 
mouse melanoma, but not human melanoma was found to express dopamine D1 
receptors (195). In D1 receptor deficient melanoma cells, a specific D1 receptor 
inhibitor was found to bind to cells, though this was thought to occur by non-specific 
binding to melanin (195). In a third study, dopamine was found to react with cell 
culture medium to form hydrogen peroxide and dopamine semiquinones/quinones 
(196).   
In a structure search of the PubChem database, Chloro-APB hydrobromide was 
active in 31 of 497 bioassays tested (197). On the database, activity against D1 and 
D2 dopamine receptors was assessed to be 0.0055-1.3µM (197). Activities which 
were non-specific for dopamine receptors ranged from 3.5-39.8µM suggesting that 
the observed 5.6µM IC50 of Chloro-APB hydrobromide on our melanocytes was 
likely a nonspecific mechanism (197). Taken together, our decision was not to 
proceed any further with this compound.  
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In the second arm of the screen where compounds were selected for enhanced 
toxicity of cisplatin, 5 compounds were initially identified. Of these, three were 
purchased however no compound confirmed. This represented a false positive rate of 
0.4% (5/1280). Although the cut-off for compounds being selected was initially set 
high with a 50% enhanced toxicity of cisplatin, this was appropriate based upon the 
observed results with Ercc1 proficient and deficient melanocytes. Although a 
lowered cut-off may have discovered a genuine hit compound, it would almost 
certainly have resulted in a compound with insufficient activity for further 
development and would have increased the false positive rate. 
We then investigated the effect of the recently discovered nitrofuran 
compound, Bio1E7, on melanoma. This had been identified by Dr Hironori Ishizaki 
and Dr Elizabeth Patton in a previous small molecule screen and appeared to show 
contracted and less melanocytes in a zebrafish screen. Around this time, clinical 
efficacy of nifurtimox was being demonstrated against neuroblastoma (168). It was 
therefore tantalising that nifurtimox may also be active in melanoma, and that the 
recently discovered Bio1E7 may be a more potent analogue. In support, our results 
indicated that this nitrofuran compound was significantly more active on our 
melanoma cell lines than various commercially available derivatives including 
nifurtimox itself. Furthermore, structure activity relationships indicated that the nitro 
group attached to the furan ring was essential for Bio1E7 activity. This indicated that 
Bio1E7 was acting as a nitrofuran family member and activity was not due to an 
active group present in the side chain.  
It is predicted that the mechanism of Bio1E7 was through production of 
superoxide during nitrofuran activation by cellular nitroreductases. In support of this 
Dr Hironori Ishizaki had shown that intracellular ROS levels were increased in A375 
cells following Bio1E7 treatment. Furthermore, we showed that toxicity of Bio1E7 
was enhanced by cisplatin treatment. In addition, this also occurred upon treatment 
with nifurtimox suggesting combinational therapy in patients may be beneficial. We 
propose that treatment with Bio1E7 or nifurtimox for neuroblastoma be combined 
with cisplatin to increase clinical efficacy.  
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Studies in the literature have suggested that the NER pathway was crucial to 
the survival of E.coli following nitrofuran treatment however this was conflicting 
with early research (167). Following this, we examined the effect of Bio1E7 on our 
Ercc1 proficient and Ercc1 deficient cells. We showed that Bio1E7 is equipotent on 
both cell lines and did not show hypersensitivity on the Ercc1 deficient cell line as 
might be expected for a compound where NER was essential for mitigating its 
toxicity. This indicates that contrary to Ona et al., Bio1E7 and nitrofuran induced 
DNA damage does not require NER for its repair in human cells (167). It is 
hypothesised that in human cells, superoxide is formed as a result of nitrofuran 
activation leading to formation of DNA single strand breaks (164, 165, 198). That 
being said, DNA double strand breaks can also be formed when transcription 
machinery replicates past ROS-induced lesions or lesions occur in close proximity in 
opposite strands (198). In light of this, we wonder how nitrofurans may function in 
cancer harbouring defects in homologous recombination, such as BRCA1/2 deficient 
breast or ovarian cancer. Although in Table 3.3 we used PEO4 human ovarian cells 
carrying BRCA2 mutations, a secondary mutation is known to have occurred in this 
cell line reactivating the BRCA2 protein activity (199). 
In a cell line specificity assay comparing the toxicity of Bio1E7 on a panel of 
cell lines, we noticed that Bio1E7 had less of an effect on cell lines which were 
pigmented. Upon addition of more pigmented cell lines to our panel, we showed that 
pigmentation appears to be protective over nitrofuran toxicity. This is likely to 
function by melanin absorbing the superoxide produced upon nitrofuran activation 
(171, 172). In the treatment of melanoma, we therefore propose that nitrofurans will 
be of limited benefit and greater clinical efficacy would be attained on amelanotic 
melanoma. 
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4 Chapter 4: Establishing in vitro endonuclease assays for 
screening ERCC1-XPF inhibitors  
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4.1 Aim of chapter 
The aim of this chapter was to develop an in vitro endonuclease assay for 
ERCC1-XPF suitable for high throughput screening and compound validation 
following an in silico screen. In addition, we aimed to establish in vitro FEN1 and 
DNase1 assays suitable for compound screening and assessing compound specificity. 
 
4.2 Introduction  
4.2.1 ERCC1 is a target to overcome chemoresistance 
As previously discussed in section 3.4, ERCC1-XPF has been linked with poor 
responses to chemotherapy in numerous cancer types, including non-small cell lung 
cancer, squamous cell carcinoma and ovarian cancer (184–191). Furthermore, it has 
been shown that a MAPK pathway-dependent increase occurs for both ERCC1 and 
XPF proteins levels following cisplatin treatment in melanoma cells (176). This 
increase is thought to partly account for the chemoresistance of melanoma to 
cisplatin treatment. This led us to propose that inhibition of ERCC1-XPF could be 
used to overcome chemoresistance in many cancers. To demonstrate this we used a 
mouse xenograft model of melanoma to show that, while ERCC1-proficient 
xenografts were resistant to cisplatin treatment, isogenic ERCC1-deficient melanoma 
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Figure 4.1: Response of Ercc1 proficient and deficient xenografts to cisplatin. 10
7
 cells 
in 0.1ml of medium were injected subcutaneously into both flanks of 8- to 12-week-old 
female nude mice, together with 0.1ml matrigel (BD Biosciences, Oxford, UK) to facilitate 
xenograft establishment, on day X. Ten animals were injected with each cell line, and 
xenograft growth was monitored twice weekly. When the mean size of xenografts had 
reached 0.1cm
3
 (day 0), mice were randomized into two groups of five for each cell line. 
One group was untreated, while the other was treated on the days indicated (arrows) with 
6mg/kg cisplatin i.p. The time taken from injection for xenografts to reach the threshold size 
to start treatment is indicated by the bar on the Days axis. The mean tumour volume for each 
group ± SEM is shown relative to the mean tumour volume at the start of treatment. Animals 
were culled when a tumour reached 1cm
3
. The SEM increases disproportionately as the 
experiment proceeds owing to culling of animals with the largest tumours. Figure adapted 
from Song et al. (149). 
 
4.2.2 Published assays for ERCC1-XPF 
An in vitro endonuclease assay for ERCC1 was first published in 1998 by de 
Laat et al. who utilized recombinant ERCC1-XPF and demonstrated in vitro 
structure specific cleavage (100).  They showed that recombinant ERCC1-XPF is 
active on a range of radioactively labeled DNA substrates including stem-loop, 
splayed arm, flap, and structures with 3′ or 5′ overhangs; in all cases, structure 
specific cleavage occurs on the ds-DNA strand 5′ to the ds/ss-DNA junction (100). 
The stem-loop DNA substrate proposed by de Laat et al. has since become the 
standard assay for in vitro ERCC1-XPF activity (100, 102, 106, 112, 115). Until 
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recently, the assay was based upon radioactively labeled DNA substrates, however 
Bowles et al. modified this substrate to include 6-FAM on the 5′ end and the Dabcyl 
quencher on the 3′ end (102). While this modified assay was not published at the 
time of our work, this is a similar modification to that we developed independently 
and utilize herein. Furthermore de Laat et al., and latterly Bowles et al. have shown 
that the minimum loop size required for cleavage is 6nt, but the preference is for 
larger, 22-40nt loops (100, 102).  
 Furthermore, de Laat et al. showed that the ERCC1-XPF endonuclease had a 
metal ion preference (100). They showed that the endonuclease is inactive at high 
magnesium concentrations of 10mM, and has greater activity around 1-2mM  (100). 
Furthermore, they utilised the in vitro endonuclease assay to show that the favoured 
metal ion is not the biologically relevant magnesium, but manganese with an optimal 
concentration of 0.2-1mM (100). Interestingly, mutation of XPF residues Glu690 and 
Glu725 led to reduced nuclease activity in the presence of magnesium but not with 
manganese, suggesting an altered active site incompatible with the greater stringency 
requirements of magnesium binding, compared to those required for manganese 
binding (115). This suggests that in vitro the ERCC1-XPF endonuclease assay works 
better with manganese and not magnesium which is the biologically relevant metal 
cofactor (102, 106). 
 
4.2.3  Production of recombinant ERCC1-XPF protein 
For a drug discovery programme, significant quantities of recombinant 
ERCC1-XPF would be required. Expression of full-length ERCC1-XPF in E.coli 
leads to predominantly aggregated protein, while only small quantities of soluble 
protein can be purified from expression in Hela cells or baculovirus-infected Sf9 
insect cells (106, 115). Bowles et al. have since published a modified purification 
protocol for full-length ERCC1-XPF protein resulting in a modest 100-150µg of 
purified ERCC1-XPF per 2 litres of E.coli culture (102). Expression of a truncated 
ERCC1-XPF complex in E.coli is possible in greater yields using Δ95ERCC1-
Δ666XPF, lacking the ERCC1 N-terminus and the XPF helicase-like domain (106).  
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In our assays we opted to utilise the same truncated versions of ERCC1 and 
XPF as we found soluble complex to be expressed at good levels for purification (see 
Chapter 2 materials and methods for details of expression and purification) (106). 
These proteins have ERCC1 lacking the proposed nuclear localisation signal and 
XPF lacking the helicase-like domain. This truncated complex had previously been 
shown to be active by Tsodikov et al. and shown to have the same structure 
preference as full-length protein (106). Interestingly, a comparison of the enzyme 
kinetics between the truncated and full length ERCC1-XPF by Tsodikov et al. 
indicated Kcat values of 0.003min and 0.17min respectively, indicating the full 
length complex was ~60 fold more active (106). This was latterly confirmed by 
Bowles et al. who showed that full-length ERCC1-XPF has a Kcat of 0.19min (102). 
In addition, they expressed an alternative truncation of the ΔERCC1-XPF complex, 
but did not observe activity (102). They proposed that the slightly longer truncation 
that they produced may have acidic linkers on XPF which may inhibit the XPF active 
site or bind DNA (102). Alternatively, they proposed that the activity observed by 
Tsodikov et al. was due to non-specific nuclease activity (102). 
 
4.2.4 Enzymes to investigate compound specificity 
The ERCC4 endonuclease motif comprises of the ERCC4 endonuclease 
domain and the HhH2 domain (200). In the ERCC1-XPF complex, the catalytic 
domain in ERCC1 is degenerate and lacks key residues for activity. This ERCC4 
endonuclease motif is also present in other proteins including the MUS81-
EME1/EME2 complex, the FANCM/FAAP24 complex and in the Archaeal Hef 
protein (Hef is the Archaeal homologue of FANCM) (200). Of the other ERCC4 
family proteins, apart from XPF, only MUS81 and Archaeal Hef retain catalytic 
activity (200). This is shown in Figure 4.2. 
The MUS81/EME1 complex is a Holliday junction resolvase and is known to 
perform bilateral cleavage on Holliday junction-like structures (201). In vitro, 
Mus81-Mms4 (yeast homologue of MUS81-EME1) from yeast has been shown to 
cleave a variety of DNA substrates including Holliday junction structures, DNA 
forks and DNA flap structures (202). Furthermore cleavage by Mus81-Mms4 has a 
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substrate preference distinct from Rad1-Rad10 (yeast homologues of ERCC1-XPF) 
(203). Although Mus81-Mms4 and Rad1-Rad10 are both structure specific 
endonucleases acting 5′ to the DNA damage lesions, the Mus81-Mms4 complex has 
a 100-fold greater preference for flap structures over DNA forks (203). This has also 
been demonstrated for human MUS81-EME1 (204). In addition Bastin-Shanower et 
al. showed that cleavage by Mus81-Mms4 occurs 5nt upstream of the DNA junction 
and that the gap in the ds-DNA must be 4nt or less for cleavage to occur (203). 
 
 
Figure 4.2: Figure showing ERCC4 endonuclease family members. Proteins which form 
heterodimer pairs are indicated by parenthesis. The active ERCC4-like domains are shown in 
red and ERCC4-like domains which lack essential residues and are catalytically inactive are 
shown in grey with crosses. Helicase-like domains are shown in green and inactive helicase-
like domains are shown in green with crosses. Figure modified from (205). 
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While ERCC1-XPF and MUS81-EME act upon structures with 3′ overhangs or 
3′ flaps, the flap endonuclease 1 (FEN1) family of proteins resolve the counterpart 5′ 
flap structures (200). The FEN1 family of proteins in addition to containing FEN1, 
also contains the XPG endonuclease which in NER acts with ERCC1-XPF to 
perform the dual incision and remove the damaged DNA (200). Although 
functioning in the same DNA damage pathways and containing a single helix-
hairpin-helix motif, both FEN1 and XPG proteins share low homology to ERCC1-
XPF (206). 
 
4.2.5 FEN1 assay 
The flap endonuclease 1 (FEN1) protein is a DNA endonuclease involved in 
DNA repair during the final ligation step of NER and BER (207–209) and is required 
for the repair of alkylating agents and UV induced DNA damage. In addition, FEN1 
can function as a DNA exonuclease during DNA replication and is critical for the 
processing of Okazaki fragments (210).  
Several in vitro FEN1 assays have been reported in literature however the 
majority of these are based upon radiolabeled substrates. In 2004, Tumey et al. 
developed a series of FEN1 inhibitors utilizing a fluorescent FEN1 assay (208, 209). 
This assay was proposed by Dorjsuren et al. to be unnecessarily complicated and 
they subsequently reported an alternative fluorescent based assay (207).  This 
utilized three oligonucleotides annealed together with one labeled with TAMRA and 
another with the black hole quencher (BHQ-2) (207). Herein we utilize a modified 
version of the FEN1 assay as published by Dorjsuren et al. (See section 4.3.7).  
In vitro, FEN1 is known to cut branched DNA substrates on the opposite strand 
to ERCC1-XPF, but has been shown not to cleave DNA substrates with closed loops 
(100). FEN1 typically cleaves structures containing flaps with 5′ tails and is capable 
of cleaving either DNA or RNA strands (211). Furthermore, cleavage is absent in 
structures which contain only single stranded overhangs (100). 
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4.2.6 DNase1 assay 
To ensure compounds were not non-specific endonuclease inhibitors, we used 
an additional counter screen against the deoxyribonuclease I (DNase1) endonuclease. 
DNase1 is a waste management endonuclease expressed in cells in a cell-
autonomous manner to degrade low molecular weight DNA following induction of 
apoptosis in differentiated cells (212). In addition, DNase1 is also secreted from cells 
to degrade DNA from necrotic cells and bacteria (212). This nuclease was chosen as 
DNase1 is known to display activity against a wide range of substrates including 
RNA, single stranded DNA, and chromatin bound DNA with a preference for double 
stranded DNA (213, 214). 
DNase1 is known to function by cleaving phosphodiester bonds on one DNA 
strand at a time, acting from the minor grove of the DNA (213). This cleaves DNA to 
release 5′ phosphorylated di-, tr-, and oligonucleotide products (215). The catalytic 
efficiency of DNase1is then reduced on the small products formed as the preferred 
substrate size of DNase1 is structures of 4-6 bp or greater (213, 215). Furthermore, 
catalytic efficiency is shown to be DNA sequence dependent. Indeed, sequences 
containing AT repeats have a narrower minor grove than DNA of mixed sequence 
resulting in a lower catalytic efficiency (213).  
 
4.2.7 Validation of screening assays 
In order to assess the suitability of assays for high throughput screening and for 
compound validation, a statistical measure of the assay’s performance must be 
utilized. In 1999, Zhang et al. reported a statistical measure known as the Z-factor 
(Z′) (216). This measure categorizes assays based upon their calculated Z′ value, 
whereby those achieving a value of 1 are an ideal assay, those between 1 and 0.5 are 
excellent, and those attaining less than 0.5 are only suitable as a second confirmation 
assay with another assay. The assay Z′ is calculated using the following equation: 
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In addition to the assay Z′, assay robustness can also be quantified by a method 
published by Sittampalam et al. (217).  This method relies on the SD of the controls 
and considers that compounds which have a signal of 3SD or greater from the control 




4.3.1 Developing an in vitro endonuclease assay for ERCC1-XPF 
A well established in vitro endonuclease assay for ERCC1-XPF has been 
reported utilizing recombinant ERCC1-XPF and a short 46-mer DNA 
oligonucleotide that forms a stem-loop structure (100, 106, 112, 115). At the time of 
establishing this project, the assay was only radioactive based. As we were 
embarking on a drug screening project, it was necessary to develop an assay more 
amenable to high throughput screening, ideally based upon an analogous fluorescent 
substrate. We therefore decided to label the previously published 46-mer 
oligonucleotide with a fluorophore and a fluorescent quencher. As such, we had the 
46-mer DNA oligonucleotide synthesized with 6-FAM on the 5′ end and a black hole 
quencher on the 3′ end. These were selected as 6-FAM has an excitation of 495nm 
and emission of 525nm whereas BHQ1 has a peak absorbance in the 480-580nm 
range (peak absorbance is at 534nm).  
In the absence of ERCC1-XPF, the DNA oligonucleotide forms a stem-loop 
structure positioning the fluorophore and quencher in close proximity resulting in 
low levels of fluorescence. In the presence of ERCC1-XPF, this results in structure 
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specific cleavage of the DNA oligonucleotide and release of the fluorophore from the 
quencher. The resulting fluorescence can then be measured with a fluorimeter using 




Figure 4.3: Schematic of the in vitro endonuclease assay for ERCC1-XPF. The 46-mer 
DNA oligonucleotide contains complementary DNA sequences at the 5′ and 3′ ends with a 
22nt polythymine loop. The oligonucleotide has a fluorophore (6-FAM) on the 5′ end and a 
quencher (BHQ1) on the 3′ end. In the presence of ERCC1-XPF, this cleaves the DNA 
strand releasing the fluorophore and allowing fluorescence. 
 
With regards to ERCC1-XPF, most of the previous assays were based upon 
using full length recombinant ERCC1-XPF. Unfortunately however, expression of 
full length ERCC1-XPF has been mostly performed in baculovirus infected insect 
cells. This is problematic as a screening project requires large quantities of protein 
that would not be practical based upon the published yields obtained for ERCC1-
XPF using this expression system (115). Although it is possible to express full length 
ERCC1-XPF in a bacterial expression system, yields are low (106, 115). A truncated 
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Δ95ERCC1-Δ666XPF complex has also been published and shown to have activity in 
the analogous radioactive assay (106). This complex is expressed using an ERCC1 
construct lacking the putative nuclear localisation signal and an XPF construct 
lacking the helicase-like domain. Although the helicase-like domain is not essential 
for activity, its presence results in greater activity (106). That being said, as we are 
seeking inhibitors of the XPF nuclease domain and ERCC1-XPF protein-protein 
interaction, the additional domains are surplus to our requirements. 
 
4.3.2 Enzyme activity increases during long term pre-incubation 
Optimization of the standard ΔERCC1-XPF assay had previously been 
published by Tsodikov et al. using 100nM ΔERCC1-XPF and 100nM of the 
radioactive DNA substrate (106). Upon adopting similar conditions, we observed 
similar levels of activity (see section 4.3.4) and a 3-4 fold assay window after 3 
hours. This assay typically showed a Z′ of 0.6-0.8 and so was suitable to measure 
activity of inhibitors.  
As the assay had low levels of activity, we wanted to see if activity was 
maintained over a long period of time. For this assay, we utilized the metal cofactors 
manganese, magnesium, cobalt and zinc. Here we found that manganese has more 
immediate activity in the endonuclease assay (and as such is the predominantly used 
metal ion in the literature), while magnesium, which is thought to be the biologically 
relevant metal ion, had a reduced activity. As shown in Figure 4.4, upon measuring 
the assay over a long period, manganese continued to result in a steady increase in 
fluorescence. Interestingly however, magnesium resulted in a large increase in 
activity at around 48-72 hours which did not occur with any of the other metal 
cofactors tested. This increased activity was unexpected and the reason for this 
increase was unknown.  
Interested by the increased activity with magnesium, we set about developing 
an assay based around this observation. We found that if ΔERCC1-XPF protein was 
incubated at RT for 72 hours prior to the addition of substrate we would observe this 
higher activity level immediately after starting the reaction. We term this pre-
incubation. Furthermore, conditions required for pre-incubation were independent of 
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protein concentration and could be performed in PBS with 5% glycerol, or in 
reaction buffer. This assay was setup as detailed in Chapter 2 materials and methods.  
 
Figure 4.4: Long term fluorescence measurements of the ΔERCC1-XPF assay. The 
standard assay was setup using 0.5mM of MnCl2, MgCl2, CoCl2, ZnCl2 or no metal ion as a 
cofactor. The fluorescence was measured 5 hours after setup and then at every 24 hours 
thereafter. Data points show fluorescence after background subtraction ± SEM. 
 
4.3.3 Metal ion specificity of the ΔERCC1-XPF assays  
We then sought to determine what the optimal metal cofactor concentration 
was for each of the two ΔERCC1-XPF assays. Furthermore, high concentrations of 
metal cofactors are known to be inhibitory to ΔERCC1-XPF and as such the optimal 
concentration was likely to differ between cofactors. To determine the metal ion 
preference for the assays, we utilized the standard assay and the pre-incubated assay 
which had been pre-incubated for 72 hours and setup in the presence of MnCl2, 
MgCl2, NiCl2, KCl, CaCl2 or ZnCl2 metal cofactors. Reactions were then started by 
addition of DNA substrate.  
As shown in Figure 4.5A, for the standard ERCC1-XPF assay, there is a 
preference for low concentrations of the Mn
2+
 metal cofactor with the optimal 
concentration of 0.625mM. Although less activity is observed with Mg
2+
, the optimal 
concentration of this was 2.5mM. The other metal cofactors tested did not show 
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activity. Interestingly, in a separate experiment (data not shown) Ni
2+
 was a potent 
inhibitor of the assay that also out competed Mn
2+
 in the assay. 
In Figure 4.5B, we show an analogous experiment with the pre-incubated 
ΔERCC1-XPF assay. As we alluded to in Figure 4.4, following pre-incubation with 
Mg
2+
 we get enhanced activity, however this does not happen with Mn
2+
. In Figure 
4.5B, we show that the optimal Mg
2+
 concentration is 1.25mM and no other metal 
ions show activity in this assay. That being said, as the Mg
2+
 pre-incubated assay has 
significantly more activity (Figure 4.5B), this assay is measured at 30 minutes post 
substrate addition compared to the standard assay (Figure 4.5A) which is measured at 
3 hours post substrate addition.  
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Figure 4.5: Metal ion preference of ΔERCC1-XPF assays. (A) The standard ERCC1-XPF 
assay was setup using 100nM recombinant ΔERCC1-XPF and 200nM substrate. The assay 
was performed with varying concentrations of metal cofactors as indicated. (B) The pre-
incubated ERCC1-XPF assay was setup using 50nM recombinant ΔERCC1-XPF following 
72 hours pre-incubation then the reactions were started by addition of 200nM substrate. Pre-
incubated reactions were setup at varying concentrations of metal cofactors as indicated. The 
fluorescence was measured and background fluorescence was subtracted. 
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4.3.4 The pre-incubated ΔERCC1-XPF assay has greater activity  
In order to quantify the increased activity that we observed between the 
standard ΔERCC1-XPF assay and the pre-incubated ΔERCC1-XPF assay, we 
performed enzyme kinetic assays. In Figure 4.6A, we show a Michaelis-Menton Plot 
for the standard ERCC1-XPF assay. Here we measure the Vmax to be 304fmol/min 
with a protein concentration of 100nM. Therefore, we calculate the Kcat of the 
enzyme to be 0.011min. Although the rate is low, it is similar to published kinetics 
for truncated ΔERCC1-XPF of 0.003min (106). Although we consider our 
measurement to be in line with Tsodikov et al., this discrepancy may reflect our 
better preparation of ΔERCC1-XPF protein (106). 
In Figure 4.6B we show a Michaelis-Menton plot for the pre-incubated 
ΔERCC1-XPF assay and calculate the activity to be approximately 200 fold higher 
than in the standard ERCC1-XPF assay. We show that the pre-incubated ERCC1-
XPF assay has a Vmax of 34pmol/min at a protein concentration of 50nM. 
Therefore, we calculated the Kcat to be 2.448min. Interestingly, the published Kcat 
for full length ERCC1-XPF activity is 0.17-0.19min (106, 102). By pre-incubation, 
we achieve activity levels 13 fold greater than published for the full length ERCC1-
XPF.  
In addition, we show in Figure 4.6 that the KD for the stem-loop substrate 
differs between the two assays. The standard ΔERCC1-XPF assay shows a KD of 
0.8µM whereas the pre-incubated ΔERCC1-XPF assay shows a KD of 28.9µM. This 
indicates that although the pre-incubated assay is 200 fold more active, it has a 35 
fold reduced affinity for the DNA substrate. 
Due to the small discrepancies in activity, we consider the activity of our 
standard ERCC1-XPF assay is in accordance with published data (106). 
Furthermore, this assay also shows a similar metal ion preference to published data. 
Interestingly, our pre-incubated assay is 200 fold more active. It is likely that this 
difference may be partly accounted for by the presence the magnesium cofactor 
rather than manganese as magnesium is the biologically relevant metal cofactor. The 
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reason for this increased activity and change in metal preference is unknown, but is 
investigated in a later section. 
 
Figure 4.6: Michaelis-Menton plots for the standard ERCC1-XPF assay and the pre-
incubated ERCC1-XPF assays. (A) Showing the Michaelis-Menton Plot obtained for the 
standard ERCC1-XPF assay using 100nM ΔERCC1-XPF. The insert shows the determined 
kinetic parameters (B) Showing the Michaelis-Menton Plot obtained for the pre-incubated 
assay using 50nM ΔERCC1-XPF. The ΔERCC1-XPF protein had been pre-incubated for 72 
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hours prior to assay. Insert shows the determined kinetic parameters. Kinetic parameters 
derived using the SigmaPlot v12.0 enzyme kinetics module. 
 
4.3.5 Substrate cleavage specificity of the ΔERCC1-XPF assays 
In section 4.3.2, we showed that there was increased activity of the pre-
incubated ERCC1-XPF assay compared to the standard ERCC1-XPF assay. 
Therefore, we wanted to ensure that both ERCC1-XPF assays retained cleavage 
specificity. ERCC1-XPF is known to be a structure specific endonuclease that 
cleaves the stem-loop substrate 2nt upstream of the DNA junction on the 5′ ds-DNA 
strand. Based upon literature, the position of the expected cleavage site for the 
ERCC1-XPF assay is shown in Figure 4.7A (100, 102, 106). 
Shown in Figure 4.7B is a DNA ‘sequencing-like’ gel, whereby the reaction 
products are run out on a 12% acrylamide/urea gel, and the relative positions of DNA 
bands are imaged due to their 6-FAM labels. Here we show that the standard 
ΔERCC1-XPF assay does indeed result in a major 10nt product as predicted with 
minor products at 9 and 11nt. To our surprise, the pre-incubated ΔERCC1-XPF assay 
showed an altered specificity and instead resulted in a product of 4nt. Additional 
minor cleavage products can also be observed in positions estimated to be 5nt, 7nt, 
9nt and 11nt.  
In addition, upon cleavage, only the pre-incubated ERCC1-XPF assay resulted 
in loss of the 46-mer DNA substrate band. This indicates that this assay had reached 
completion whereas the standard assay had not. Neither of the nuclease only, or 
metal cofactor only controls showed cleavage. These controls show that in the 
absence of the metal cofactor the enzyme is not active, and that in the absence of 
ERCC1-XPF protein there are no non-specific nucleases present in the buffer 
accounting for activity. Although Bowles et al. suggest cleavage by the truncated 
ΔERCC1-XPF protein is due to non-specific nuclease activity (102), the enzyme 
specificity in the standard assay as observed here, and the metal ion specificity 
observed in section 4.3.3 suggests this is not the case. We propose cleavage is due to 
specific activity of ΔERCC1-XPF and not due to non-specific cleavage from 
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contaminating proteins in the protein preparations or buffer. The purity of our 
standard ΔERCC1-XPF protein preparation is shown in Figure 4.8A. 
 
 
Figure 4.7: Gel based specificity assay of the standard ΔERCC1-XPF, and pre-
incubated ΔERCC1-XPF assays. (A) Showing a schematic representation of the observed 
main cleavage sites in the stem-loop DNA oligonucleotide (B) Showing reaction products 
run out on a ‘sequencing-like’ gel and imaging of 6-FAM labels. Standard ERCC1-XPF 
assay performed using 200nM ΔERCC1-XPF and 200nM substrate for 3 hours and the pre-
incubated assay was performed using 50nM ΔERCC1-XPF (72 hour pre-incubation) and 
200nM substrate for 1 hour. 
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4.3.6 Protein breakdown during pre-incubation 
To understand what molecular changes had occurred to ERCC1-XPF during 
this pre-incubation period to result in the greater activity, we ran a protein gel and 
stained it with coomassie protein stain. As shown in Figure 4.8A, we noticed a 
specific breakdown which occurred over the same period as the pre-incubation. This 
occurred in all protein batches tested and was characterized by an initial breakdown 
of ΔERCC1 and ΔXPF followed by a further breakdown to two doublet bands, one 
set just above 17kDa, and one set just below 17kDa. A smeared band was also 
characteristic of breakdown and was centered at 11kDa. 
To identify which protein each of the fragments originated from, we performed 
Western blotting on the breakdown fragments. In Figure 4.8B, we performed a 
Western blot using the ERCC1 FL-297 polyclonal antibody which was raised against 
the entire sequence of ERCC1. In Figure 4.8C, we perform a Western Blot using the 
XPF Ab-5 monoclonal antibody with an undefined epitope. In order to directly 
visualize fragments from Western blots, and attribute each of the bands to either 
ΔERCC1 or ΔXPF, we overlaid the Western blots visualizing ERCC1 through the 
blue colour channel and XPF through the red channel. This is shown in Figure 4.8D. 
As shown in Figure 4.8D, the ΔERCC1-XPF protein showed some initial 
breakdown without pre-incubation. This is typical of ERCC1-XPF when stored and 
typically occurred within 1-2 weeks after purification without affecting activity. At 
48 hours we then begin to observe major breakdown of ΔERCC1-XPF occurring. At 
72 hours, the XPF western (Figure 4.8C) clearly identifies the two doublets, one 
above 17kDa and one below 17kDa. Furthermore, ERCC1 breakdown products are 
also identified in the same region (Figure 4.8B), and in the merge appears to 
correspond to the lower band of the XPF doublets. An attempt by Dr Martin Wear 
from the University of Edinburgh to identify each of the fragments by Mass 
spectroscopy was unsuccessful due to the presence of ERCC1 and XPF peptides in 
all bands. 
Although protein breakdown occurs during the same time scale as the 
ΔERCC1-XPF pre-incubation, it is unknown whether this is the cause of increased 
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activity, or whether increased activity is as a result of another factor occurring during 
the pre-incubation period.  
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Figure 4.8: Identification of ΔERCC1-XPF breakdown during pre-incubation (A) 
Coomassie gel of ΔERCC1-XPF complex immediately after purification (left panel), and of 
breakdown fragments following pre-incubation (right panel). The length of pre-incubation is 
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indicated. (B) ERCC1 western blot of breakdown fragments (C) XPF western blot of 
breakdown fragments (D) Merged westerns of breakdown fragments, ERCC1 is shown in 
Blue, XPF is shown in Red. The positions of molecular weight markers are shown. 
 
Although on the denaturing SDS-Page gel there was significant breakdown, we 
wanted to know whether this resulted in loss of fragments from the native complex. 
To answer this, we attempted to perform size-exclusion chromatography and native 
gels on the proteins however results were inconclusive.. 
In order to understand if these aberrations to the primary structure of the 
protein resulted in secondary structure change, our collaborators Dr Preeti Bakrania 
and Dr Barbara Saxty from MRC Technology performed circular dichroism and 
demonstrated an 11.3% loss in the α-helical structure following 72 hour pre-
incubation. This is accompanied by a similar increase in random structures and no 
change (<1%) to either β-sheet or β-turn structures. Although it was unclear what 
regions of ΔERCC1 or ΔXPF are involved to cause this change, it corresponds to 
loss of structure in approximately 51 of the 452 residues. In addition, as the 
secondary structure is not radically changed following breakdown, this supports the 
notion that the ΔERCC1-XPF protein remained as a single complex following pre-
incubation. 
 
4.3.7 FEN1 assay 
In order to assess the specificity of our ERCC1-XPF inhibitors, we sought to 
establish specificity assays. The first of these was a FEN1 assay. In the literature, 
there was a previously published assay using three oligonucleotides, one of which 
acted as a backbone, another was labeled with a quencher, a third which acted as a 
flap structure was labeled with a fluorophore (207). Once annealed, these three 
oligos would form a structure as shown in Figure 4.9A whereby the quencher and 
fluorophore would be in close proximity and result in low levels of fluorescence. The 
authors show that this assay reaches 3 fold activity over background after 30 minutes 
and that FEN1 cuts specifically in the position indicated in Figure 4.9A (207). For 
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our purposes, we opted to utilize a 6-FAM fluorophore and BHQ1 quencher instead 
of the TAMRA and BHQ2 as used by Dorjsuren et al. (207). We predict that this 
should not affect the assay but should facilitate compatibility with the filter set 
present on the fluorimeter. 
 
 
Figure 4.9: Schematic of FEN1 assay substrates. (A) The FEN1 assay oligos were 
annealed to form a structure as shown. This FEN1 assay is based upon an assay published by 
Dorjsuren et al. except for a change to the fluorophore and quencher (207). (B) Showing the 
DNA stem-loop substrate as used for the ERCC1-XPF assay. Indicated is the site where 
FEN1 was observed to cleave as demonstrated in Figure 4.11. 
 
 
 Chapter 4: Establishing in vitro endonuclease assays 120 
Upon testing the FEN1 assay using 20nM of recombinant FEN1 protein and 
50nM of the annealed FEN1 substrates as published by Dorjsuren et al., after 30 
minutes we observed high levels of  background fluorescence and only 1.25 fold 
activity over background levels (207). This is shown in Figure 4.10. In comparison, 
we also utilized the stem-loop from the ERCC1-XPF assay as although an 
unpublished observation by de Laat et al. stated it did not cut this radiolabelled 
structure (100), we had predicted that the addition of fluorophore and quencher may 
present as non-base paired bases. The observed cleavage site is indicated in Figure 
4.9B. In the FEN1 assay with 20nM recombinant FEN1 protein and 50nM of the 
stem-loop DNA substrate (ERCC1 substrate), we achieved low levels of background 
and 5.2 fold activity after 30 minutes (see Figure 4.10). Furthermore, we showed that 
this assay had a Z′ of 0.91 indicating highly reproducible results and a robust assay.  
Additional attempts to anneal the standard FEN1 substrate were made 
however the increased fluorescence upon FEN1 addition indicates that a proportion 
of the substrate was correctly annealed. It is thought that the high background 
observed was either due to a proportion of un-annealed substrate, or poor quenching 
of annealed substrate. Furthermore, a DNA ‘sequencing-like’ gel performed on this 
substrate indicated cleavage of the flap strand was at the predicted position (data not 
shown). As the FEN1 assay performs better with the ERCC1-XPF stem-loop DNA 
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Figure 4.10: Substrate selection for the FEN1 assay. The FEN1 assay was setup at room 
temperature using 20nM FEN1 protein using either the stem-loop DNA structure (ERCC1 
substrate) or the FEN1 specific substrate. The ERCC1 substrate achieves >4 fold activity 
over background in the assay with a Z′ of 0.91 after 30 minutes. The FEN1 substrate 
achieves 1.25 fold activity with a Z′ of 0.51 after 30 minutes. Fluorescence ± SEM shown. 
 
4.3.8 DNase1 assay 
A standard DNase1 (Deoxyribonuclease 1) assay was adopted from Dr Preeti 
Bakrania and Dr Barbara Saxty from MRC Technology. This assay utilized a 15 mer 
DNA oligonucleotide labeled with the 6FAM fluorophore on the 5′ end, and a BHQ1 
quencher on the 3′ end. This assay uses 0.5ng Lyophilized DNase1 from bovine 
pancreas and 200nM of the DNase1 substrate. Furthermore, this assay reached 10 
fold activity after 30 minutes and had a Z′ of 0.86. Optimisation of this assay was 
performed by Dr Preeti Bakrania. In addition, this assay also functioned on the 
ERCC1-XPF substrate with suitable fold activity and Z′ values for screening. 
 
4.3.9 Substrate cleavage specificity of nucleases 
In order to check the substrate cleavage specificity of the FEN1 and DNase1 
assays, we once again utilized the DNA ‘sequencing-like’ gel using the stem-loop 
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DNA oligonucleotide. As shown in Figure 4.11B, the FEN1 assay resulted in a major 
product of 4nt indicating that FEN1 does recognize the fluorophore and quencher as 
non-base paired bases. This is also shown in the schematic of Figure 4.11A. In 
addition, minor cleavage products were observed at 5nt, 6nt, 7nt, 8nt and 9nt. Also 
shown in Figure 4.11 is the DNase1 assay which, as expected, resulted in multiple 
cleavage sites on the stem-loop DNA substrate. These cleavage sites were 
predominantly in the double stranded region of the DNA at positions 5-11nt. 
Furthermore, no cleavage occurred in the single stranded polythymine loop or 
occurred on DNA less than 4 nt in length however this was not surprising as DNase1 
is known to have a preference for ds-DNA. In addition, cleavage was also observed 
to occur on the 3′ strand of the ds-DNA as shown by an increased fluorescence in the 
35-46 nt region. The cleavage sites are schematically represented in Figure 4.11A. 
Figure 4.11B indicates that DNase1 is not dependent upon addition of metal 
cofactors though this is not the case as the DNase1 used was a crude preparation 
known to contain calcium chloride. 
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Figure 4.11: Substrate cleavage specificity of the standard ΔERCC1-XPF, pre-
incubated ΔERCC1-XPF, FEN1 and DNase1 assays. (A) Schematic representation of the 
cleavage sites of the ΔERCC1-XPF, FEN1 and DNase1 assays. (B) The standard and pre-
incubated assays were performed as documented in Figure 4.7B. The FEN1 assay was 
performed with 20nM FEN1 and 200nM stem-loop substrate for 3 hours. The DNase1 assay 
was performed with 0.5ng DNase1 and 200nM stem-loop substrate for 30 minutes.  
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4.3.10 Inhibition of the ERCC1-XPF, FEN1 and DNase1 assays by 
Aurintricarboxylic acid 
To test the suitability of our assays to identify inhibitors, we screened all of the 
assays against the general nuclease inhibitor Aurintricarboxylic acid (ATA). This 
nuclease inhibitor is known to have a wide range of activities on targets including 
DNA helicases, DNA nucleases, RNA nucleases, DNA polymerases and kinesin 
proteins (218–221). Interestingly, we observed a difference in the IC50 for ATA 
between the standard ΔERCC1-XPF assay and the pre-incubated ΔERCC1-XPF 
assays. In Figure 4.12, we show that the IC50 in the standard ERCC1-XPF assay was 
0.8µM. In the pre-incubated ERCC1-XPF assay, this increased to 15.1µM. The cause 
of this discrepancy is unknown. Furthermore, a similar increase was also observed 
for the binding affinity for the DNA substrate. In section 4.3.4, we showed the KD 
for the substrate to be 0.8µM and 28.9µM respectively.  
The FEN1 assay also showed inhibition by Aurintricarboxylic acid. Here the 
IC50 was determined to be 0.2µM which was similar to Dorjsuren et al. who had 
previously shown this to be 0.59µM (222). This is considered to be equivalent as the 
IC50 values are within 3 fold. Importantly as we are using a different DNA substrate 
to Dorjsuren et al., this supports the suggestion that our assay is acting similarly to 
the reported assay (222). 
The DNase1 assay using the DNase1 specific substrate showed an ATA IC50 
of 6.6µM. This was similar to that obtained using the ERCC1 substrate and to that 
obtained by Dr Preeti Bakrania and Dr Barbara Saxty from MRC Technology. 
Furthermore, previous publications have shown that ATA inhibits DNase1 with an 
IC50 of 5-9µM (220, 223). This indicates that the sensitivity to inhibition of our 
assay is in accordance with published literature. 
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Figure 4.12: Inhibition of the ΔERCC1-XPF, FEN1 and DNase1 assays by 
Aurintricarboxylic acid (A) Inhibition of the standard ΔERCC1-XPF assay by 
Aurintricarboxylic acid (ATA) performed as documented in section 2.2.14. (B) Inhibition of 
the pre-incubated ΔERCC1-XPF assay by ATA performed as documented in section 2.2.15. 
(C) Inhibition of the FEN1 assay by ATA performed as documented in section 2.2.16. (D) 
Inhibition of the DNase1 assay by ATA performed as documented in section 2.2.17. Activity 
expressed as a percentage of the non-treated control ± SEM. 
 
4.4 Discussion 
The aim of this chapter was to develop an in vitro endonuclease assay for 
ERCC1-XPF suitable for high throughput screening. In order to do this, we utilised 
an existing assay based upon radioactively labelled substrates and converted it to a 
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fluorescent based assay. In addition, we sought to establish additional assays suitable 
for compound screening and to assess the specificity of ERCC1-XPF inhibitors. 
While we decided to utilise a truncated complex of ΔERCC1 and ΔXPF due to 
more favourable expression characteristics, it had previously been reported that full 
length ERCC1-XPF had more activity (106). That being said, full length ERCC1-
XPF protein also contained the putative ERCC1 nuclear localisation signal and the 
XPF helicase domain. In addition, since we are not targeting these domains, the 
favourable expression of the truncated ΔERCC1-XPF makes this more advantageous. 
The role of the putative ERCC1 nuclear localisation signal is unknown however it is 
thought that the XPF helicase like domain contributes to activity by binding to DNA. 
Bowles et al. propose that this domain binds at the ss- to ds-DNA junction inside the 
stem-loop. We believe this not to be the case as it is not required for cleavage 
specificity as proposed by Bowles et al. and because the domain is too large to fit 
into the stem-loop (102). Instead we propose this may contribute to activity by acting 
as a clamp, holding the DNA into the active site. This is shown in the model which 
we propose in section 1.4.5. Furthermore, as the expression constructs for full length 
ERCC1-XPF proteins were generated before the full XPF sequence was known, 
these proteins harbour an 11 amino acid truncation on the N-terminus. It is unknown 
whether these amino acids would contribute to the activity, or stability of the protein.  
To our surprise, upon investigating the effect of changing the metal cofactor in 
the ERCC1-XPF assay, we noticed that after 48 hours the activity suddenly 
increased. Interestingly, this increase in activity seemed to be limited to magnesium 
and did not occur with manganese which is typically used in the assay. Furthermore, 
magnesium is the biologically relevant metal ion. 
By utilising this phenomenon, we found that by pre-incubating the enzyme at 
room temperature for 72 hours prior to using it in the assay, we could achieve 
activity levels 200 fold higher than the standard ERCC1-XPF assay. Furthermore, 
when using the standard ERCC1-XPF assay, we achieved structure specific cleavage 
2nt upstream of the DNA junction. When using the pre-incubated ERCC1-XPF assay 
we achieved significantly greater cleavage however the specificity had then changed. 
With this assay we still observed specific cleavage but the major cleavage product 
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now occurred 8nt upstream of the ds/ss-DNA junction. We therefore wonder whether 
this assay still represents structure specific cleavage recognising the DNA junction of 
the stem loop or whether this assay now recognises the ds-DNA end. 
In order to understand what was happening to ERCC1-XPF during this pre-
incubation period to result in these changes, we first ran SDS-Page gels and stained 
these with coomassie stain. Here we discovered that during this period, protein 
breakdown was occurring. Size exclusion analysis although inconclusive suggested 
that the native complex remained the same size. Circular dichroism performed by Dr 
Preeti Bakrania and Dr Barbara Saxty from MRC Technology on the pre-incubated 
ΔERCC1-XPF complex indicated an 11.3% loss in the α-helical structure to random 
structure. While inconclusive, we predict that the pre-incubated ERCC1-XPF 
represents a protein complex that has an altered protein secondary structure resulting 
from breakdown in the primary protein structure. We hypothesize that this results in 
either a greater flexibility, or a loss of a regulatory control within the complex to 
achieve greater levels of activity. Furthermore, as this occurs only with magnesium, 
it is likely that the greater flexibility may allow magnesium to bind in a more 
favorable conformation in the active site. This may account for the greater activity. 
We documented two in vitro ΔERCC1-XPF assays with vastly different 
properties. We believe that the standard ΔERCC1-XPF complex is biologically more 
relevant to how ERCC1-XPF functions in vivo (though lacking the XPF helicase 
domain and ERCC1 nuclear localisation signal) than the pre-incubated ERCC1-XPF 
assay as it displays structure specific cleavage as predicted. From the literature, the 
published enzyme kinetics are 17 fold higher for full length ERCC1-XPF compared 
to our truncated ΔERCC1-XPF activity levels. 
In order to screen compounds for specificity against ERCC1-XPF, we then set 
about establishing a FEN1 assay. This was chosen as FEN1 is a closely related 
enzyme, but with a different specificity to ERCC1-XPF. Furthermore, as an already 
established assay was published, and protein was commercially available, this best 
suited our requirements. Should additional assays be required for demonstrating 
compound specificity in the future, establishing an assay based upon MUS81-EME1 
or XPG ought to be considered.   
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We first adopted a previously published FEN1 assay and adapted the 
fluorophore and quencher to meet our needs (222). Unfortunately however this assay 
had high background levels and a low fold activity window. We therefore considered 
that this was not of use for screening. It is thought that this was due to un-annealed 
substrate however as an increase in fluorescence was observed in the assay, this 
suggests that at least a proportion was correctly annealed. Another explanation might 
be that the base pairing at the fluorophore and quencher is insufficient to hold the 
modifications in close proximity so allowing fluorescence of the annealed substrate. 
Instead we investigated the possibility of using the ERCC1-XPF stem-loop substrate. 
Here much greater fold activity was observed. In contrast to previous literature (100), 
we did observe specific cleavage with this substrate. Here we observe cleavage of the 
DNA oligonucleotide on the ds-DNA end where the fluorophore and quencher are 
present rather than at the stem-loop end. In the literature, this assay was performed 
using radioactively labelled structures which would form a neat base-paired end; this 
is in contrast to our oligonucleotide whereby the fluorophore and quencher may 
present to FEN1 as non-paired bases. It is therefore thought that in our case, FEN1 
recognises this region and specifically cleaves the 5′ strand 4nt downstream of the 
fluorophore.  
The additional specificity assay that we chose for screening ERCC1-XPF 
inhibitors was for DNase1. This was a good choice of nucleases as DNase1 has 
activity on a wide range of substrates (213, 215) thus the specificity is not as tightly 
controlled compared to the nuclease activities of ERCC1-XPF or FEN1. In addition, 
cleavage specificity of DNase1 on the stem-loop DNA substrate was as expected 
based upon literature. We showed that cleavage occurred exclusively within the ds-
DNA region and did not occur on DNA of less than 4 nt in length (213). No cleavage 
was observed in the ss-DNA region though it is unknown whether this is due to the 
lower activity on ss-DNA versus ds-DNA, or whether this is because of the 
polythymine sequence which is also known to cause a lower activity (213). 
We then investigated the ability of the assays to be inhibited by the general 
nuclease inhibitor Aurintricarboxylic acid. As predicted this resulted in inhibition of 
all the assays. Of note, inhibition of FEN1 was similar to previously published by 
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Dorjsuren et al. (222). Potent inhibition of DNase1 was also observed. Furthermore, 
we showed that the IC50 of ATA against DNase1 is in accordance with previous 
literature (220, 223). Interestingly, the standard and pre-incubated ERCC1-XPF 
assays showed differences in ATA potency of 0.8µM and 15.1µM respectively. 
Furthermore, a similar difference also occurred in the binding affinity for the stem-
loop substrate whereby the standard assay had a KD of 0.8µM and the pre-incubated 
assay had a KD of 28.9µM showing that although pre-incubated ERCC1-XPF has 
greater activity, it also has a lower binding affinity for DNA. It is likely that the 
differences in affinity for DNA and ATA may be due to different methodology to 
perform these assays or may be due to the changes occurring during pre-incubation. 
In addition, as pre-incubation only occurs with magnesium, it is likely that the 
greater flexibility may allow magnesium to bind in a more favorable conformation in 
the active site, and this alteration may result in the altered binding affinities. 
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5 Chapter 5: In silico screen and compound validation for 
inhibitors of ERCC1-XPF 
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5.1 Aim of chapter 
The aim of this chapter was to identify an ERCC1-XPF HhH2 domain inhibitor 
and an XPF endonuclease domain inhibitor through in silico screening. Here, we use 
biochemical, biophysical and cell based techniques to identify and characterise 
ERCC1-XPF inhibitors. 
 
5.2 Introduction  
5.2.1 ERCC1-XPF HhH2 domain  
ERCC1-XPF interaction through their HhH2 domains is an obligate 
requirement for a stable ERCC1-XPF complex and so is essential for catalytic 
activity. Development of small molecule inhibitors of the HhH2 domain interaction 
would be expected to sensitise cells to chemotherapeutics whose DNA-damaging 
effects are repaired by ERCC1-XPF-dependent pathways. Given the expected high 
affinity and the hydrophobic nature of this interaction, it will be considerably more 
difficult to block than an enzyme active site. However, the successful development 
of the p53/MDM2 interaction inhibitor, nutlin, demonstrates what can be achieved 
(224). Mutagenesis studies indicate that disruption of the ERCC1 Phe293 interaction 
with XPF is sufficient to prevent complex formation (93, 109). Furthermore, 
availability of an ERCC1-XPF HhH2 domain crystal structure (PDB code 2A1J) 
(106) provides an attractive first step for rational drug design programmes.  
 
5.2.2 XPF endonuclease domain 
Inhibition of the XPF catalytic domain would inhibit all known functions of 
ERCC1-XPF in DNA repair. The presence of Mg
2+
 coordinated in the active site 
provides an ideal target for metal ion chelation with only weak DNA contacts being 
made by this domain. There is currently no crystal structure for the human XPF 
endonuclease domain, although the Archaebacterial XPF crystal structures (PDB 
code 2BGW) (126) has been used to generate a human homology model that could 
aid the search for active site inhibitors (see Figure 5.8). Inhibition of the nuclease 
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domain of XPF is however problematic, due to shared mechanistic activity with 
closely related nucleases, thus designing the necessary specificity into inhibitors will 
be challenging. It is of note that drug discovery programmes have been, or are 
currently being pursued for another structure-specific endonuclease, Flap 
Endonuclease 1 (FEN1), involved in the final ligation step of NER and base excision 
repair (BER) (207–209), for Apurinic/apyrimidinic Endonuclease (APE1) required 
for BER (225, 226) and the RAD51 recombinase, involved in HR (227). 
 
5.2.3 Inhibition of the XPF helicase-like domain as a target for 
drug discovery 
The helicase-like domain could be an attractive target for drug discovery, 
particularly when considering the single Arg153Pro substitution resulted in 
hypersensitivity to UV and ICL agents (95). It would also be anticipated that 
inhibition of this domain would result in decreased nuclease activity, since truncated  
Δ95ERCC1-Δ666XPF shows 60-fold reduced activity in vitro compared to the full-
length complex (106). However, our current understanding of the DNA and protein-
protein interactions is insufficient for a drug screening programme to target this 
region. In addition, no crystal structures exist for this domain and a homology model 
would be of only limited value due to insufficient sequence homology to other 
helicases with known crystal structures. 
 
5.2.4 ERCC1/XPA interaction 
The nonspecific PK-C and CHK1 inhibitor, UCN-01, inhibited NER by 
causing a reduction in ERCC1 binding to XPA (228). Upon DNA damage and UCN-
01 treatment, an accumulation of DNA-bound XPA was observed, but there was a 
decrease in DNA-bound ERCC1. In silico modelling of UCN-01 binding to ERCC1 
calculated a binding energy of -4.81 kcal/mol (123). UCN-01 was proposed to bind 
into the XPA interaction site on ERCC1, disrupting the interaction of Tyr145 and 
Tyr152 in ERCC1, with several hydrogen bonds stabilising the UCN-01/ERCC1 
interaction (123). An in silico screen for potential inhibitors of the XPA interaction 
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site on ERCC1 was performed, but no compounds were investigated for in vitro or in 
vivo activity (123). 
Inhibition of the ERCC1/XPA interaction is an attractive drug target due to the 
existence of crystal structures and known inhibitors. Inhibition of this site in vitro 
and in vivo has been shown with a synthetic XPA peptide and is also proposed for 
UCN-01 (112, 123). However, an inhibitor of this interaction would only disrupt 
NER and would not affect the role of ERCC1-XPF in ICL or DSB repair. Thus, 
synergistic use of an ERCC1/XPA inhibitor with a DNA crosslinking agent, such as 
cisplatin, would likely only be of limited benefit.  
 
5.2.5 XPF/RPA interaction  
Inhibition of the XPF/RPA interaction may prove to be an effective drug target 
as RPA has a role in both NER and ICL repair, thus inhibition could potentiate 
toxicity of a range of chemotherapeutic agents (69, 127, 128). However, not enough 
is known about the interaction site and no crystal structures of interaction exist, so a 
drug discovery programme based on this target would be premature.  
 
5.2.6 XPF/SLX4 interaction  
The XPF/SLX4 interaction is an emerging drug target (130, 131, 136). 
Disruption would sensitise cells to interstrand crosslinking agents without disrupting 
the role of ERCC1-XPF in NER. Currently, a drug discovery programme targeting 
this interaction would be challenging as the XPF/SLX4 interaction site awaits 
detailed mapping. Furthermore, the relevant crystal structures are unavailable and 
low SLX4 sequence conservation between species would hamper confidence in 
homology modelling.  
 
5.2.7 ERCC1/FANCG interaction  
If the interaction between ERCC1 and FANCG is confirmed it could represent 
an attractive and novel drug target that would specifically block the role of ERCC1-
XPF in ICL repair (137, 139). Deletion of ERCC1 or FANCG interacting regions 
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results in sensitivity to crosslinking agents, but it is unknown whether mutation of 
specific interaction sites on either protein is sufficient to sensitise cells. Further 
mapping of the interaction site would be necessary before attempting to identify 
inhibitors of this interaction. 
 
5.2.8 Effect of emodin on ERCC1 transcription  
Emodin was first proposed to have activity against ERCC1 in 1999 when 
Chang et al. discovered that emodin resulted in an up regulation of ERCC1 
expression and resulted in enhanced repair of UV and cisplatin induced DNA 
damage (229). In 2010 Ko et al. published a contrary observation (230). In this 
paper, they showed that protein and mRNA levels of ERCC1 and Rad51 were 
reduced following emodin treatment and that this occurs due to a MAPK pathway 
dependent mechanism (230). In a separate paper, they then showed that emodin 
decreased expression of ERCC1 protein and mRNA levels through transcriptional 
inhibition of ERCC1 (231). They then showed that emodin is capable of down 
regulating the expression of Rad51, ERCC1 and up-regulation of Thymidine 
phosphorylase (necessary for capecitabine activation as used in the paper) (232). 
From the data, a direct role of emodin in inhibiting ERCC1-XPF is not excluded. 
Furthermore, activity of emodin as an inhibitor of ERCC1 (transcriptional inhibitor 
or otherwise) remains to be corroborated by an independent lab. A recent paper 
published by Deloia et al. has shown that ERCC1 mRNA levels do not correlate with 
ERCC1 protein levels (233). It is likely this may partly explain the contradictory 
findings of emodin.  
 
5.2.9 ERCC1-XPF as a target for a drug discovery  
Developing inhibitors against the ERCC1-XPF complex will be challenging. 
The most tractable target is the XPF endonuclease site itself, due to lower affinity for 
the DNA substrate than the affinity of the various protein-protein interactions 
involved in the different repair roles of ERCC1-XPF. Inhibition of this site would 
block all the known functions of ERCC1-XPF needed for the repair of 
chemotherapy-induced DNA damage. However, the lack of a crystal structure for 
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this domain of human XPF and the existence of a number of endonucleases with 
similar divalent cation-based cleavage mechanisms will complicate the search for 
compounds of the desired specificity. The only other target whose inhibition would 
prevent all repair roles of ERCC1-XPF is the interaction domain needed for 
heterodimer formation. The large hydrophobic surface area of the interaction domain 
makes this a formidable target, but a single amino acid deletion in this region does 
completely block activity (93, 109). 
Inhibition of other protein-protein interactions made by the complex could also 
be tractable to a drug discovery programme. For instance, if there is a requirement to 
enhance sensitivity to a chemotherapeutic that causes lesions repaired exclusively by 
NER, then targeting the ERCC1/XPA interaction site should be considered and has 
the advantage of existing crystal structures and drug and peptide inhibitors. If instead 
the requirement is to block repair of just ICLs then inhibitors of ERCC1/XPF 
interactions with SLX4 or RAD52 may also be effective therapies, but these 
interactions are not yet sufficiently well understood to be the direct focus of drug 
discovery programme. In this chapter, we opt to identify inhibitors for the ERCC1-
XPF interaction domain and XPF endonuclease domain. 
 
5.3 Results 
5.3.1 Species differences between the ERCC1-XPF HhH2 domains 
The ERCC1 and XPF proteins show a high degree of conservation between 
eukaryotic species and form stable heterodimer complexes. In Archaebacteria, only 
XPF is present and forms stable homodimer complexes (126). While a lot is known 
about ERCC1-XPF, a large part of current knowledge is from species other than 
human. The HhH2 domain of ERCC1 and XPF is essential for dimerization, we 
therefore sought to determine the similarity of the ERCC1 and XPF HhH2 regions 
between species at a molecular level (106, 112). This has implications for our choice 
of cell lines, and for species to be utilized for future in vivo experiments. 
The crystal structure of the human HhH2 domain (PDB Code: 2A1J) (106) and 
the Archaeal XPF HhH2 domain (PDB Code: 2BGW) (126) are available on the 
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Protein Data Bank (PDB). While mice have taught us a lot about ERCC1-XPF, no 
crystal structure exists for mouse ERCC1 or XPF. Furthermore, as future in vivo 
experiments will likely be performed on mice (and potentially zebrafish), we wanted 
to understand the level of structural similarity and so generated PHYRE
2
 models 
(Protein Homology/Analogy Recognition Engine v2.0) of their ERCC1 and XPF 
(154). In addition, so that a comparison could be drawn between species and an 
estimate of the PHYRE
2
 model accuracy could be established, PHYRE
2
 models were 
generated for the human and A. pernix proteins. 
In Figure 5.1, we show the protein-protein dimerization surfaces of the ERCC1 
and XPF HhH2 domains for human, archaebacteria, mouse and zebrafish. As 
expected, the PHYRE
2
 models generated for both human and A. pernix were reported 
by the PHYRE
2
 server to be 99.8-99.9% accurate and showed no discernible 
difference to the published crystal structures (106, 126). Furthermore, confidence in 
all models was reported to be greater than 99.8% as assessed by the PHYRE
2
 server 
indicating a high degree of accuracy and confidence in all models.  
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Figure 5.1: Showing the difference in HhH2 domains of ERCC1 and XPF between 
species. Shown are the protein-protein dimerization surfaces of the HhH2 domains for 
human, the Archaebacteria A. pernix, mouse and zebrafish. All models were generated using 
the PHYRE
2
 server (154). A. pernix forms homodimer XPF structures. As a result, the XPF 
HhH2 domain is represented instead of ERCC1 for A. pernix. This is aligned to the same 
orientation as the other ERCC1 proteins. 
 
Based upon the PHYRE
2
 prediction, all ERCC1 and XPF proteins adopt a 
HhH2 fold motif characteristic of XPF protein family members (234). In the primary 
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amino acid sequence, differences between the proteins are revealed as shown in 
Figure 5.2. Consequently, as shown in Figure 5.1, this results in significant 
alterations to the tertiary protein structure and consequently the protein surface. The 
most diverse structures from human ERCC1 and XPF are for A. pernix though this is 
likely due to A. pernix forming XPF homodimers rather than the typical ERCC1-XPF 
heterodimer of eukaryotes. As predicted, the eukaryotic mouse and zebrafish 
structures show a high degree of similarity to human XPF.  
 
 
Figure 5.2: Sequence alignment of the ERCC1 and XPF sequences between species. 
Sequence alignment performed using ClustalW2 multiple sequence alignment tool. Amino 
acids are coloured so that small, hydrophobic, and aromatic residues are coloured red. Acidic 
residues are coloured blue. Basic residues are coloured magenta and hydroxyl, sulfhydryl or 
amine residues are coloured green. An asterisk indicates a conserved residue, a colon 
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indicates conservation with strongly similar properties, and a period indicates conservation 
with weakly similar properties. 
 
The most significant difference between the HhH2 domains between species 
were amino acid changes in positions equivalent to that of human ERCC1 Phe293 or 
XPF Phe905 as indicated in Figure 5.2. In the residue analogous to human XPF 
Phe905 of A. pernix and mice, this is substituted with a tyrosine residue. In zebrafish, 
the phenylalanine is absent and in the PHYRE
2
 model is substituted with the adjacent 
methionine residue. Unlike a phenylalanine or tyrosine residue, the methionine lacks 
an aromatic side chain. Importantly, the residue analogous to human ERCC1 Phe293 
is conserved in mouse and zebrafish and in the PHYRE
2
 model all are positioned in 
the same spatial orientation as each other. Although A. pernix does not have ERCC1, 
the analogous tyrosine residue in XPF is in a similar orientation. 
Additionally, in mouse there are substantial changes to the surface of XPF 
bridging the site of the binding pockets for ERCC1 Phe293 and Ile264 (see Figure 
5.3). In this chapter, we aim to discover ERCC1-XPF interaction inhibitors which 
bridge multiple binding pockets; these are therefore likely to display species specific 
activity. This will be especially true for mouse. Furthermore, use of the Ercc1 
proficient and deficient mouse cell lines for screening ERCC1-XPF HhH2 interaction 
inhibitors designed against the human sequences will be unadvisable.  
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Figure 5.3: Figure showing the differences between the XPF protein surfaces between 
species. Showing the surface of XPF for each species as generated using a PHYRE
2
 model 
(154). The ERCC1 binding pockets on human XPF are identified. 
 
5.3.2 Target identification and in silico screening for inhibitors of 
the ERCC1-XPF HhH2 domain 
The human ERCC1-XPF HhH2 domain is proposed as an in silico drug target 
as the crystal structure is available (106) and interaction is essential for the activity 
and stability of the ERCC1-XPF heterodimer (234). In this domain, the principal 
target site was identified as a pocket formed on XPF which the ERCC1 Phe293 
residue binds to. This was proposed for a variety of reasons: ERCC1 Phe293 is 
conserved in eukaryotic species (103), ERCC1 binds into a large 280Å
2
 pocket on 
the XPF protein surface (234) and finally, ERCC1 Phe293 is essential for interaction 
of the ERCC1 and XPF HhH2 domains as deletion of this residue was sufficient to 
abrogate interaction (93, 109). The binding site for this residue on the XPF protein 
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surface is identified in Figure 5.4. To discover compounds with greater binding 
affinity and specificity, additional pockets on the XPF HhH2 domain surface were 
sought. In collaboration with Professor Malcolm Walkinshaw and Dr Steven Shave 
from the University of Edinburgh, a surface triplet propensities (STP) program was 
utilized to predict additional, and unique protein binding sites (235). Two additional 
pockets on the XPF surface where the ERCC1 Ile264 and Cys238 residues bound 
were chosen. The locations of these binding sites are shown in Figure 5.4. Neither of 
these additional pockets have been previously reported in the literature. 
 
 
Figure 5.4: Showing the drug targets on the XPF HhH2 surface. Showing the XPF HhH2 
domain surface following removal of ERCC1. Drug target sites are indicated by arrows and 
are identified by the corresponding ERCC1 amino acid which interact with this region. 
Figure created in PYMOL v0.99 using the ERCC1-XPF HhH2 domain crystal structure 2A1J 
(106). 
 
This is a protein-protein interaction and there is widespread scepticism about 
their suitability as drug targets, due to the strong protein-protein interactions that 
would need to be disrupted. The strength of interaction between ERCC1 and XPF 
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has not been reported. To determine the strength of their interaction, we used a 
BIAcore SPR assay in collaboration with Dr Martin Wear from the University of 
Edinburgh. In Figure 5.5, we used recombinant ΔXPF covalently bound to the 
BIAcore SPR surface and directly measured the interaction with ΔERCC1. We 
calculated the binding affinity to be 4.6nM demonstrating a tight interaction. 
Furthermore, with a fast on-rate, and slow off-rate, this indicates formation of a 
stable ΔERCC1-XPF complex on the BIAcore SPR surface. While such a strong 
interaction is unfavourable for inhibitor design, published mutagenesis suggests that 
only the Phe293 pocket needs to be inhibited to disrupt the formation of ERCC1-
XPF complex. Inhibiting de novo complex formation in vivo may be more achievable 
than inhibiting preformed ERCC1-XPF complex. In practice this may mean the 
binding affinity required of inhibitors to achieve complex disruption will be reduced. 
 
 
Figure 5.5: BIAcore SPR analysis of ERCC1 binding to XPF. Characterisation of the 
interaction of ΔXPF with ΔERCC1 using BIAcore T100. Reference corrected single cycle 
kinetic titration SPR binding curves (black), monitored on a surface of 276 response units 
(RU) of covalently stabilized ΔXPF, for various concentrations of ΔERCC1. Graph shows 
change in response against time. A three-fold dilution series from 2.5nM to 200nM of 
ΔERCC1was injected over the ΔXPF bound surface and the apparent on- and off-rate 
constants and KD (inset) were determined by globally fitting (red) a 1:1 kinetic binding 
model, with mass transport considerations, to the sensorgrams using the instrument analysis 
software. Assay performed by Dr Martin Wear. 
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Following target site identification, an in silico screen was performed by Dr 
Steven Shave as described in Chapter 2 materials and methods. Here Dr Steven 
Shave virtually screened the Chembridge, Maybridge and Specs dataset (subset of 
the 5 million compound EDULISS database) for compounds which bound to either 
single, or a combination of pockets (156). The combination of pockets chosen to 
screen were the F&C, F&I, I, F and I&C pockets. Screening to detect compounds 
which bound to all three pockets was not performed as only three compounds 
capable of binding to both the F&C pockets had been detected. Theoretical binding 
affinities were calculated and the compounds were ranked by their theoretical ligand 
efficiencies. This is a measure of binding affinity and is calculated by the Gibbs free 
energy as a ratio to the number of non-hydrogen atoms (236). The top scoring 
compounds purchased for follow up validation are shown in Table 5.1. Compound 
structures are searchable online from the EDULISS database 
(http://eduliss.bch.ed.ac.uk/test/index.jsp) via their Compound ID’s (156).  
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Table 5.1: Compounds from the ERCC1-XPF HhH2 domain in silico screen selected for 
further investigation. Showing the Compound ID, theoretical docked affinity, theoretical 
ligand efficiency and target site of inhibitors. Compounds were targeted to either a single, or 
combination of Phe293, Ile264 or Cys238 pockets on XPF as indicated. 
 
 In Figure 5.6, we show the structure and docking poses for four of the in 
silico compounds which herein we demonstrate to display activity against ERCC1-
XPF. Furthermore, we show the structure of three control compounds which are 
proposed to have activity against ERCC1-XPF. UCN-01 (Figure 5.7A) is proposed to 
be an inhibitor of the ERCC1/XPA interaction. Emodin (Figure 5.7B) is reported to 
be a transcriptional inhibitor of ERCC1, though our evidence suggests this to be an 
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endonuclease domain inhibitor (see section 5.3.4). Aurintricarboxylic acid (Figure 
5.7C) is known to be a general nuclease inhibitor, though no activity against ERCC1-




Figure 5.6: Showing structure and docking pose of the proposed ERCC1-XPF HhH2 
domain inhibitors. Compound structures were generated using ChemAxon Marvin Sketch. 




Figure 5.7: Showing the structures of control compounds. (A) Showing the structure of 
UCN-01 which inhibits the ERCC1/XPA interaction. (B) Showing the structure of Emodin 
which we propose to inhibit the XPF endonuclease domain. (C) Showing the structure of the 
known general nuclease inhibitor, Aurintricarboxylic acid. Compound structures were 
generated using ChemAxon Marvin Sketch. 
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5.3.3 Target identification and an in silico screen of the XPF 
endonuclease domain 
In addition to developing an ERCC1-XPF HhH2 interaction domain inhibitor, 
we also sought to develop an inhibitor of the XPF endonuclease domain. This had the 
advantage over the HhH2 interaction domain inhibitors in that protein-DNA 
interactions were likely to be lower affinity than the 4.6nM ERCC1-XPF interaction.  
The main problem with this target site is the lack of published human XPF 
endonuclease domain crystal structure thus posing a technical problem for in silico 
design. Instead a crystal structure for the Archaebacteria A. pernix was available. 
Unlike the HhH2 domains, this region does show a high degree of similarity between 
species and the essential amino acids required for catalysis are conserved. The same 
is true for other species including mouse and zebrafish. As such, a PHYRE model 
was generated by Dr Steven Shave and energy minimalisation performed to refine 
the structure and allow in silico screening to be performed. A comparison of the 
PHYRE model and the A. pernix crystal structure of the XPF endonuclease domain is 
shown in Figure 5.8A and 5.8B. 
The in silico screen of the EDULISS database was then performed by Dr 
Steven Shave as detailed in Chapter 2 materials and methods (156). As the reliability 
of a PHYRE model for in silico screening is limited by the quality of the model, the 
in silico screen was performed independently on both the A. pernix XPF crystal 
structure and the human XPF PHYRE model. For this screen, the newly available 
Autodock Vina program was used (237). This program has a more sophisticated and 
rigorous docking process and had not been available for use at the time of the 
ERCC1-XPF HhH2 screen. For this reason compounds were ranked according to 
their Vina score upon binding to the target rather than the previously used ligand 
efficiency.  
The top scoring 200 compounds were ranked and those with a Vina score less 
than -7.5 were subsequently purchased for validation. These are shown in Table 5.2. 
One of these compounds termed compound #44 shows activity against ERCC1-XPF 
and its structure and docking pose are shown in Figure 5.8C and 5.8D. Herein, we 
show the data which lead us to conclude that this is an inhibitor of ERCC1-XPF. 
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Figure 5.8: Showing the structures of the XPF nuclease domain from A. pernix and 
human XPF as used for in silico screening. (A) Showing the nuclease domain from A. 
pernix (PDB Code: 2BGW) (126). (B) Showing the nuclease domain of a PHYRE generated 
model of human XPF (154). (C-D) Showing the structure and docking pose for the proposed 
XPF endonuclease domain inhibitor Compound #44. Compound structures were generated 
using ChemAxon Marvin Sketch. Docking poses were generated using the in silico docking 
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Table 5.2: Table of compounds selected from the XPF endonuclease domain in silico 
screen for further investigation. Showing the Compound ID, Vina Score and Screening 
model used for compound identification. Compounds were identified by an in silico screen 
performed against the Archaeal XPF crystal structure from A. pernix (PDB Code: 2BGW) 
(126), or a PHYRE generated model of human XPF (154). 
 
5.3.4 Screening ERCC1-XPF inhibitors in the ERCC1-XPF, FEN1 
and DNase1 assays 
To determine whether the compounds were inhibitory against ERCC1-XPF 
and, if so, whether they also had activity in the counter screening assays, compounds 
in Table 5.1 and 5.2 were plated into a 96 well format. From this, the standard 
ERCC1-XPF assay, the pre-incubated ERCC1-XPF assay, and the DNase1 assays 
were screened at 100µM. If compounds showed activity, then they were followed up 
with a concentration series to determine the IC50 values. The FEN1 assay was then 
performed on selected compounds which showed favourable ERCC1-XPF activity. 
Results for compounds which either inhibited the in vitro ERCC1-XPF endonuclease 
assay, or were identified in the BIAcore SPR assays (see section 5.3.5) are shown in 
Table 5.3. 
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UOE #44 XPF endonuclease domain NA NA NA NA 












UCN-01 ERCC1/XPA interaction domain NA ND NA NA 

















Table 5.3: Activity of ERCC1-XPF inhibitors in the ERCC1-XPF, FEN1 or DNase1 
assays. Showing the compound IC50 and 95% confidence intervals indicated in parenthesis. 
Assays performed as documented in Chapter 2 materials and methods. *Compounds UOE #1 
and UOE #2 resulted in an apparent increased activity in the standard ERCC1-XPF assay 
however this was unreliable (see text). NA indicates compounds which show no activity, ND 
indicates compounds whose activity has not been determined. ATA denotes compound 
Aurintricarboxylic acid. Dose-response curves for active compounds are shown in Figure 
4.12 or in Sections 10.2 to 10.5 of the Appendix.   
 
In Figure 4.12 we observed the IC50 for ATA on the pre-incubated ERCC1-
XPF to be higher than that for the standard ERCC1-XPF assay, the majority of IC50s 
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for other compounds were also higher in this assay. This included emodin, which we 
propose to directly inhibit ERCC1-XPF, which had a low (6.1µM) IC50 on the 
standard ERCC1-XPF, but a much greater (254.5µM) IC50 on pre-incubated 
ERCC1-XPF.  
In the standard, but not the pre-incubated ERCC1-XPF assays, compounds 
UOE #1 and UOE #2 consistently resulted in an increased activity of the protein. The 
magnitude of this increase was unreliable and thus could not be quantified. The 
reason for this increase is unknown, but it is possible that these compounds are 
weakly fluorescent in the presence of protein.  
The ERCC1-XPF interaction inhibitor compounds UOE #18 and UOE #26 
showed activity in the ERCC1-XPF assays. Furthermore, compound UOE #18 was 
specific for ERCC1-XPF, had a 4-fold higher IC50 for the pre-incubated assay, and 
showed no activity on either FEN1 or DNase1. Compound UOE #26 on the other 
hand showed ~20-fold higher IC50 values for the pre-incubated ERCC1-XPF, FEN1 
and DNase1 assays. This indicates that this compound has specificity for the standard 
ERCC1-XPF assay.  
Although it is difficult to determine the reason for the differences in the 
inhibitor performances between the standard and pre-incubated ERCC1-XPF assays, 
it is anticipated this may be due to the protein breakdown known to have taken place 
in this protein. If this breakdown facilitates greater flexibility within the ERCC1-
XPF protein, it might be anticipated that some drugs will have weaker binding 
affinities.  If breakdown is the reason for the difference between the ERCC1-XPF 
assays, this is unfavourable for UOE #18 and UOE #26 binding. It is likely that 
breakdown may result in loss, or a change to the binding sites as it is already known 
there is an 11.3% loss in α-helical structure (see section 4.3.6).    
Of the XPF endonuclease domain inhibitors, UOE #44 showed no activity for 
ERCC1-XPF in vitro. This was disappointing and in contradiction to results obtained 
in the BIAcore SPR assay (see next section). UOE #45 and UOE #46 on the other 
hand did show activity against ERCC1-XPF. However, as the IC50s were high, and 
non-specific binding had previously been demonstrated by BIAcore SPR analysis for 
these compounds, no further action was taken with these compounds. 
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5.3.5 Biophysical binding of ERCC1-XPF inhibitors can be 
demonstrated in a BIAcore SPR assay to ERCC1-XPF 
proteins 
To directly measure whether our inhibitors biophysically interacted with 
ERCC1-XPF, a BIAcore SPR assay was performed. For interaction inhibitors 
recombinant ΔXPF was used, whereas for endonuclease inhibitors, recombinant 
ΔERCC1-XPF complex was used. This was because interaction inhibitors may not 
be able to disrupt preformed ERCC1-XPF complex on the BIAcore SPR surface. 
Initially all compounds were screened at a single concentration of 200µM. 
Compounds which showed indication of specific interaction to ERCC1-XPF were 
carried forward to a concentration assay. Here, a concentration series was performed 
from a maximum concentration of 500µM. The control compound aurintricarboxylic 
acid (ATA) was excluded from the concentration series at this stage as super-
stoichiometric binding of 1:40 was observed and once bound, the compound did not 
dissociate. Two additional compounds were excluded from the screen of 
endonuclease domain inhibitors for similar reasons as detailed in Table 5.4.  
In Table 5.4, we show the summary of results obtained from screening both the 
ERCC1-XPF HhH2 interaction domain inhibitors and the XPF endonuclease domain 
compounds. Of the endonuclease domain compounds, most showed super-
stoichiometric binding resulting in unrealistic binding kinetics. These were therefore 
classed as non-specific inhibitors. Of the ERCC1-XPF HhH2 interaction domain 
inhibitors, compounds UOE #1, #2 and #18 were confirmed as specific inhibitors. Of 
the XPF endonuclease domain compounds, only compound UOE #44 was confirmed 
as a specific inhibitor.  
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Table 5.4: BIAcore SPR Results. Showing kinetic parameters following single 
concentration and subsequent concentration series screen. Results for all ERCC1-XPF HhH2, 
XPF endonuclease domain and control compounds which showed activity on the BIAcore 
surface are shown. Table shows the Compound ID, proposed Target site, result from 
BIAcore SPR assay including the KD (M) and Rmax (RU). Three compounds with 
unfavourable activity on the surface are indicated with asterisks and were excluded from the 
concentration screen.ERCC1-XPF interaction domain inhibitors bound to ΔXPF protein. 
XPF endonuclease domain inhibitors and control compounds bound to ΔERCC1-XPF 
protein. 
 
The control compounds emodin and UCN-01 also showed specific binding to 
ΔERCC1-XPF protein. This was interesting as, although UCN-01 had previously 
been proposed to inhibit the ERCC1-XPA interaction, direct biophysical evidence 
had not been demonstrated. This confirms interaction with ERCC1-XPF and supports 
the notion of inhibiting the ERCC1-XPA interaction. The other control compound 
emodin was also interesting. Literature suggests that this compound inhibits ERCC1-
XPF through transcriptional regulation. We show for the first time that this may 
instead act by directly inhibiting ERCC1-XPF. That being said, although physical 
interaction has been demonstrated to ΔERCC1-XPF protein indicating direct 
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inhibition, an additional indirect mechanism of inhibition as has previously been 
reported cannot be excluded (230, 231). As an additional control, we attempted to 
bind the ERCC1-XPF stem-loop DNA substrate to ERCC1-XPF on the BIAcore. 
This was unsuccessful with no evidence of binding. It is thought that this is due to 
ERCC1-XPF being immobilised on the BIAcore chip in a conformation 
unfavourable to the DNA being slotted over the complex. As proposed by our model 
of ERCC1-XPF in Figure 1.5, DNA binding would require significant flexibility in 
both the DNA structure and the ERCC1-XPF proteins. 
In Figure 5.9, we show the obtained concentration series profiles for the 
ERCC1-XPF interaction inhibitor compound UOE #18 binding to recombinant 
ΔXPF protein. In Figure 5.9A, the sensogram plot shows a concentration dependent 
increase in response (the green line indicates the observed binding for 500µM 
compound and the subsequent lower lines indicate responses following two-fold drug 
dilutions). At steady state, the response was measured and was plotted against 
concentration. This is shown in Figure 5.9B. From this graph the maximum 
achievable response (Rmax) was projected and the KD calculated. In Figure 5.9B, 
the red line indicates an observed KD of 537.2µM. The Rmax was estimated to be 
68.06RU indicating near-stoichiometric binding of 1:2. As UOE #18 has a Mr of 
224.3 and is therefore considered almost fragment-like, near-stoichiometric binding 
is common for compound fragments and so UOE #18 is not excluded as a useful 
inhibitor solely upon this observation.  
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Figure 5.9: BIAcore SPR Results for UOE #18. (A) Showing the sensogram profile of 
increasing UOE #18 drug concentrations plotted with response (RU) versus time (seconds). 
(B) Showing response (RU) plotted against UOE #18 drug concentrations (M). The green 
line and data point represents 500µM UOE #18 and subsequent concentrations are 2-fold 
dilutions thereof. Determining kinetic parameters are shown in Table 5.4. 
 
5.3.6 Binding of inhibitors to ΔERCC1-XPF results in protein 
stabilization 
A thermal denaturation assay was utilised as an additional biophysical method 
to demonstrate interaction of compounds that had shown specific binding in the 
BIAcore SPR assay with ERCC1-XPF. This assay, although more subjective than the 
BIAcore SPR assay, has the advantage of proteins being in solution rather than 
constrained by being bound to the sensor chip. In this assay, ΔERCC1-XPF protein 
 
 Chapter 5: In silico screen and compound validation 155 
was thermally denatured in the presence of the environmentally sensitive SYPRO 
Orange dye. SYPRO Orange is a fluorescent dye whereby its fluorescence is 
quenched in an aqueous solution  With increasing temperature, hydrophobic regions 
of ERCC1-XPF become exposed allowing SYPRO Orange to bind to the protein and 
become unquenched thus allowing a direct readout of protein denaturation. Upon 
interaction of inhibitor compounds, binding could stabilize the ΔERCC1-XPF protein 
resulting in a positive shift in the melting temperature. Alternatively, ERCC1-XPF 
interaction inhibitors may be able to break apart the ERCC1-XPF heterodimers; this 
could destabilize the individual proteins and manifest as a decrease in melting 
temperature. 
To validate the assay with inhibitors, we utilised UCN-01 (ERCC1/XPA 
inhibitor), DNA (ERCC1-XPF substrate) and UOE #18 (shows activity in all other 
assays) as control compounds and a positive Tm shift was observed for all. ATA was 
a poor control for this assay as in the BIAcore SPR assay, it bound at 
superstoichiometric ratios. In addition, three randomly selected compounds which do 
not show activity in the other assays were also selected and were inactive in this 
assay. We then screened compounds UOE #1, #2, #26 and #44 as these had shown 
activity against ΔERCC1-XPF in the endonuclease or BIAcore SPR assays. Initially 
all of the proposed inhibitors were screened at a single concentration of 500µM. 
Although higher than concentrations used for previous experiments, such as the 
BIAcore SPR analysis, affinity decreases with temperature (anecdotal evidence 
suggests that for every 10 degrees above 20°C, there is a four-fold reduced binding 
affinity). It was therefore imperative that, unless drug precipitation was observed, 
higher concentrations were used in order to maximise the possibility of observing a 
temperature shift. In this assay, we observed a stabilisation of the ΔERCC1-XPF 
complex with compounds UOE #18, #26, UCN-01 and emodin resulting in a Tm 
increase of +1.7°C, +2.5°C, +1.1°C and +3.2°C respectively. Results are shown in 
Table 5.7. 
To validate the observed ΔTm of +1.7°C for compound UOE #18 at 500µM, a 
concentration assay was performed. In Figure 5.10A, we show the relative 
fluorescence units (RFU) of the SYPRO Orange dye plotted against temperature. We 
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show that in the absence of ΔERCC1-XPF, there is no auto-fluorescence of the 
compound, or of the buffer and that the dye is not affected by either. In the presence 
of ΔERCC1-XPF, typical thermal denaturation profiles are observed with a single 
transition temperature. Upon addition of UOE #18, a concentration dependent 
positive shift is observed. This is better visualized in Figure 5.10B where the inverse 
of the ΔRFU relative to the ΔT (-ΔRFU/ΔT) is plotted against temperature. These 
minima therefore represent the inflection point on the lines of Figure 5.10A. This 
represents the Tm value for each condition. As shown in Figure 5.10B, a 
concentration dependent increase in Tm is observed with compound UOE #18. This 
is graphically represented in Figure 5.11B where Tm is plotted against concentration. 
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Figure 5.10: Showing thermal denaturation profiles of compound UOE #18 against the 
ΔERCC1-XPF protein. (A) Showing the thermal denaturation profiles of compound #18 
against 5µM ΔERCC1-XPF (+ EX) including compound only controls (- EX). Assay 
performed from 20°C to 80°C with 30 second 1°C intervals. Data measured by relative 
fluorescence units of the SYPRO Orange dye. (B) Plot of –ΔRFU/ΔT versus temperature to 
determine the change of transition temperature (Tm) of ΔERCC1-XPF due to UOE #18.    
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To validate this result with a known binder to ERCC1-XPF, we decided to 
utilize the ERCC1-XPF stem-loop DNA substrate. In a solution based assay, as 
opposed to the surface of a BIAcore chip, it is anticipated that the DNA substrate 
would bind to ERCC1-XPF. We show in Figure 5.11A that with 5µM ΔERCC1-XPF 
used, we observe a concentration dependent increase in ΔTm which plateaus at 
around 5µM DNA. This supports interaction of DNA and ΔERCC1-XPF at a 
stoichiometric ratio of 1:1. In addition, this suggests that the majority of the 
recombinant ΔERCC1-XPF protein in the preparation is properly folded and capable 
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Figure 5.11: Showing the change in transition temperature (Tm) caused by DNA and 
compound UOE #18 in a ΔERCC1-XPF thermal denaturation assay. (A) Showing the 
effect of the ERCC1-XPF DNA stem-loop substrate on the stability of ΔERCC1-XPF. 
Protein concentration was 5µM indicating 1:1 binding of DNA to ΔERCC1-XPF protein. 
Values ± SEM (n=3) (B) Showing the effect of compound UOE #18 plotted with Tm versus 
drug concentration. Tm values derived from Figure 5.10B ± SEM (n=3).  
 
5.3.7 Activity of ERCC1-XPF inhibitors in a cell based assay 
In addition to the biophysical and biochemical techniques, we sought to 
validate ERCC1-XPF inhibitor compounds in a cell based assay. The reason for this 
was that for an ERCC1-XPF inhibitor to be used therapeutically it must show activity 
 
 Chapter 5: In silico screen and compound validation 160 
in cells. In addition, as we sought to discover inhibitors of the tight ERCC1-XPF 
interaction, these may not be able to disrupt preformed ERCC1-XPF complex. As 
such, the in vitro endonuclease assay may not be able to identify ERCC1-XPF 
inhibitors that could only disrupt de novo ERCC1-XPF protein synthesis. The 
principle behind this assay was to determine whether we could recreate the 
hypersensitivity of cells to cisplatin using molecular inhibitors of ERCC1-XPF, 
analogous to the effects of genetic deletion in the Ercc1 deficient melanocytes 
described in section 3.3.2 Although this is an indirect measure of ERCC1-XPF 
inhibition, activity in this assay would be supportive of on-target activity and 
necessary for compounds to be progressed as potential ERCC1-XPF inhibitors.  
The initial assay was an IC50 curve for each compound performed on the A375 
human melanoma cell line. This allows us to gauge the toxicity of each compound 
and select an appropriate concentration for use in the enhancement of cisplatin 
sensitivity assay. While a majority of compounds had high IC50 values on their own, 
this is expected for an ERCC1-XPF inhibitor compound as cells deficient in ERCC1 
grow equally well as ERCC1 proficient cells in vitro in the absence of exogenous 
genotoxic stress (Table 5.5 and Table 5.6).  
To assess the ability of compounds to overcome cisplatin resistance, 
compounds were plated with human A375 melanoma cells at varying concentrations 
against cells treated with, and without cisplatin. Compounds were assessed against 
two concentrations of cisplatin, 0.3µM cisplatin and 0.6µM cisplatin. These were 
chosen as 0.3µM is below the cisplatin IC50 concentration, and 0.6µM was chosen 
to be around the IC50 value. Cells were treated for 5 days then growth was measured 
by the SRB assay. Obtained OD values were normalized to their respective 
compound, and cisplatin only controls. Enhanced toxicity was assessed by a reduced 
growth rate following normalization. In this assay, 60% of the compounds showed 
greater than 10% enhancement of cisplatin toxicity. Results obtained for the different 
compounds are shown in Table 5.5 and Table 5.6. 
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Table 5.5: Showing activity of ERCC1-XPF interaction inhibitors in cell culture. Table 
shows the ERCC1-XPF inhibitors and their designed target pockets. For each compound, the 
IC50 in A375 cells and their enhancement of cisplatin sensitivity are shown. Dose response 
curves for UOE #1, UOE #2, UOE #18 and UOE #26 are shown in Section 10.1 of the 
Appendix. 
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Table 5.6: Showing activity of XPF endonuclease domain inhibitors in cell culture. 
Table shows the XPF endonuclease domain inhibitors and whether they were designed 
against the Archaeal XPF structure or the human PHYRE XPF model. For each compound, 
the IC50 in A375 cells and their enhancement of cisplatin sensitivity are shown. Dose 
response curves for UOE #38, UOE #44 and UOE #46 are shown in Section 10.1 of the 
Appendix. 
 
 A more elaborate experiment was subsequently performed on compounds 
UOE #1, #2 and #18 to quantify their ability to shift the IC50 value of cisplatin. Here 
cisplatin toxicity curves were performed in the presence and absence of a fixed 
concentration of ERCC1-XPF inhibitors. Two concentrations of ERCC1-XPF 
inhibitor were chosen based upon the IC50 in cell culture and the concentration 
which enhanced the toxicity of cisplatin in the previous experiment. Concentrations 
of compounds did not exceed their IC50 values. Cell growth was assessed by SRB 
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staining and values were normalized to their respective compound only control 
values meaning the effect on the cisplatin IC50 can be directly measured. As shown 
in Figure 5.12, compounds UOE #1, #2 and #18 all shift the IC50 of cisplatin. The 
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Figure 5.12: Showing activity of ERCC1-XPF HhH2 interaction inhibitors on the A375 
human melanoma cells. (A-C) Showing the ability of UOE #1, #2 and #18 to enhance the 
toxicity of cisplatin. Growth of A375 cells assessed following 5 day drug treatment by SRB 
assay. Growth values normalised to no-cisplatin treated control for each drug concentration. 
Data show values ± SEM. Data obtained by Ashley Whitham. 
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5.3.8 Summary of ERCC1-XPF inhibitors 
In summary, through the in silico screening that was performed in 
collaboration with Dr Steven Shave and Professor Malcolm Walkinshaw, we have 
identified a number of ERCC1-XPF inhibitor compounds. In this chapter we 
identified UOE #1, #2, #18, #26 and #44 and demonstrate activity in a range of 
assays.  
UOE #1 and #2 for instance both show enhancement of cisplatin sensitivity in 
cell culture, and show biophysical binding to ΔXPF in a BIAcore SPR assay. These 
compounds are not able to inhibit the in vitro endonuclease assay, however this is 
likely because interaction inhibitors spanning the interaction surface are unable to 
prise apart the preformed complex. We therefore present these compounds as 
inhibitors of de novo ERCC1-XPF complex formation. 
UOE #26 on the other hand was designed as an ERCC1-XPF interaction 
inhibitor spanning the Ile264 and Cys238 pockets on XPF. With this compound, 
although we observed no enhanced activity with cisplatin in cell culture, or binding 
to XPF in the BIacore SPR analysis however interaction with the complex was 
demonstrated in the thermal denaturation assay. Furthermore, this compound was 
potent in the in vitro endonuclease assay and was specific for ERCC1-XPF. 
UOE #18 is our favored compound from the in silico screening hits as activity 
was observed in all of the assays. In the in vitro endonuclease assay, a high IC50 was 
observed against ERCC1-XPF. In cell culture, this compound was active at a much 
lower concentration and showed an enhancement of cisplatin toxicity. Furthermore, 
physical binding was demonstrated by the BIAcore SPR assay to XPF and 
interaction was demonstrated to ERCC1-XPF complex in the thermal denaturation 
assay. We predict that the lower IC50 in cell culture may be due to the ability of this 
compound to inhibit de novo complex formation. 
UOE #44 was designed by the in silico screening to be an inhibitor of the XPF 
endonuclease domain. While activity was observed in cell culture, and biophysical 
binding to ERCC1-XPF was demonstrated in the BIAcore SPR assay and the thermal 
denaturation assay, we did not observe activity in the in vitro endonuclease assay. 
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We are therefore unsure of how this compound may be acting, and if it is an ERCC1-
XPF inhibitor. 
Taking the results summarized in Table 5.7 into consideration, we propose 
UOE #1, #2 and #18 to be specific inhibitors of the ERCC1-XPF interaction domain. 
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Table 5.7: Summary of results attained for proposed ERCC1-XPF inhibitor 
compounds. Table shows the proposed binding site of inhibitors, activity on A375 cells 
when combined with cisplatin, their activity in a BIAcore SPR assay and activity in a 
thermal denaturation assay. *Aurintricarboxylic acid (ATA) was excluded as it bound with 
1:40 stoichiometry and did not disasociate, see section 5.3.5. 
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5.4 Discussion 
In this chapter, we aimed to identify inhibitors of the ERCC1-XPF DNA repair 
endonuclease. Here, we utilised a rational in silico based screening approach and 
sought to identify inhibitors of the ERCC1-XPF HhH2 interaction domain, and the 
XPF endonuclease domain. 
In a review of the protein-protein and protein-DNA interactions, three principal 
target sites were identified. The first of these was the interaction between ERCC1 
and XPA. This interaction is known to be required to recruit the ERCC1-XPF 
complex to sites of DNA damage to allow the incision step of the NER DNA repair 
pathway to proceed (112). Should this interaction be blocked, NER would be 
inhibited. Furthermore, previous work in this area has led to the development of a 
peptide inhibitor of this region and the drug UCN-01 being proposed as a non-
specific inhibitor of this site (123, 228). In addition, Barakat et al. have already 
performed an in silico screen targeting this region (123). A patent protecting the 
ERCC1/XPA crystal structure has also been filed (238). In order to overcome 
cisplatin resistance however, this interaction is not required for all forms of cisplatin 
induced DNA damage. It is for these reasons that we chose not to pursue this 
interaction further. 
The second interaction that we identified was the ERCC1 HhH2 domain. This 
interaction has the advantage over the ERCC1-XPA interaction in that it is required 
for repair of all forms of cisplatin DNA damage. It is therefore anticipated that if this 
region could be inhibited, the obligate interaction required for protein stability would 
be disrupted destabilising both ERCC1 and XPF. 
In the protein-protein interaction domain, we identified two amino acids which 
lock into the reciprocal partner protein: ERCC1 Phe293 and XPF Phe905. It has 
previously been shown that the ERCC1 Phe293 is required for interaction between 
ERCC1 and XPF and deletion of this residue abrogates interaction (93, 109). Based 
upon a crystal structure of this region, this residue is situated in a deep 280Å
2
 pocket 
on the XPF surface (106). The analogous XPF Phe905 residue on the other hand has 
not been demonstrated to be essential for interaction and the pocket on ERCC1 is 
only 220Å
2 
(234). This pocket is also less structurally defined and therefore less 
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tractable to in silico screening. We therefore favoured an in silico screen for 
compounds targeting the pocket on XPF occupied by the ERCC1 Phe293. 
In addition to the XPF Phe293 pocket for in silico based drug design, it was 
important to select additional pockets on the XPF surface. This would not only 
increase the binding affinity of compounds to the target protein, but could also 
engineer specificity into the small molecule. For these reasons, the additional Ile264 
and Cys238 pockets were identified. 
As our knowledge of the ERCC1-XPF complex comes from a variety of 
species, we wanted to understand the molecular similarity. In addition, it is planned 
that we would perform xenograft experiments should a high potency lead compound 
be discovered. These would either be performed in mice or in zebrafish. Although 
unconventional, xenografting in zebrafish is an emerging tool as has the advantage of 
being rapid and higher throughput than mouse models, and also requires less 
compound. Understanding the species differences between the HhH2 domains was 
therefore necessary to influence our choice in cell culture and xenograft models. 
Interestingly, the crystal structures and our PHYRE
2
 generated models 
revealed that there are substantial differences between the HhH2 domains, 
particularly between human and A. pernix (106, 126, 154). Although they both adopt 
an HhH2 fold motif, the surfaces of the domains are considerably different. This is 
likely due to A. pernix forming XPF homodimers and thus the surfaces must be 
different to facilitate this. The HhH2 domains between the eukaryotic species are 
more similar, but still with notable differences. Interestingly, the zebrafish structure 
is more similar to human than mouse as mouse XPF has an enlarged bridge between 
the Phe293 and Ile264 pockets. It is therefore important that for in vivo and cell 
culture models that the appropriate species are chosen. Importantly, for interaction 
inhibitors which span multiple binding sites, mouse models must be used with 
caution.  
As the protein-protein interaction surface in the ERCC1-XPF complex is large 
and predominantly hydrophobic, identification of small molecules able to inhibit this 
region will be formidable task. Furthermore, the binding affinity of ERCC1 for XPF 
interaction has not previously been published. We therefore used BIAcore SPR 
 
 Chapter 5: In silico screen and compound validation 170 
analysis and demonstrated the KD of this interaction to be 4.6nM, confirming the 
expected strong interaction. On the other hand, mutational studies of ERCC1 Phe293 
have shown that deletion of this residue is sufficient to abrogate interaction of the 
two proteins (93, 109). We therefore predict that inhibitors of the Phe293 binding 
pocket on XPF may be sufficient to inhibit complex formation, or at the very least, 
disrupt key DNA interactions made by the HhH2 domains.  
The third interaction that we identified was the XPF endonuclease domain. 
Like the ERCC1-XPF interaction domain, this is also required for the repair of all 
forms of cisplatin induced DNA damage. This target is more straightforward 
compared to the previous target however it does have its own challenges. One 
challenge faced with this region is that no crystal structure is published. Instead, a 
PHYRE model was utilised in addition to the crystal structure for the nuclease 
domain of A. pernix. In this region, there is a high degree of conservation and key 
active site residues are conserved. Therefore the PHYRE model was assessed to be 
suitable for in silico screening. An additional challenge faced by the drug discovery 
programme on this region is designing specificity into compounds as the mechanism 
of action is expected to be similar to other nucleases.  
In order to discover inhibitors of our chosen target domains, we decided to use 
an in silico screening approach. This was chosen as we had already identified 
specific target domains on our protein. The benefit of in silico screening means that 
compounds purchased for follow up validation already have predicted affinity for the 
target, thus higher hit rates compared to the high throughput approach are expected. 
Furthermore, due to the tight ERCC1-XPF interaction, inhibitors of this region may 
not be able to disrupt preformed ERCC1-XPF complex. As such, a high throughput 
screening approach based around an in vitro endonuclease assay may not be able to 
identify ERCC1-XPF inhibitors that could only disrupt de novo ERCC1-XPF protein 
synthesis.  
Following the in silico screen, we purchased a number of the proposed 
compounds for follow up validation. We show in Table 5.7 a summary of the results 
obtained for active compounds. We propose compounds UOE #1, #2, #18 and #26 to 
inhibit the interaction domain of ERCC1-XPF and UOE #44 to inhibit the 
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endonuclease domain of XPF. Furthermore, we show direct biophysical evidence 
that the control compounds UCN-01, Emodin and ATA bind to ERCC1-XPF.   
In the in silico screen only 3 compounds were proposed to bind to both the 
Phe293 and Cys238 binding pockets on XPF. Interestingly, two of the three 
compounds, UOE #1 and #2, were discovered to have activity. As shown in Table 
5.7, both of these compounds enhance the toxicity of cisplatin with a 1.38-fold and 
1.27-fold shift in the IC50 of cisplatin, respectively. Furthermore, these compounds 
both bind to XPF in the BIAcore SPR assay with KD of 17.8µM and 275.5µM 
respectively. In the thermal denaturation assay there was immediate protein 
precipitation with UOE #1. This may be explained by UOE #1 disrupting complex 
stability thus resulting in protein precipitation, or alternatively by non-specific 
binding to ΔERCC1-XPF as is believed to be the case for the non-specific inhibitor 
ATA. UOE #2 was fluorescent and prevented thermal denaturation measurements. In 
the in vitro endonuclease assay, neither of these compounds showed inhibition of 
ΔERCC1-XPF however this might be expected as they are proposed to inhibit the 
Phe293 and Cys238 pockets on XPF which would be inaccessible with ERCC1 
bound. These compounds may be more suited to inhibiting de novo ERCC1-XPF 
complex formation.  
 Through the in silico screen, we also identified one compound which inhibits 
the Phe293 pocket. As summarised in Table 5.7 we show that UOE #18 is also able 
to enhance the toxicity of cisplatin in cell culture and results in a 1.26-fold shift in 
the IC50 of cisplatin. This showed binding to XPF in the BIAcore SPR assay with a 
KD of 537.2µM. In confirmation of this, we show that in thermal denaturation, we 
observe a concentration dependent increase in the Tm. This indicated UOE #18 binds 
to ERCC1-XPF and increases complex stability.  Although this is an interaction 
inhibitor, this could be explained by UOE #18 dislodging the ERCC1 Phe293 from 
the XPF pocket and inhibiting ERCC1-XPF activity without breaking the 
heterodimer apart. Furthermore, this could explain why a high IC50 is observed in 
the in vitro endonuclease assay. Activity against de novo ERCC1-XPF complex 
formation is therefore expected to be greater than in vitro.  
 In Table 5.7, we show compound UOE #26 is an interaction domain inhibitor 
binding to the Ile264 and Cys238 pockets on XPF. While this compound showed no 
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binding to XPF in the BIAcore assay, we observed a positive Tm shift in the thermal 
denaturation experiment with this compound and showed that it also displayed 
specific activity against ERCC1-XPF in an in vitro endonuclease assay. Furthermore 
no activity was observed in cell culture with this compound. The lack of activity in 
the BIAcore SPR assay could be for various reasons. One of these is that XPF was 
immobilised and the protein was cross-linked to the chip. It is possible that 
immobilisation may be in an unfavourable conformation for inhibitors which bind to 
the Ile264 pocket on XPF. 
 Of the compounds purchased for follow up validation from the endonuclease 
screen, only one, UOE #44, showed specific binding to ERCC1-XPF in the BIAcore 
SPR assay. Interestingly 7 of the 17 endonuclease domain inhibitor compounds 
showed non-specific binding kinetics to ERCC1-XPF in the BIAcore SPR assay. In 
cell culture, UOE #44 also showed enhanced toxicity of cisplatin however no change 
in Tm was observed in the thermal denaturation assay. In addition, no activity was 
observed in the in vitro endonuclease assay as would be expected for this compound. 
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6.1 Aim of chapter 
Following successful identification of ERCC1-XPF inhibitors in Chapter 5, we 
sought to identify additional ERCC1-XPF inhibitors which were of greater potency. 
This chapter is based around an ERCC1-XPF drug development project in 
collaboration with Professor Malcolm Walkinshaw from the University of Edinburgh 
and Dr Barbara Saxty from MRC Technology, London. Herein we present inhibitors 
discovered through an additional in silico screen and a high-throughput ERCC1-XPF 
inhibitor screen.  
 
6.2 Introduction 
6.2.1 Crystal structures of ERCC1-XPF 
The ERCC1-XPF complex in its entirety has not yet been crystallised. 
Currently crystal structures only exist for the ERCC1 central domain and the 
ERCC1-XPF HhH2 domains as summarised in Table 6.1 (106). During 
overexpression of the truncated ΔERCC1-XPF protein analogous to our protein, 
Tsodikov et al. noticed a protein fragment spanning the ERCC1 central domain was 
produced by proteolytic degradation (106). Upon size exclusion chromatography, 
this fragment eluted separately (106). Tsodikov et al. crystallised this ERCC1 
fragment which consisted of ERCC1 residues 96-214 (106). They propose that the 
ERCC1 linker (ERCC1215-219) is unstructured and flexible to allow the ERCC1 
central domain and HhH2 domain to adopt different orientations (106). 
Consequently, this results in the linker region being exposed and proteolytically 
sensitive (106). The ERCC1 central domain crystals grew in 3-5 days in a hanging 
drop format (using 1:1 protein:reservoir solution) (106). Crystallisation of the 
ERCC1-XPF HhH2 domains was also performed using co-expressed ΔERCC1220-297 
and ΔXPF848-916 proteins (106). The ERCC1-XPF HhH2 crystals grew in 5-10 days in 
the same hanging drop format (106). 
Although not human ERCC1-XPF, the crystal structure of the XPF homodimer 
from Aeropyrum pernix gives valuable insight into the structure of the human XPF 
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endonuclease domain and shows how the domains might associate in the human 
complex (126). To generate crystals of ApeXPF, Newman et al. used a truncated 
protein consisting of residues ApeXPF19-231 (full length protein is 248 amino acids) 
(126). In addition, Newman et al. crystallised the ApeXPF complex with a 15 mer 
DNA duplex (126). These crystals were generated using a protocol developed by 





Structure method Description Ref 
2A1I 
X-Ray Diffraction with 
resolution of 1.90 Å 




X-Ray Diffraction with 
resolution of 2.70 Å 
Crystal Structure of the Complex between the C-
Terminal Domains of Human XPF and ERCC1 
(106) 
2BHN 
X-Ray Diffraction with 
resolution of 3.20 Å 
XPF from Aeropyrum pernix (126) 
2BHN 
X-Ray Diffraction with 
resolution of 2.80 Å 
XPF from Aeropyrum pernix, complex with DNA (126) 
2JNW Solution NMR Solution structure of a ERCC1-XPA heterodimer (112) 
2KN7 Solution NMR Structure of the XPF-single strand DNA complex (111) 
Table 6.1: Summary of structures available for the ERCC1 and XPF proteins in the 




6.3.1 Structure activity relationship for compound UOE #18 
In Chapter 5, we showed that compound UOE #18 shows specific inhibition of 
recombinant ΔERCC1-XPF in an in vitro endonuclease assay, showed specific 
binding to ΔERCC1-XPF in a BIAcore SPR assay, stabilised ΔERCC1-XPF in a 
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thermal denaturation assay and enhanced the toxicity of cisplatin in a cell culture 
assay. We therefore sought to investigate whether analogues of this compound would 
show greater potency in vitro and whether structural modifications of UOE #18 
would disrupt activity. 
Based upon the predicted in silico binding pose of UOE #18 into the Phe293 
binding pocket on XPF shown in Figure 6.1A, we predicted that the naphthalene ring 
is critical for binding into the pocket. Attached to the naphthalene ring is a 
pyrazolone ring substituted with a methyl group which is also likely to confer 
specificity to this inhibitor. We therefore purchased commercially available 
analogues of UOE #18 which contained modifications to these groups. 
Following purchase, we tested in vitro activity in the ΔERCC1-XPF, FEN1 and 
DNase1 assays. We show in Figure 6.1 that derivative UOE #18_6 has been 
modified with a naphthalene ring substituted for a benzene ring. Based upon the in 
silico docking pose of UOE #18, a modification of this nature would abolish binding. 
A PubChem search of this compound showed it had previously been demonstrated to 
be active in 27 of the 920 screens. Unconfirmed or undefined activity was reported in 
a further 77 of the screens. In the in vitro endonuclease activity, UOE #18_6 
confirmed our prediction and showed no activity against ERCC1-XPF.  
Compound UOE #18_7 was selected as this showed activity in a range of other 
screens in the PubChem search similar to UOE #18_6. This was documented to be 
active in 13 of the 573 screens tested and was unconfirmed or undefined in a further 
19 screens. This compound differed from UOE #18 in that it had an additional 
functional group off the pyrazole ring. We predicted that the additional functional 
group may be responsible for the non-specific activity in the PubChem screens. In 
our assays, this compound was fluorescent, which may account for the compound 
scoring as a false positive in many of the published screens, and so we were unable 
to determine whether it had any inhibitory activity. 
Compound UOE #18_8 was purchased to investigate the effect of rotating the 
pyrazolone ring.  In addition to the ring rotation, the carbonyl group on this molecule 
had been replaced by a hydroxyl group and the methyl group had been used to link 
this to the naphthalene ring. In a PubChem search no published screens using this 
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compound had been identified. When tested in the in vitro endonuclease assays, 
although an increased potency against ΔERCC1-XPF was observed, this compound 
also showed activity against FEN1 indicating a loss in specificity. This is therefore 
deemed an unfavourable modification.  
Compounds UOE #18_9 and UOE #18_10 were both purchased as the 
pyrazolone ring was attached to the naphthalene ring from a different position to that 
of UOE #18. In addition, both of these compounds contain additional functional 
groups. No specificity data were found in a PubChem search for either of these 
compounds. It was unknown whether the change in the compound backbone or 
whether the additional side chains would be advantageous to binding. In the in vitro 
endonuclease assays, no additional increase in potency against ΔERCC1-XPF was 
observed with #18_9 however a decreased IC50 from 158.4µM to 59.6µM was 
observed with UOE #18_10. Furthermore, both compounds retained specificity 
against FEN1 and DNase1. 
Compound UOE #18_11 was purchased in order to test whether a modification 
to the naphthalene ring would be tolerable. Based upon the naphthalene ring binding 
into the hydrophobic Phe293 pocket on XPF, it might be expected that the 
hydrophilic hydroxyl group would be incompatible with binding. A nitrogen atom 
was also inserted into this ring. As expected in the endonuclease assay, no activity 
was observed against ΔERCC1-XPF however interestingly, activity was observed 
against DNase1 with an IC50 of 491µM. 
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Figure 6.1: Structure activity relationship between UOE #18 and its compound 
derivatives. (A) Showing the structure and docking pose of UOE #18 which is predicted to 
inhibit the ERCC1 Phe293 pocket on XPF. (B) Structures of compound UOE #18 
derivatives. (C) Activity of compound UOE #18 and its derivatives in the standard ΔERCC1-
XPF, FEN1 and DNase1 assays. Showing the compound IC50 and 95% confidence interval 
indicated in parenthesis. The standard ERCC1-XPF assay was performed as documented in 
Chapter 2 materials and methods. The FEN1 and DNase1 assays were performed by Vera 
Lúcia Freitas Rodrigues as documented in Chapter 2 materials and methods. 
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6.3.2 Second in silico screen for ERCC1-XPF inhibitors 
In order to discover new compounds with an increased potency, a second high 
throughput screen was performed by Dr Doug Houston and Professor Malcolm 
Walkinshaw from the University of Edinburgh. This screen principally differed from 
the previous in silico screen in two ways: firstly a more sophisticated docking 
protocol was utilized (discussed in Chapter 2 materials and methods), and secondly 
the ERCC1 protein surface in the ERCC1-XPF interaction domain was also targeted.  
From the compounds identified through in silico screening, 100 from each of 
the target sites were purchased for validation in the ΔERCC1-XPF, FEN1 and 
DNase1 assays. Of these, 5 compounds (1C3, 1D6, 1F7, 2C5, 2E11) showed activity 
in the endonuclease assay as shown in Table 6.2. An additional three compounds 
were detected from an analogous screen by Dr Preeti Bakrania and Dr Barbara Saxty 
from MRC Technology, but these either did not confirm, or had a high IC50 meaning 
no further development was appropriate. In comparison to the previous in silico 
screen, the hit rate is similar. In the first screen as documented in Chapter 5, one 
compound out of 58 was observed to have an IC50 less than 50µM indicating a hit 
rate of 1.7%. In this second in silico screen, 5 compounds had an IC50 less than 
50µM, also indicating a hit rate of 1.7%. Furthermore, as 4 of these compounds were 
XPF endonuclease domain inhibitors, the hit rate for this screen was much greater 
(4%: 4/100 compounds). 
Additional in silico screening was performed around the 5 in silico hit 
compounds by Dr Doug Houston and Professor Malcolm Walkinshaw. Here they 
generated site points for the 5 hit compounds binding to ERCC1-XPF and screened 
the Edinburgh University Ligand Selection System (EDULISS) database for new 
compounds sharing similar molecular properties. The 6 compounds from each screen 
with the greatest theoretical binding affinity were purchased for screening and we 
identified two additional hits, UOE #2C5_2 and UOE #2E11_1. Unfortunately 
however, when repurchased from a different source compounds 1F7 and 2E11 failed 
to show activity. These were subsequently dropped from further investigation.  
 
 


































2E11* XPF Endonuclease domain 48.8 
(36.4-65.4) 
NA NA 






Table 6.2: Activity of ERCC1-XPF inhibitors discovered by the second in silico screen. 
Compounds screened in the standard ERCC1-XPF assay, FEN1 assay and DNase1 assay as 
documented in Chapter 2 materials and methods. Showing the compound IC50 and the 95% 
confidence intervals indicated in parentheses. NA indicates compounds which showed no 
activity. *Repurchased compounds failed to show activity. 
 
6.3.3 High throughput screen and validation of ERCC1-XPF 
inhibitors 
In addition to the second in silico screen a high throughput compound screen 
was performed by Dr Preeti Bakrania and Dr Barbara Saxty from MRC Technology. 
This was performed using the standard ΔERCC1-XPF assay in 384 well format with 
100nM substrate and 100nM ΔERCC1-XPF in 20µl reaction volumes. The protein 
used was supplied by Dr Martin Wear from the University of Edinburgh in weekly 
batches to negate issues surrounding protein breakdown which occurs between 1-2 
weeks post purification. 
The MRC Technology compound library consisting of 101,440 compounds 
was screened at 20µM. From this, 384 compounds were identified by a 3x SD cut-off 
and compounds displaying <70% residual activity. In follow up assays, 87 
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compounds repeated signifying a 23% hit conformation rate. Of these 49 had an 
IC50 value <200µM and these were further reduced to 30 compounds following 
structural triage to remove frequent hitters and unfavorable structural motifs. Finally 
the IC50 was confirmed for 24 of these compounds. In the DNase1 counter screen, 
only 1 compound showed activity.  A summary of compounds discovered through 
the in silico screening and the high throughput screen are shown in Table 6.3. 
In Table 6.3, hit compounds from both in silico and high throughput screens 
were clustered by Dr Tim Chapman from MRC Technology into groups of structural 
similarity. It is expected that compounds in each groupings will have similar 
mechanisms of action. One cluster of note is cluster 2 as compound MRCT_9 was 
observed to have a similar structure to a previously published FEN1 inhibitor which 
utilized metal ion chelation of the FEN1 active site. A second compound MRCT_9 
MOD was identified by Dr Tim Chapman. This is also shown in Table 6.3. 
A selection of the compounds from Table 6.3 was then purchased for follow up 
validation. Techniques documented in Chapter 5 were employed to characterize 
potential ERCC1-XPF inhibitors. For each of the compounds, we gained FEN1 IC50 
data, thermal denaturation data, PubChem search data and BIAcore SPR data for 
binding to the ΔERCC1-XPF complex in collaboration with Dr Martin Wear. 
Compounds which showed favourable activity in these assays were also subjected to 















































































































































































































































































































































































































Table 6.3: Results table of ERCC1-XPF inhibitor compounds. (A) Showing the working 
ID for each compound. (B) Showing the compound cluster. Compound clustering performed 
by Dr Tim Chapman from MRC Technology, London. (C) IC50 data generated from the 
standard ΔERCC1-XPF, DNase1 and FEN1 assays. Assays were performed either by Dr 
Preeti Bakrania and Dr Barbara Saxty from MRC Technology, or Ewan McNeil. FEN1 
assays were performed by Ewan McNeil. NA denotes non-activity, ND denotes not 
determined, FLU denotes a fluorescent compound. (D) Enhancement of sensitivity to 
cisplatin in A375 human melanoma cells. The control IC50 for cisplatin (CDDP) is 570nM. 
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The IC50 for CDDP in the presence of the different inhibitors was determined. Values given 
are for the fold enhancement of sensitivity to CDDP, calculated from the ratio of 
control/treated IC50s, in the presence of the stated inhibitor concentration. Cell culture 
assays were performed by Ann-Marie Ritchie. (E) Showing the change in thermal stability of 
ΔERCC1-XPF protein in the presence of each compound. Assay performed using 5µM 
ΔERCC1-XPF and 500µM compound. A positive Tm shift of 0.5°C or greater indicates an 
increase in protein stability. (F) BIAcore SPR analysis of compounds binding to ΔERCC1-
XPF protein. A single concentration screen was performed then a concentration series screen 
was performed on those which displayed specific binding. BIAcore SPR assay performed in 
collaboration with Martin Wear from the University of Edinburgh. (G) PubChem database 
search showing activity in previously published assays. N denotes the number of screens 
published using each compound, A denotes the number of screens the compound was active 
in, and U denotes screens whereby activity was inconclusive or an IC50 was not determined. 
 
6.3.4 Crystallisation trials of ΔERCC1-XPF 
In order to determine the mechanism of compounds binding to ERCC1-XPF 
and direct compound development, it is favourable to generate protein crystals in the 
presence of the inhibitors. We therefore started crystallisation trials on the ΔERCC1-
XPF protein in collaboration with Dr Jacqueline Dornan and Professor Malcolm 
Walkinshaw. For these trials, we opted to use the truncated ΔERCC1-XPF protein 
shown in Figure 6.2 by the red bars. This was chosen for several reasons, firstly 
inhibition and biophysical binding of compounds to this protein had already been 
demonstrated. Secondly this protein could be expressed in significant quantities 
which would be necessary for crystallisation trials, and finally it contained the XPF 
endonuclease and ERCC1-XPF interaction domains which were being targeted in our 
screening attempts. Of note, no crystals have been published for the XPF 
endonuclease domain and therefore crystals would be greatly beneficial to the drug 
screening project. 
Before attempts to crystallise the complex with inhibitors, we first sought to 
crystallise the ΔERCC1-XPF complex on its own. To perform this, a number of 
conditions surrounding previously published ERCC1-XPF crystallisation conditions 
were set up as per Chapter 2 materials and methods (106). In addition crystallisation 
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screens were setup at 5°C and 19°C using protein within 4 days of purification as 
breakdown is known to occur at 1-2 weeks at 5°C, and quicker at higher 
temperatures. Initial attempts were unsuccessful; therefore, a batch of ΔERCC1-XPF 
was prepared by Dr Martin Wear whereby the His-tags had been cleaved off by a 
thrombin digestion and subsequent purification. This crystallisation attempt was also 
unsuccessful. Although some of the wells showed crystals forming, upon X-Ray 
diffraction a characteristic salt profile was observed and was thought to be due to 
metal ions in the crystallisation solution forming phosphate crystals with the PBS 5% 
glycerol protein buffer.  
The reason for failure of crystals to form is likely due to the instability of the 
ΔERCC1-XPF protein. That being said, published crystals of the ERCC1-XPF HhH2 
domains were generated from a breakdown product though this was formed during 
purification rather than protein storage (106). For the progression of this project and 
as the majority of ERCC1-XPF inhibitors discovered are likely XPF endonuclease 
domain inhibitors, it is thought that production of a truncated XPF endonuclease 
domain protein may have more success. The proposed protein is shown in Figure 6.2 
by the blue bar. It is thought that this may have greater stability due to the absence of 
the HhH2 domains. We predict greater success may be achieved with this truncated 
protein if it could be stably expressed in sufficient yields.   
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Figure 6.2: Schematic figure of ERCC1-XPF complex used for crystallisation. Shown in 
red is the ΔERCC1-XPF protein that we utilised for crystallisation attempts. Indicated by 
grey bars are the regions of ERCC1-XPF that have previously been crystallised (106). 
Indicated by a blue bar is the region of XPF protein that is proposed to be expressed for 
future crystallisation trials.  
 
6.4 Discussion 
In the previous chapter, we identified UOE #18 through an in silico screening 
approach which was proposed to disrupt the ERCC1-XPF interaction domain by 
binding to the Phe293 pocket. We had previously shown in Chapter 5 that this 
compound showed specific inhibition of ΔERCC1-XPF and bound biophysically to 
the ΔXPF protein. Furthermore, we also showed that this compound had activity in 
cell culture. In order to better understand the mechanism of inhibition of this 
compound, and to investigate whether we could discover a more potent analogue of 
UOE #18, we purchased several analogues with significant structural modifications.  
Of these modifications, two had structural modifications to the naphthalene 
ring which was proposed by the in silico docking to bind into the ERCC1 Phe293 
pocket on XPF; these were UOE #18_7 and UOE #18_11. Compound UOE #18_7 
had a benzene ring substituted for the naphthalene ring, and as a result did not inhibit 
ΔERCC1-XPF. Compound UOE #18_11 had a hydroxyl and nitrogen added into the 
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naphthalene ring. This was predicted to add a hydrophilic charge and be 
incompatible with binding to the hydrophobic pocket. As expected, this compound 
also did not inhibit ΔERCC1-XPF. 
One of the compounds, UOE #18_8 had a modification to the pyrazole ring 
whereby the ring was rotated and the carbonyl replaced with a hydroxyl. With this 
modification, although a slight improvement was observed over the parent compound 
against ERCC1-XPF, a loss in specificity indicated an unfavourable modification. 
Compounds UOE #18_7, UOE #18_9 and UOE #18_10 all possessed the 
naphthalene and pyrazole rings but had additional side-chain modifications off the 
pyrazole group. UOE #18_9 and UOE #18_10 also had the pyrazole ring attached to 
the naphthalene ring at a different point to the parent compound. Although a 
compound possessing this drug backbone change and without the additional side-
chain was not available as a direct comparison to UOE #18, it appears that this 
modification does not make a significant difference to activity. With regards to the 
side-chains, one was fluorescent, one showed no activity, and one showed an 
improved activity. We therefore predict that further exploration of different side 
chains or further changes to the pyrazole ring may result in a more potent inhibitor.  
Following identification of additional ERCC1-XPF inhibitors through the 
second in silico screen and the high-throughput screen, we performed experiments to 
validate these as inhibitors. Initially these were clustered by Dr Tim Chapman from 
MRC Technology into 12 groups containing compounds with similar chemical 
structure and properties. One of these clusters in particular was clustering 2 in which 
Dr Tim Chapman noticed structural similarity of MRCT_9 to a published FEN1 
inhibitor. Although the published inhibitor was not available, a closely related 
analogue was purchased. In Table 6.3, we showed that MRCT_9 and MRCT_9 MOD 
(FEN1 analogue) were both active against FEN1 and ΔERCC1-XPF. Furthermore, 
compound MRCT_9 identified from the high throughput screen had a significant 
increase in specificity for ERCC1-XPF compared to FEN1 and showed no activity 
against DNase1.  
Of the 31 compounds identified as ERCC1-XPF inhibitors in Table 6.3 
(excluding UOE #18 analogues and control compounds), 18 were purchased for 
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follow-up validation. Of these 6 showed no activity in cell based assays, though this 
could be due to low cell permeability with two of these, MRCT_5 and MRCT_21 
possessing a similar chemical structure. In the thermal denaturation assay, only 3 of 
the 18 compounds showed no activity. Of these only 1 bound to ERCC1-XPF on the 
BIAcore SPR analysis indicating that the other 2 compounds may inhibit ERCC1-
XPF through a non-direct mechanism. In the BIAcore SPR assay, 9 of the 31 
compounds showed binding to ΔERCC1-XPF protein. Although this is low, the lack 
of a positive control for the SPR surface means that a stringent cut-off for binders 
versus non-binders had to be used. It is therefore possible that weak binding by some 
of these inhibitors was missed and so excluded from the concentration screen.  
To conclude, 3 of the 18 compounds are active in all of the assays tested. 
These are MRCT_16, MRCT_20 and UOE_#18. In addition, a further 9 compounds 
showed specific inhibition of ERCC1-XPF and were active in the cell based assay. 
Interaction of these compounds with ERCC1-XPF was observed for 8 of the 9 
compounds in one of the two biophysical techniques used. We therefore present 11 
compounds as ERCC1-XPF inhibitors and have a further 13 that may also be 
inhibitors following additional validation experiments. 
Finally we attempted to generate crystals of ΔERCC1-XPF protein so that we 
could crystallise our compounds in the presence of ERCC1-XPF and determine their 
mechanism of binding. Although crystallisation screens are not generally expected to 
produce crystals that diffract well, their benefit and use is in informing us whether a 
protein is likely to produce a crystal or not, and guide further screening (240). 
Furthermore, it is considered that screening 300 crystallisation conditions is 
sufficient to answer this (240, 241). In addition, following a review of success rates 
following crystallisation trials, Segelke considers that given there is a wide range of 
success rates for crystallisation trials (2-68%), the problem with crystallisation is not 
with arriving at the appropriate conditions, rather “finding a protein that crystallises” 
(241). Once conditions suitable for crystallisation are determined, optimisation of 
precipitant, buffer, protein concentration, pH, additives and seeding are necessary to 
optimise crystal formation (242). Given the number of crystallisation screens that 
were performed on both His-tagged, and non-His-tagged ΔERCC1-XPF protein at 
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both 5°C and 19°C, we suggest that this complex is not crystallisable, possibly due to 
its poor stability. For future crystallisation trials, we suggest that expression of the 
XPF nuclease domain on its own might have a greater chance of success. 
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7.1 Malignant melanoma 
Malignant melanoma is a major problem in the UK with 11,877 cases 
diagnosed and 2,203 deaths recorded in the year 2009. Interestingly, although it is 
not the most common form of skin cancer, it results in more cancer deaths. 
Furthermore, malignant melanoma is the sixth most common cancer in the UK and is 
the second most common cancer in young people aged 15-34. Worryingly, although 
incidence rates continue to rise faster than that of any other cancer, the standard 
therapy for metastatic disease is ineffective (33). Furthermore, although targeted 
therapies are beginning to emerge, no substantial long term benefit (i.e. improved 5 
year survival) has yet been observed (45, 51). 
The work presented in this thesis aimed to partly address this problem. In 
Chapter 3, we performed a phenotypic drug screen to identify compounds that were 
active against melanoma. Through this, we characterised a series of nitrofuran 
compounds demonstrating that these are active in melanoma and enhanced the 
toxicity of existing chemotherapeutics. In subsequent chapters, we identified the 
ERCC1-XPF structure specific endonuclease as a target to overcome 
chemoresistance in metastatic melanoma. We established in vitro specificity assays 
and performed in silico and high throughput screens for ERCC1-XPF inhibitors. In 
this thesis, we identified and characterised ERCC1-XPF inhibitor compounds and 
showed activity in vitro and in cell culture. 
 
7.2 Screen for compounds active against melanoma 
In Chapter 3, we compared the effect of standard chemotherapeutic agents on 
melanoma and melanocyte cell lines. We showed that the alkylating agent 
dacarbazine, which is the standard chemotherapeutic for melanoma, does not require 
ERCC1 for its repair. In contrast, the chemotherapeutics cisplatin and oxaliplatin 
which both cause monofunctional, inter- and intrastrand crosslinks require ERCC1 
for repair. We then showed using propidium iodide FACS cell cycle analysis in 
melanocyte cells that cisplatin treatment results in a characteristic S phase and G2 
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phase arrest. This also resulted in an increase in the sub-G1 population and in 
Annexin-V staining, this was shown to be the result of apoptosis. In the human 
melanoma A375 cell line, we observed an S phase and G2 phase arrest after 24 hours 
of treatment however by 48 and 72 hours of treatment, this was reduced. Although 
this result was surprising, we proposed this may be due to a coping strategy 
employed by the cells to permit continued growth in the presence of cisplatin. 
 
7.3 Nitrofurans  
We then performed a phenotypic drug screen in collaboration with Dr 
Elizabeth Patton and identified a number of compounds which showed activity 
against melanocytes or enhanced the toxicity of cisplatin. In validation experiments, 
compounds either did not repeat or results obtained did not justify further 
investigation. We then investigated a nitrofuran compound termed Bio1E7 that had 
been identified by Dr Hironori Ishizaki and Dr Elizabeth Patton in a previous small 
molecule screen. This compound showed structural similarity to another nitrofuran 
compound called nifurtimox that is currently used for the treatment of the African 
Trypanosomal Chagas disease (164). In addition, this compound is also used in 
cancer therapy and is in clinical trials for the treatment of neuroblastoma (168, 169). 
These compounds were proposed to act by being metabolised to generate superoxide 
formation (164). Some reports suggest that these compounds required an NER 
dependent DNA repair mechanism (167), using our ERCC1 proficient and deficient 
cell lines we showed that this was not the case. As superoxide formation is known to 
result in single and double stranded DNA breaks (198), we expect the homologous 
recombination pathway to be involved in nitrofuran induced DNA damage. Our 
future experiments include determining if cells harbouring BRCA1/2 mutations are 
hypersensitive to nitrofuran compounds as these are expected to be hypersensitive to 
nitrofuran induced double strand breaks. Finally, we showed that the toxicity of these 
compounds was abrogated by the presence of melanin pigment in our cell lines. 
Although pigmentation levels were not experimentally altered, we wonder whether 
future induction of pigmentation could protect cells from nitrofuran toxicity. Future 
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experiments could also include determining whether cell lines expressing either 
eumelanin or pheomelanin will have a differential toxicity to nitrofuran compounds. 
 
7.4 ERCC1-XPF  
We then investigated the role of ERCC1-XPF in DNA repair and showed this 
to be required for the repair of cisplatin induced DNA damage. Interestingly, as 
malignant melanoma has elevated expression of DNA repair protein in response to 
chemotherapy, we wondered whether this is the cause of the chemoresistance of 
melanoma to cisplatin therapy. A xenograft experiment in our lab had previously 
shown that deletion of ERCC1 from melanoma resulted in susceptibility of tumours 
to cisplatin treatment (149). We therefore proposed the ERCC1-XPF endonuclease as 
a drug target to overcome chemoresistance. 
In order to develop inhibitors of ERCC1-XPF we established a fluorescence 
based in vitro endonuclease assay using recombinant ΔERCC1-XPF. While we 
utilised a truncated ΔERCC1-XPF which is known to have a reduced activity 
compared to full length ERCC1-XPF, the expression yields were greater favouring 
this protein for a drug discovery programme. Interestingly, during our optimisation, 
we observed a phenomenon whereby pre-incubating our protein at room temperature 
prior to the assay resulted in 200-fold greater activity levels. Furthermore, this 
activity was now greater than that reported for full length protein. Although the 
reason for this is unknown, importantly this increased activity only occurs with the 
biologically relevant metal ion and not manganese which is used in the standard 
assay and all other published assays (100, 102, 106, 112, 115). When investigating 
the cleavage specificity of our proteins, we confirmed that the standard assay had 
specificity as previously published (100, 106). The pre-incubated protein however 
had an altered specificity. We therefore favoured the standard ΔERCC1-XPF assay 
for future screening. 
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7.5 In silico screening 
In order to identify an ERCC1-XPF inhibitor compound, initially we opted to 
use an in silico drug screening approach in collaboration with Professor Malcolm 
Walkinshaw from the University of Edinburgh. Here we identified the ERCC1-XPF 
interaction domain and the XPF endonuclease domain as our principal drug targets. 
Our collaborators then performed the in silico screen and compounds were selected 
for in vitro validation. Although one of our target sites was a protein-protein 
interaction, a precedent for targeting such domains has been established for 
MDM2/p53 interaction by Nutin compounds (224). Similarly to XPF, MDM2 also 
possesses a deep hydrophobic pocket tractable to drug design (224). Using a range of 
biochemical, biophysical and cell culture assays, we screened the compounds and 
characterised their activity. In addition, we utilised in vitro FEN1 and DNase1 assays 
to demonstrate that these compounds were specific. 
One compound in particular, UOE #18 was of particular interest to us. This 
compound was designed to be an ERCC1-XPF interaction inhibitor binding to the 
Phe293 pocket on XPF. We demonstrated this compound to show specificity against 
ERCC1-XPF in the in vitro endonuclease assay and showed no activity against either 
FEN1 or DNase1. Furthermore, we demonstrated biophysical binding of this 
compound to recombinant ΔXPF protein in a BIAcore SPR assay and showed a 
stabilisation of the ΔERCC1-XPF complex in a thermal denaturation assay. In cell 
culture, using a human melanoma cell line we showed that this compound does 
enhance the toxicity of cisplatin, and was able to shift the IC50 of cisplatin. 
We then purchased analogues of UOE #18 to perform basic structure activity 
studies with this compound. We showed that the compound predicted to have no 
activity based upon the in silico docking pose indeed lacked activity. Compounds 
with minor modifications to the compound backbone either had no change in 
activity, or resulted in a loss of specificity. We show that compounds with particular 
side chains were able to increase potency. Based upon the information gained, we 
recommend investigating these compounds further to determine whether a further 
increase in potency could be observed. Using the in vitro endonuclease assay to 
identify interaction inhibitors is problematic as it requires an inhibitor to disrupt the 
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protein-protein interaction between ERCC1-XPF for it to be able to bind. Although 
inhibition of this assay by UOE #18 suggests that it is able accomplish this, the 
resultant IC50 is much greater than that observed for cell culture assays where UOE 
#18 is able to inhibit de novo complex formation. Interestingly, identification of 
nutlin as a MDM2/p53 inhibitor was performed by BIAcore SPR analysis and 
confirmed in cell culture (224). It will be interesting to see if the UOE #18 
derivatives also have greater activity in cell culture compared to UOE #18. 
 
7.6 High throughput screen 
In collaboration with Dr Barbara Saxty from MRC Technology London a high 
throughput drug screen was performed using our standard ΔERCC1-XPF assay. In 
addition, in collaboration with Professor Malcolm Walkinshaw from the University 
of Edinburgh a more sophisticated in silico screen was performed. Through a 
combination of these screens, and the aforementioned screening, a list of 31 ERCC1-
XPF inhibitors was documented in Chapter 6. Using the biochemical, biophysical 
and cell culture techniques described in Chapter 5, we showed that 11 of the 18 
compounds investigated are ERCC1-XPF inhibitor compounds. We now need to 
purchase analogues of these compounds to perform structure activity relationships on 
each of the compound classifications. 
 
7.7 Crystallisation 
To determine the mechanism of binding of inhibitors to ERCC1-XPF and to 
direct further screening efforts, we performed protein crystallisation trials using our 
ΔERCC1-XPF protein. Unfortunately however these trials were unsuccessful and 
this was likely due to protein instability when stored for a long period of time. We 
therefore recommend attempting to express the XPF endonuclease on its own as this 
may be more stable and have a greater chance of success. Preliminary expression 
trials are currently underway in our lab. For ERCC1-XPF interaction inhibitors it will 
be necessary to express the ERCC1-XPF HhH2 interaction domain and crystallise 
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this in the presence of inhibitors. Although this complex has previously been 
crystallised, it would rely on compounds being able to disrupt the preformed 
complex. Therefore it might be necessary to express and crystallise the XPF HhH2 
domain in the absence of ERCC1. That being said, if this could be purified as a 
monodisperse protein, it is likely that there will be issues with protein stability which 
may hamper crystallisation attempts. 
 
7.8 Future plans 
In order to further the project it will be nessesary to develop compounds with 
greater potency for ERCC1-XPF. As we have already identified numerous inhibitors 
of ERCC1-XPF the most likely method will be to perform structure activity 
relationship experiments on each of the compound clusters. These efforts however 
will likely be limited by the activity of the in vitro endonuclease assay which would 
primarily be used to perform this screening. As this assay uses 100nM protein per 
reaction detection of compounds in this concentration range would need to inhibit at 
stoichiometric concentrations. Another option will be to express full length ERCC1-
XPF proteins as these have been shown to have more activity and are active at lower 
protein concentrations (102, 106). Furthermore, anecdotal evidence suggests that 
storage of these proteins is more stable than ΔERCC1-XPF. Attempts are currently 
underway to express the full length protein using a modified purification protocol as 
published by Bowles et al. (102). If successful, it will also be interesting to see 
whether the pre-incubation phenomenon is an artefact of the truncated ΔERCC1-
XPF, or whether it also occurs to full length ERCC1-XPF.   
In addition, while the in vitro endonuclease assay is particularly suitable to 
endonuclease domain inhibitors, demonstrating inhibition by interaction domain 
inhibitors with this assay is problematic. This is because interaction inhibitors are 
designed primarily to disrupt de novo complex formation and are likely to be unable 
to disrupt the tight protein-protein interaction formed by ERCC1 and XPF. In order 
to optimise interaction inhibitors, a cell culture assay will need to be utilised. This 
may be based upon fluorescently tagging ERCC1- XPF to directly monitor protein 
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levels, or by using either standard or in-cell Western blotting techniques to detect 
ERCC1 and XPF protein levels.  
The next main step for our ERCC1-XPF inhibitor compounds will be to 
demonstrate direct inhibition of DNA repair in cells. Attempts to demonstrate this are 
currently underway by others in our lab. It is anticipated that this will either be 
demonstrated using a COMET assay, or by the repair of a reporter plasmid 
introduced into cells following DNA damage. 
In addition, we are also interested in demonstrating in vivo activity of our 
inhibitors. We therefore plan to perform xenograft experiments in either zebrafish or 
mice. While xenografting in zebrafish is not commonplace, it is an emerging tool for 
compound screening and has the advantage of being higher throughput when 
compared to mouse modelling.  
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10.1 Cell culture dose-response curves on A375 human melanoma 
cells 
A375 IC50 - UOE #1
Log[Concentration] (µM)

























A375 IC50 - UOE #2
Log[Concentration] (µM)
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A375 IC50 - UOE #18
Log[Concentration] (µM)

























A375 IC50 - UOE #26
Log[Concentration] (µM)
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A375 IC50 - UOE #38
Log[Concentration] (µM)
























A375 IC50 - UOE #44
Log[Concentration] (µM)
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A375 IC50 - UOE #46
Log[Concentration] (µM)
























10.2 Standard ERCC1-XPF assay dose-response curves 
Standard ERCC1-XPF - UOE #18
Log[Concentration] (µM)
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Standard ERCC1-XPF - UOE #26
Log[Concentration] (µM)
























Standard ERCC1-XPF - UOE #45
Log[Concentration] (µM)
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Standard ERCC1-XPF - UOE #46
Log[Concentration] (µM)

























Standard ERCC1-XPF - Emodin
Log[Concentration] (µM)
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10.3 Pre-incubated ERCC1-XPF assay dose-response curves 
Pre-incubated ERCC1-XPF - UOE #18
Log[Concentration] (µM)

























Pre-incubated ERCC1-XPF - UOE #26
Log[Concentration] (µM)
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Pre-incubated ERCC1-XPF - UOE #45
Log[Concentration] (µM)

























Pre-incubated ERCC1-XPF - UOE #46
Log[Concentration] (µM)
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Pre-incubated ERCC1-XPF - Emodin
Log[Concentration] (µM)

























10.4 FEN1 assay dose-response curves 
FEN1 - UOE #26
Log[Concentration] (µM)
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10.5 DNase1 assay dose-response curves 
 
DNase1 - UOE #26
Log[Concentration] (µM)
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